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Laboratory Medicine Best Practices: 
Developing Systematic Evidence Review and Evaluation 
Methods for Quality Improvement 




BACKGROUND AND PURPOSE:  This report summarizes the third phase of an 
ongoing effort sponsored by the Division of Laboratory Science and Standards (DLSS), 
Centers for Disease Control and Prevention. The purpose is to develop new systematic 
evidence review and evaluation methods for identifying pre- and post-analytic laboratory 
medicine practices that are effective at improving healthcare quality.1  This effort began 
in 2006, when CDC convened the Laboratory Medicine Best Practices Workgroup 
(Workgroup), a multidisciplinary panel of experts in such fields as laboratory medicine, 
clinical medicine, health services research, and health care performance measurement. 
The Workgroup also includes two ex officio representatives from the Centers for 
Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA). 
An outcome of Phase 1 (2006 – 2007)  was to act on a Workgroup recommendation to 
enlarge the search for evidence to unpublished studies, including assessments 
performed for the purposes of quality assurance, process improvement and/or 
accreditation documentation. Phase 2 (2007-2008) involved a pilot test of further refined 
methods to obtain, review, and evaluate published and unpublished evidence, along with 
collecting observations via key informant interviews about organizational and 
implementation issues successfully addressed by other recommending bodies about the 
development and dissemination of guidelines and best practice recommendations.  
These evidence review methods were adapted from those established by the GRADE 
group, The Guide to Community Preventive Services (Community Guide), the Agency 
for Healthcare Research and Quality (AHRQ) (US Preventive Services Task Force 
(USPSTF), Evidence-based Practice Centers (EPCs), and Effective Healthcare 
Program), and others, and modified to better accommodate the non-controlled study 
designs typically found in quality improvement research. 
Phase 3 (2008-2010), the subject of this report, involved further development  of 
methods for identifying evidence-based laboratory medicine quality improvement best 
practices, and validated these methods with reviews of practices associated with three 
topics: patient specimen identification, critical value reporting, and reducing blood culture 
contamination.  
SYSTEMATIC EVIDENCE REVIEW AND EVALUATION METHODS:  Methods 
developed in earlier phases were refined and applied to identify and frame review topics 
and questions, and then collect, screen, abstract, standardize, summarize, and evaluate 
                                                                
1 The LMBP Initiative relies on the Institute of Medicine‘s six healthcare quality domains of safety, 
effectiveness, patient-centeredness, timeliness, efficiency, and equity for measuring and evaluating 
laboratory medicine practice effectiveness (Committee on the National Quality Report on Health Care 
Delivery, 2001). 
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evidence from published and unpublished sources for specific practices/interventions. 
The approach to implementing these evidence review steps adopted the vocabulary of a 
framework commonly used in evidence-based medicine (Ask-Acquire-Appraise-Analyze-
Apply-Assess, or ―A-6‖, (Shaneyfelt et al 2006)). These methods include the guidance 
provided to expert panelists, who were asked to (1) review and finalize study quality 
ratings drafted by the review team; (2) evaluate and rate the magnitude of effect sizes 
obtained from these studies and their consistency; (3) use these ratings to assess the 
overall strength of a body of evidence for a given practice; (4) present their evaluation 
findings; and then (5) translate their findings for each practice into a draft evidence-
based recommendation. 
The expert panels‘ evidence reviews, evaluations, and draft recommendations became 
the basis for consideration of best practice recommendations by the Workgroup (serving 
in its capacity as the ―Recommending Body‖). As with earlier phases, methods for 
including rating and evaluating study findings for a practice-specific evidence base were 
adapted from protocols from several organizations involved with public health and 
healthcare-related evidence reviews and recommendations.2 
A key Phase 3 objective was to examine the utility and feasibility of including 
unpublished assessments or studies as part of the systematic evidence reviews of 
laboratory medicine practices (LMBP).  Established steps for collecting evidence from 
unpublished sources included: 
1. Obtaining the support and endorsement of key stakeholder organizations to 
encourage clinical laboratories and healthcare organizations to participate in 
the LMBP pilot test. 
2. Identifying healthcare organizations/facilities likely to have completed relevant 
unpublished laboratory medicine practice assessments, based on: 
a. Conference papers or other public presentations. 
b. Relevant publications that implied the author(s) or others might have 
additional data beyond what was reported (e.g., more recent data, or data 
more encompassing in scope or care setting) 
c. Personal knowledge of Workgroup and Expert Panel members and the 
CDC/Battelle team. 
d. Calling attention to an online site where facilities could voluntarily register 
their interest in being contacted to gauge whether available data would be 
appropriate for inclusion. 
 
3. Identifying and contacting a senior laboratory scientist, laboratory director, or 
other appropriate representatives (e.g., involved in patient safety, quality 
management, clinical research, regulatory/accreditation compliance) to 
                                                                
2 The Guide to Community Preventive Services (http://www.thecommunityguide.org/index.html), the US 
Preventive Services Task Force (http://www.ahrq.gov/clinic/uspstfix.htm), The GRADE Working Group 
(http://www.gradeworkinggroup.org/index.htm), AHRQ (EPCs 
http://www.ahrq.gov/Clinic/epcpartner/epcresmat.htm and Effective Healthcare Program 
http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-
reports/?pageaction=displayproduct&productid=318) The Cochrane Collaboration 
(http://www.cochrane.org/). 
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describe the aims of the LMBP project and explore the circumstances under 
which the organization would consider participating in the pilot test. 
4. Providing additional information about the project to the facility point-of-
contact to share with colleagues and obtain a preliminary assessment from 
the organization‘s Institutional Review Board (IRB) chair for release of de-
identified data from previously completed studies What was found early on at 
the end of the first year of this initiative is that we weren‘t going to be able to 
adopt conventional ways  for doing evidence reviews to laboratory medicine 
quality improvement practices due to generally insufficient published 
evidence.  There was a recognition that Available evidence/data was likely to 
come from quality improvement efforts which don‘t tend to get published. 
5. Extending a formal invitation to the organization and providing more general 
guidance about the type of information needed from unpublished studies. 
6. Establishing any formal confidentiality safeguards or conditions under which 
the information would be provided for the purposes of the pilot test of LMBP 
systematic review methods. 
7. Reviewing study information and other material received, and follow-up with 
additional information requests as needed. 
To minimize the burden on pilot test participants and maintain consistency with 
published evidence, only previously completed studies were requested (i.e., no new 
data), and it was suggested that these studies might be derived from multiple types of 
sources, including internal assessments, case studies, Failure Mode and Effects 
Analyses (FMEA), and quality improvement project studies. Facilities were also 
requested to provide data that contained no personal patient health information. A 
commitment was made to de-identify all data and studies submitted, and each facility 
was offered the option to remain anonymous in the pilot test evidence summaries and 
findings.  
All studies and/or assessments, published and unpublished, acquired for the pilot LMBP 
evidence reviews were screened using the same criteria for relevance and 
completeness (i.e., had at least one effectiveness finding for a practice being reviewed 
with an outcome measure associated with the review question).  Studies that met the 
inclusion criteria were then abstracted by at least two independent reviewers, 
summarized in a standardized format, and included in evidence summaries and meta-
analyses for each practice reviewed. The evidence summaries and LMBP study quality 
rating criteria were used to categorically rate individual study quality, and the individual 
study and meta-analysis summary effect sizes were also categorically rated to produce 
an overall strength of evidence rating for each practice, using the following four-step 
approach: 
1. Categorically rating individual study quality (good, fair, poor), based on a 10-
point scale with specified criteria evaluating four quality dimensions 
a. Study  
b. Practice  
c. Outcome measure(s)  
d. Findings/result(s) 
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2. Categorically rating the observed effect size(s) (substantial, moderate, 
minimal/none) reported in each individual study with a ―good‖ or ―fair‖ study 
quality rating and relevance to the review question (direct, less direct, 
indirect). (Studies with ―poor‖ quality ratings are excluded from the practice 
evidence base and the effect-size meta-analyses). 
 
3. Assessing the consistency of all study effect sizes based on their direction 
and magnitude. 
4. Rating the overall strength of a body of evidence using the ratings from the 
three previous steps is based on the number of good and fair quality studies 
that found a substantial or moderate effect size. 
The following are the established rating categories for the overall strength of a 
body of evidence:  
High:  An adequate volume of evidence is available and includes consistent 
evidence of substantial healthcare quality impact from studies without major 
limitations. 
Moderate:  Some evidence is available and includes consistent evidence of 
substantial healthcare quality impact from studies without major limitations; 
OR an adequate volume of evidence is available and includes consistent 
evidence of moderate healthcare quality impact from studies without major 
limitations. 
Suggestive:  Limited evidence is available and includes consistent evidence 
of moderate healthcare quality impact from a small number of studies without 
major limitations; or the quality of some of the studies‘ design and/or conduct 
is limited.  
Insufficient:  Any estimate of an effect on healthcare quality impact is too 
uncertain. Available evidence of effectiveness is:  
– Inconsistent or weak; OR 
– Consistent but with a minimal effect; OR 
– Contained in an inadequate volume to determine effectiveness 
EVIDENCE-BASED IDENTIFICATION OF BEST PRACTICES: The rating categories 
for the overall strength of a body of evidence related to a potential best practice 
translates into recommendation rating categories.  These rating categories reflect the 
extent to which there is confidence that the available evidence demonstrates that the 
practice(s) will do more good than harm: 
Recommend:  The practice should be identified as a ―best practice‖ for 
implementation in appropriate care settings, taking into account variations 
and applicability in implementation and/or care settings. This 
recommendation results from a ―High‖ or ―Moderate‖ overall strength of 
evidence rating for improving healthcare quality, and accounts for available 
information related to additional harms and benefits. 
No recommendation for or against: A potentially favorable impact on 
healthcare quality is not of sufficient size, or not sufficiently supported by 
evidence to indicate that it should be identified as a ―best practice‖ for 
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implementation in appropriate care settings. This recommendation results 
from a ―Suggestive‖ or ―Insufficient‖ overall strength of evidence rating, and 
accounts for available information related to additional harms and benefits. 
Recommend against:  The practice should not be identified as a ―best 
practice‖ for implementation because it is not likely to result in more good 
than harm.  This recommendation results from a ―High‖ or ―Moderate‖ overall 
strength of evidence rating for adversely affecting healthcare quality, and 
accounts for available information related to additional harms and benefits. 
There is an important distinction between evidence of effectiveness for healthcare 
quality improvement and evidence related to other aspects of implementation, such as 
feasibility, cost, applicability (e.g., to specific care settings and populations), and other 
harms and benefits. Only the evidence of effectiveness was systematically reviewed.   
Further methods refinements for these implementation aspects will be considered in 
future reviews. 
PHASE 3 EVIDENCE REVIEW RESULTS:  Seven practices met the pilot test minimum 
criteria for available evidence to be considered for systematic reviews:  two for the 
Patient Specimen Identification topic, two for the Communicating Critical Values topic, 
and three for the Blood Culture Contamination topic. 
Patient Specimen Identification: Practices associated with this review topic are 
designed to reduce patient specimen and/or test result identification errors and assure 
accurate identification of specimens and/or test results. Practices for which enough 
evidence was available from unpublished and published sources to be included in the 
evidence review were: 
 Barcoding Systems - Electronic bar-coding of both patient identification and 
specimen used to establish positive identification of specimen as belonging to 
patient. This involves the use of bar code scanners and capability to barcode 
specimens. 
 Point-of-Care-Testing Barcoding Systems - Automated patient and 
sample/test result identification system using bar-coded patient identification 
and bar code scanners when using a testing device at or close to the patient.  
Critical Values Communication:  Practices associated with this review topic are 
designed to assure timely and accurate communication of critical value laboratory test 
results to a licensed responsible caregiver who can act on these results. Practices for 
which enough evidence was available from unpublished and published sources to be 
included in the evidence review were: 
 Automated Notification – Automated alerting system or computerized 
reminders using mobile phones, pagers, email or other personal electronic 
devices to alert clinicians of critical value laboratory test results. 
 Call Center – Critical value notification process centralized in a unit 
responsible for communication of critical value laboratory test results to the 
licensed caregiver. 
Blood Culture Contamination: Practices associated with this review topic are designed 
to reduce blood culture contamination rates (i.e., false positive blood culture test results 
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associated with contaminants in blood culture specimens), which routinely result in 
unnecessary repeat tests and antimicrobial drug therapy associated with adverse clinical 
and economic outcomes (e.g., increased hospital length of stay, side effects, and cost of 
therapy). Practices for which enough evidence was available from unpublished and 
published sources to be included in the evidence review were: 
 Dedicated Phlebotomy – Use of certified phlebotomists (rather than nursing 
or other staff) to draw blood specimens for analysis, acknowledging that 
100% of phlebotomist blood draws use venipuncture collection. 
 Venipuncture (vs. Intravenous catheter) collection – Puncture of a vein 
through the skin vs. use of a thin flexible tube inserted into the body to 
withdraw blood for analysis 
 Pre-packaged Prep Kits - Pre-packaged aseptic supplies for drawing blood 
specimens by venipuncture that are prepared in-house or commercially 
purchased 
Preliminary results (December 2009):  Based on the strength of evidence, the 
following were identified as ―best practice‖ recommendations.  
Patient Specimen Identification: 
 The use of barcoding systems (vs. no barcoding) is identified as a best practice for 
reducing patient specimen identification errors (8 studies, log odds ratio = 2.45; 95% 
CI 1.6-3.3). 
 The use of point-of-care-testing barcoding systems is identified as a best practice for 
reducing patient test result identification errors (5 studies, odds ratio 6.55; 95% CI 
3.1 – 14.0). 
Critical Value Reporting:   
 No recommendation is made for or against identifying the use of call centers (3 
studies, Standard difference of means = 0.81, 95% CI -0.52 – 2.15) 3 or automated 
notification systems (3 studies, Standard difference of means = 0.51, 95% CI -0.4 – 
1.4) as a best practice. 
Blood Culture Contamination:  
 The use of venipuncture for sample collection when this option exists in the clinical 
setting is identified as a best practice for reducing blood culture contamination rates 
(7 studies, OR = 2.63, 95% CI 1.85-3.72).  
 The use of dedicated phlebotomy (teams) to collect blood culture specimens is 
identified as a best practice for reducing blood culture contamination rates (6 studies, 
OR = 2.76, 95% CI 2.2 - 3.5). 
                                                                
3
 When the Confidence Interval (CI) for the Odds Ratio extends below 1.0 (or below 0.0 for the Standard 
Difference of Means), we cannot determine whether there is an effect that favors the intervention over the 
comparator. 
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 No recommendation is made for or against identifying the use of pre-packaged 




 Findings from pilot LMBP systematic reviews (2006-2009), demonstrate that LMBP 
systematic review and evaluation methods may be applied to evaluate quality 
improvement practices. 
 Systematic evidence review and evaluation methods developed and tested during 
Phase 2 were refined and adapted to better address the evidence available from 
laboratory medicine quality improvement studies resulting in greater consistency and 
transparency of evidence rating and evidence.  
 Unpublished and published data from laboratory quality improvement efforts provide 
evidence of effectiveness for inclusion in systematic evidence reviews. 
 The Phase 3 pilot test findings demonstrate that LMBP systematic review methods 
for quality improvement practice evidence reviews support evidence-based 
recommendations.  The LMBP methods for summarizing and evaluating practice 
evidence of effectiveness, and rating the overall strength of a body of evidence are 
comprehensive, appropriate and can be efficiently implemented on an ongoing basis 
given sufficient organizational resources and appropriately qualified staff, but still 
require further specific refinements in Phase 4 (ending in 2011) discussed below. 
Network for unpublished evidence 
Phase 3 efforts to recruit healthcare organizations to participate in a network to provide 
unpublished evidence provided considerable insight into the factors that constrain and 
encourage participation, and the likelihood of obtaining usable evidence, including: 
 Contacts with knowledgeable representatives invested with appropriate decision-
making authority, 
 Identification and participation of organizations that use the practices being reviewed, 
 Clear communication of specific requirements for what constitutes includable 
effectiveness evidence (i.e., relevant practice and at least one outcome 
measure/finding, preferably with a baseline comparison), 
 Appropriate formal letters of invitation and endorsement of professional, accreditation 
and industry organizations, and   
 Information that meets the needs of relevant IRB chairs and other administrative 
review offices; assurances of confidentiality when requested. 
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Organizational Development and Sustainability 
 Characterization of the roles and responsibilities of the LMBP Workgroup, Expert 
Review Panels, and the staff support team evolved over the course of this phase, 
helping to further specify organizational requirements to support systematic evidence 
reviews and the production of best practice recommendations on an ongoing basis. 
 Several key factors are necessary to support and sustain the development and 
implementation of the LMBP process: 
o Transparency. The process must be open to all relevant stakeholders and the 
public; no part of it should be conducted behind closed doors. All evidence 
should be clearly presented and the review process should be clearly defined so 
that it can be replicated and produce the same results.  
o Timeliness of recommendations. Sufficient resources must be allocated to the 
LMBP process to ensure that reviews are completed in a timely fashion so that 
recommendations are disseminated while they are still relevant and likely to 
improve healthcare quality outcomes.  
o Collaboration. CDC should not operate independently, but instead should 
collaborate with existing stakeholder, professional and guideline-setting 
organizations, as well as those recognized independently as subject matter and 
methods experts.  
o Involvement of Partners. It is critical to ensure that the process be inclusive of 
not only representation of all laboratory medicine stakeholders but sufficiently 
responsive to the needs and input of all relevant perspectives and disciplines 
involved in all phases of the testing process. The partners should be diverse and 
multi-disciplinary, and must have real opportunities for providing input to impact 
the LMBP process and outcomes. 
o Independent Recommending Body. The evidence review results and 
identification of evidence-based best practices should be issued by a 
recommending body that is perceived to be independent, not subject to the 
influence of any particular faction within the field, the sponsoring agency, nor 
political considerations.  
o Organizational Commitment to Sustainability. The model must be 
sustainable, with resources available to support the process for the long-term. If 
the process is perceived as an initiative that will fade away, it will not garner the 
support necessary to make it effective.  
o Integration with Existing Efforts (Without Duplication). A number of 
organizations are already in the process of identifying and disseminating best 
practices recommendations. The CDC-led LMBP effort should integrate with 
these efforts to the extent possible through its evidence-based methods, and 
should not duplicate them. 
RECOMMENDED NEXT STEPS 
In moving towards sustained implementation, it is recommended that the Laboratory 
Medicine Best Practices systematic evidence review and evaluation methods for 
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assessing the effectiveness of quality improvement practices be further refined and 
enhanced to include some or all of the following activities. 
Methods: Review Topic Selection 
Refine and standardize the process by which systematic review topics are 
selected and associated candidate practices are nominated. Topic selection 
criteria established early in the Initiative‘s development still apply (burden of 
problem/quality gap; preventability, availability of existing knowledge, potential 
effectiveness, operational management, and potential economic benefit), but 
further refinements are needed in soliciting and responding to suggestions from 
the field. 
Methods: Analytic Framework 
Refine and standardize methods for schematic representation of a review topic 
analytic framework for each review question including: 
 Formalize a process for establishing functional requirements for practices 
associated with a selected topic area. A ―process mapping‖ approach may 
help to outline work flows and common points of intervention at which 
practices can achieve improvements in healthcare quality outcomes.  
 Identify processes from domains of application outside of laboratory medicine 
that meet the same functional requirements, increasing the likelihood that 
evidence of effectiveness from these other domains will be regarded as 
relevant to laboratory medicine practices. 
Methods: Search, Screening and Data Abstraction Methods 
 Make further improvements to the review methods and electronic data 
abstraction tool including:   
 Refine, standardize, and document literature search strategy to generate 
relevant published materials in a broader array of journals and published 
conference proceedings. 
 Develop standardized search and reporting functions for reference and study 
databases.  
 Improve guidance and standardization for screening and abstraction methods 
for reviewers. 
 Refine reviewer/user interface enhancements for data abstraction. 
 Structure and formatting of data abstraction template more directly linked with 
evidence summary templates and individual study evaluation criteria. 
 Further standardization of outcome measures, definitions, and their 
categorization to minimize topic area-specific programming and maximize 
comparability. 
 Develop and implement standardized methods for screening and capturing 
non-effectiveness evidence related to feasibility of implementation, 
applicability, economic evaluation and harms and benefits and/or other newly 
developed criteria. 
 
LMBP Phase 3 Final Report x 
Methods: Evidence Summary and Evaluation 
 Finalize evidence summary presentation formats along with development of 
standardized content and terms to facilitate and ensure consistent 
evaluations, and when applicable statistical meta-analyses, and 
recommendation statements (for the LMBP topic area Expert Panels and 
Workgroup), and for publishing and disseminating evidence reviews and 
evidence-based recommendations. 
 Specify methods for including, evaluating and synthesizing additional non-
effectiveness evidence related to implementation feasibility, economic 
evaluation, applicability (settings, populations, contextual variables) and 
harms and benefits, incorporating concepts of external validity and internal 
validity. 
 Further refine protocols for nominating, selecting, and guiding the work of 
expert panelists so that panelists have a clear idea of their roles and 
responsibilities relative to the Recommending Body and support staff, and 
panel composition is adequately diversified to represent key stakeholders‘ 
perspectives to produce unbiased and scientific evidence reviews. 
 Further refine protocols for guiding the work of the LMBP Workgroup (or if not 
overlapping a Recommending Body) so that members of this body have a 
clear idea of their roles and responsibilities relative to the expert panelists 
and support staff. 
Network Development for unpublished evidence 
 
 Further develop the network as the principal source for unpublished 
evidence. Expanding and maintaining this network is essential to the future 
sustainability of an evidence-based laboratory medicine practice 
recommendations process, as the main challenge to its success remains 
insufficient published evidence. 
 Further refine guidance to network participants on informational requirements 
for submitting evidence. 
 Develop and implement an education / curriculum strategy that familiarizes 
laboratory managers with methods for improving the quality of unpublished 
process improvement / quality assurance studies so that data from these 
studies are consistently available to inform ―best practice‖ recommendations. 
 Expand strategies to extend the breadth and depth of the network to provide 
greater opportunities for identifying participating organizations and individuals 
within those organizations responsible for relevant practice evaluations and 
quality improvement initiatives. 
 
 Maintain a network tracking database with strategic information to facilitate 
contacts, targeted follow-up as well as routine communication with network 
affiliates. 
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Organizational Development and Sustainability 
 Create a specific business plan for implementation and funding alternative 
models based on collaboration with key stakeholders. 
 Develop and implement communication, publication and other dissemination 
strategies based on collaboration with key stakeholders to optimize impact of 
evidence reviews and further the implementation of evidence-based methods 
and standards for quality improvement in laboratory medicine. 
Development of a process for assuring a pipeline of future topic areas and priorities for 
evidence reviews based on broad stakeholder engagement, including identification of 
appropriate evidence. 
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1.0 PROJECT OVERVIEW 
1.1 PURPOSE AND BACKGROUND 
Clinical laboratory services play a vital role in the delivery of individual health care and 
public health in the United States. The Department of Health and Human Services‘ 
(HHS) Centers for Medicare and Medicaid Services (CMS) certifies over 200,000 U.S. 
laboratories under the provisions of the Clinical Laboratory Improvement Amendments of 
1988 (CLIA).4 These laboratories provide more than 1,000 laboratory tests for human 
conditions, and about 500 of these tests are used daily. 
In response to the Institute of Medicine‘s call to improve quality in medicine (Institute of 
Medicine 2000, 2001), CDC‘s Division of Laboratory Science and Standards (DLSS) in 
the Office of Surveillance, Epidemiology, and Laboratory Science (OSELS) is supporting 
the development of a systematic, evidence-based process, based on transparent 
methods to identify best practices in laboratory medicine. This initiative targets the pre- 
and post-analytical phases of the laboratory total testing process (Barr and Silver 1994), 
as these phases encompass the majority of laboratory-related errors and opportunities 
for improvement. This effort began in October 2006, when CDC convened the 
Laboratory Medicine Best Practices Workgroup (LMBP Workgroup), a multidisciplinary 
advisory panel comprising experts in several fields of laboratory medicine, clinical 
medicine, health services research, and health care performance measurement. The 
LMBP Workgroup was supported by a team from DLSS and its contractor, the Battelle 
Centers for Public Health Research and Evaluation (Battelle). The overall goal of the 
effort is to develop methods for completing systematic evidence reviews and evaluations 
for making evidence-based ―best practice‖ recommendations for practices with 
demonstrated effectiveness to improve the quality of health care and patient outcomes. 
These evidence reviews and recommendations will assist professional organizations, 
government agencies, laboratory professionals, clinicians, and others, who provide, use, 
regulate, or pay for laboratory services to make decisions to improve health care quality 
based on evidence of effectiveness. 
To date, the LMBP methods development process has completed three phases. Phase 
1 (October 2006-September 2007) involved a ―proof of concept‖ test of an approach to 
searching, screening, and evaluating evidence as the basis for best practice 
recommendations. An outcome of Phase 1 was to act on a Workgroup recommendation 
and enlarge the search for evidence to unpublished assessments performed for the 
purposes of quality assurance, process improvement and/or accreditation 
documentation, and to adapt conventional systematic review methods to allow inclusion 
of unpublished quality improvement studies. Phase 2 (September 2007-November 2008) 
involved a pilot test of further refined methods to obtain, review, and evaluate published 
and unpublished evidence, along with collecting observations via key informant 
interviews about organizational and implementation issues successfully addressed by 
other recommending bodies about the development and dissemination of guidelines and 
recommendations. Phase 3 (September 2008-February 2010) used feedback and 
results obtained in Phase 2 to refine the data collection instruments and study rating 
methodology to better address the material available in laboratory medicine studies, 
                                                                
4 Centers for Medicare and Medicaid Services (http://www.cms.hhs.gov/clia/) [accessed February 1, 2010] 
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including meta-analysis of practice effect size. In addition, a standard cycle in evidence-
based medical practice reviews (Ask, Acquire, Appraise, Analyze, Apply, and Assess) 
was adapted by the project to introduce the ―A-6 Cycle,‖ to include an analysis step 
(Shaneyfelt et al. 2006). 
1.2 PHASE 3 OBJECTIVES 
More specifically, the project‘s Phase 3 had three objectives: 
 Refine, further develop and pilot test methods that had been evaluated initially in 
the proof of concept and initial pilot test phases. 
 Test the feasibility of developing a national network of facilities that would agree 
to furnish unpublished studies for use in quality improvement, practice-specific 
systematic evidence reviews. 
 Recommend an approach to implementing on a sustainable basis the process for 
systematic evidence reviews and identification of best practices for laboratory 
medicine, including developing a network of organizations to provide unpublished 
evidence. 
1.3 LABORATORY MEDICINE BEST PRACTICES WORKGROUP 
Continuing their work from the initial Proof-of-Concept phase, the LMBP Workgroup 
consists of 13 invited members, including two ex officio representatives from the Centers 
for Medicare and Medicaid Services (CMS) and the Food and Drug Administration 
(FDA). The Workgroup members are clinicians, pathologists, laboratorians, and 
specialists in systematic evidence reviews with recognized expertise in performance 
measurement, standard setting, and health services research. The Workgroup members‘ 
main functions are to provide overall guidance and feedback on developing review and 
evaluation methods for making evidence-based best practice recommendations. As the 
―Recommending Body‖ for the LMBP pilot test, the Workgroup reviewed, provided 
guidance and made recommendations on: 
– topic area selection and criteria for practice reviews (ask) 
– recruitment of Laboratory Medicine Best Practices Network affiliates for 
unpublished studies (acquire) 
– format and content for evidence summaries and draft corresponding best 
practice recommendations (analyze) prepared by Expert Panels and CDC 
/Battelle Review Team staff 
– evaluation methods (analyze) for producing evidence-based best practice 
recommendations 
– strategies and methods for presenting and disseminating recommendations 
(apply)  
– systematic evidence review methods used by Expert Panels and the 
CDC/Battelle Review Team to acquire, appraise and analyze published and 
unpublished studies 
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– strategies and alternatives for implementing an organizational structure for 
routine and sustainable use of the Laboratory Medicine Best Practices methods 
to produce systematic evidence reviews of laboratory medicine quality 
improvement practices 
1.4 ORGANIZATION OF THIS REPORT 
The following sections summarize work completed during Phase 3 and the LMBP 
methods using the ―A-6‖ cycle steps. Section 2 describes the selection of review topics, 
including selection criteria applied and the topics chosen. Section 3 outlines the 
systematic review methods developed and employed during Phase 2 and the pilot test, 
including the development of an analytic framework and one or more focused review 
questions(ASK); the search strategy for evidence from the published literature and  
unpublished sources (ACQUIRE); the screening of acquired studies then abstraction and 
standardization of information from individual studies (APPRAISE); the analysis and 
rating of an aggregated body of evidence (ANALYZE); and the translation of evidence-
based findings and  best practice recommendations into practice (APPLY). Section 4 
presents the pilot test results of the evidence reviews for practices associated with three 
topics, ―Patient Specimen Identification,‖ ―Critical Values Test Result Reporting and 
Communication,‖ and ―Blood Culture Contamination.‖ Section 5 reports Phase 3 findings 
about the need for further refinements in evidence collection, review and evaluation 
methods, enhancements needed in network development and outreach, and strategic 
goals for organizational development and implementation planning. A set of appendices 
is included; (A) lists the 2009 Workgroup members, (B) lists the three Evidence Review 
Panel members, (C) describes the roles and responsibilities of the Workgroup and 
Review panels, (D) details the literature search strategies used, (E) presents the detailed 
evidence review summaries and quality ratings, (F) provides the guidance given to 
panelists for rating study quality, and (G) the guidance given to panelists for rating effect 
size, and (H) the record structure and coding guidance for the data abstraction 
database. 
2.0 PHASE 3 TOPIC SELECTION 
For the purposes of the pilot phase, three topic areas were selected, based on the 
following criteria. To be selected, a topic area was required to: 
 address a defined quality issue/problem in laboratory medicine consistent with 
the six IOM healthcare quality aims (safety, timeliness, effectiveness, equity, 
efficiency, patient-centered), 
 be framed by at least one focused review question, 
 be associated with at least three potential practices that attempt to improve 
performance/quality outcomes related to the defined quality issue/problem, 
 have outcome measures of broad stakeholder interest that can be used to 
assess practice effectiveness, and 
 have evidence (studies/data) of practice effectiveness available from published 
sources and potentially from unpublished sources. 
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In consultation with the Workgroup, a decision was made to continue with the topic 
areas previously selected for use in the earlier Proof-of-Concept (Phase 1) and initial 
pilot test (Phase 2); (Patient Specimen Identification, and Communication of Critical 
Value Test Results), and to add a topic area (Blood Culture Contamination) that also met 
the selection criteria. 
2.1 TOPIC 1: PATIENT SPECIMEN IDENTIFICATION 
Quality Issue / Problem:  Patient specimen identification errors may contribute to 
adverse patient events and wasted resources. 
Review Question:  What are effective interventions/practices for reducing patient 
specimen and/or test result identification errors? 
Potential Interventions / Practices:  Earlier reviews of published and unpublished 
evidence indicated that sufficient evidence would likely be available to consider the 
effectiveness of one practice in two care settings: 
 Barcoding Systems - Electronic bar-coding on both patient and specimen used 
to establish positive identification of specimen as belonging to patient.  
 Point-of-Care-Testing Barcoding Systems - Automated patient and 
sample/test identification system when diagnostic testing is conducted using a 
testing device at or close to the patient.  
Possible Outcome Measures: 
 Specimen and/or test result identification errors (rates), and  
 Repeat testing (rates) due to ambiguous patient specimen/test result 
identification. 
2.2 TOPIC 2: COMMUNICATION OF CRITICAL VALUE LABORATORY TEST 
RESULTS  
Quality Issue/problem:  The reporting of critical/panic value laboratory test results that 
are incorrect, incomplete, and / or untimely can result in ineffective communication, 
which may contribute to patient adverse events.  
Review Question:  What practices are effective for timely and accurate communication 
of laboratory critical test results to responsible / licensed caregivers? 
Potential Interventions / Practices:  Earlier reviews of published and unpublished 
evidence indicated that sufficient evidence would likely be available to consider the 
effectiveness of two practices: 
 Automated notification of critical value test results via computerized alerting 
systems and/or personal electronic devices (e.g., alphanumeric pagers or SMS 
‗text‘ messaging), and  
 Customer Service (or ―Call‖) center. 
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Possible Outcome Measures: 
 Time  to receipt:  Documented time from laboratory confirmation of test result to 
caregiver receipt of result,  
 Time to treatment: Length of time from laboratory confirmation of critical result to 
resolution by clinical staff, and/or  
 Accuracy/error rate in confirmation of telephone-reported results. 
2.3 TOPIC 3: BLOOD CULTURE CONTAMINATION 
Quality Issue/problem:  Blood culture contamination may lead to false positive cultures 
that, in turn, lead to inappropriate follow-up and treatment 
Review Question:  What practices are effective for reducing blood culture 
contamination? 
Potential Interventions / Practices:  Initial reviews of published evidence indicated that 
sufficient evidence would likely be available to consider the effectiveness of three 
practices: 
 Dedicated Phlebotomy Teams: Staff certified draw blood for laboratory tests. 
 Pre-packaged Prep Kits: Pre-packaged aseptic supplies that are prepared in-
house or commercially purchased. 
 Venipuncture (vs. Intravenous Catheter):  Puncture of a vein through the skin to 
withdraw blood (vs. use of a thin flexible tube inserted into the body). 
Possible Outcome Measures: 
 Blood culture contamination rate – number and proportion of blood cultures 
growing contaminant organisms, and or  
 Positive Predictive Value (less direct outcome measure). 
3.0 SYSTEMATIC REVIEW METHODS 
This section summarizes the methods developed and piloted to collect, screen, review 
and evaluate evidence from published and unpublished sources. In Phase 3, the A5 
evidence-based laboratory medicine cycle (see, e.g., Price, Glenn, & Christenson, 2009) 
was adapted by including a sixth step (Analyze), to describe the review process used to 
identify best practices for laboratory medicine. The CDC-LMBP ―A6 cycle‖ steps are: 
(1) ASK a focused question(s) in the form of a quality issue problem statement;  
(2) ACQUIRE evidence by identifying sources and collecting potentially relevant 
studies;  
(3) APPRAISE studies by applying screening criteria then abstracting, standardizing 
and rating  information from included studies;  
(4) ANALYZE by rating the evidence base using meta-analytic techniques when 
feasible 
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a. Expert panels use the evidence summaries provided in Evidence 
Summary Tables and standardized findings to reach consensus on the 
study quality and effect size magnitude ratings to transparently translate 
the findings for each practice into a draft evidence-based 
recommendation; 
b. These evidence reviews become the basis for the practice 
recommendations reached by the Laboratory Medicine Best Practices 
Workgroup (serving in its capacity as the ―Recommending Body‖) 
(5) APPLY by disseminating evidence review findings and recommendations via 
peer-reviewed literature and other media, educational programs, and guidelines 
as appropriate, to influence and facilitate actual practice implementation to 
improve quality;  
(6) ASSESS practices to evaluate implementation performance outcomes/results to 
evaluate whether and to what extent quality improvement occurred, determine 
the applicability of practices to various settings or other important implementation 
characteristics, and consistent with continuous quality improvement, identify 
other quality issues that can be framed as new opportunities for asking questions 
that can be addressed by either new reviews and/or updated reviews to continue 
the cycle of improvement.  
 
FIGURE 1. THE EVIDENCE-BASED PRACTICE CYCLE ADAPTED FOR LABORATORY 
MEDICINE 
This general sequence of LMBP systematic review activities leading to 
recommendations is described in Figure 2 and essentially follows the sequence outlined 
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by Khan, ter Riet, Glanville et al. (2001) and those used by the Community Guide (Zaza, 
Briss, and Harris 2005) and US Preventive Services Task Force.5 
 
FIGURE 2. GENERAL SEQUENCE FOR FORMULATING EVIDENCE-BASED BEST 
PRACTICE RECOMMENDATIONS 
 
3.1 STEP 1 – ASK: DEVELOPING AN ANALYTIC FRAMEWORK 
The initial step of an evidence review once a topic area has been screened and selected 
is to ASK one or more focused questions in the form of a problem statement, and 
develop an analytic framework to clarify and define the scope of the review. The generic 
framework consists of a set of basic elements that correspond to the criteria used in 
selecting topics and relevant evidence for review. Completing an analytic framework is 
consistent with the Institute of Medicine definition of the quality of care (the degree to 
which health care services for individuals or populations increase the likelihood of 
desired health outcomes and are consistent with current professional knowledge) by 
characterizing a laboratory medicine topic as it relates to a quality issue in need of 
improvement. The analytic framework facilitates framing systematic review questions 
that can be addressed by evidence by specifying these elements: 
 Quality Issue / Problem that can be framed by: 
o Evidence of a defined quality gap that can be improved or prevented 
o Review Question (linking quality issue/gap, interventions/practices, and 
outcome measures); 
 Potential Interventions / Practices that may improve quality 
                                                                
5 For the most up-to-date overview of methods used by the US Preventive Services Task Force, consult the 
Agency for Healthcare Research and Quality (http://www.ahrq.gov/clinic/uspstmeth.htm) [accessed February 
1, 2010]. 
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 Outcome Measures (intermediate and health-related outcomes) of interest 
 Additional Harms and Benefits associated with implementing the 
intervention/practice 
 
FIGURE 3. LABORATORY MEDICINE BEST PRACTICES – BASIC ANALYTIC 
FRAMEWORK 
An initial analytic framework is based on a preliminary review of published literature, and 
is refined using additional information obtained as the evidence review progresses. 
Figures 4a, 4b, and 4c depict the analytic frameworks used to guide the three systematic 
reviews. 
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FIGURE 4A. ANALYTIC FRAMEWORK FOR PATIENT SPECIMEN IDENTIFICATION 
Review Question: What are effective interventions/practices for reducing patient specimen identification errors?  
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FIGURE 4B. ANALYTIC FRAMEWORK FOR CRITICAL VALUES REPORTING & COMMUNICATION 
 
Review Question: What practices are effective for timely and accurate communication of laboratory critical 
test results to responsible/ licensed caregivers? 
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FIGURE 4C. ANALYTIC FRAMEWORK FOR BLOOD CULTURE CONTAMINATION 
Review Question: What practices are effective for reducing blood culture contamination? 
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3.2 STEP 2 – ACQUIRE THE EVIDENCE  
3.2.1 PUBLISHED LITERATURE 
Consistent with established systematic review methods, ACQUIRING the evidence 
requires developing a search protocol applied to electronic databases, as well as other 
means and sources including hand searching of bibliographies, correspondence with 
experts in the field to identify published studies that assess candidate practices for each 
review topic. In each case, the review question(s) and analytic framework established in 
the ASK (A-1) step guided the selection of initial search terms (see Appendix D for 
details of the Phase 3 pilot test literature search strategies). 
Conducted with the assistance of a professional librarian, for all three topics the search 
strategy involved a comprehensive search of English-language literature published 
during or after 1996 using multiple databases and other strategies. These included: 
 PubMed, MedLine, CINAHL, BMJ Clinical Evidence, and Cochrane 
databases, 
 Professional guidelines electronic databases (AHRQ, Cumitech, CLSI, ISO, 
NACB), 
 Hand searching journals of relevance to the review topic, reports, conference 
proceedings, and technical reports, 
 Reference lists of relevant published studies, reviews, and other sources 
(e.g., reports, presentations, guidelines, standards), and 
 Key informants: consultation with Expert Panel and Workgroup members for 
relevant information sources.  
3.2.2 UNPUBLISHED EVIDENCE SEARCH 
One of the principal findings of the project‘s Proof-of-Concept (Phase 1) was that 
considerably more evidence might be available outside of the published and peer-
reviewed literature. It was observed that practices in laboratory medicine are not often 
subjected to experimental trials, controlled, or observational studies to assess their 
effectiveness before they are implemented. Such formal studies are hard to do, 
expensive, commonly impractical and thus difficult to justify. However, laboratories, 
hospitals, and other health care institutions often conduct less formal analyses and 
assessments of information that they collect routinely before and after they adopt new 
practices or change established practices, especially if the proposed changes involve 
reorganizing the way the laboratory works, changing management systems, or adding 
new resources (systems, instruments, people). Typically, these assessments are not 
called ―studies‖ or ―research‖, but they may be rigorous and objective evaluations of 
high-quality data and thus constitute evidence of practice effectiveness. A key Phase 2 
objective was to develop and implement methods for incorporating these unpublished 
practice assessments as studies in the systematic evidence reviews. As such, 
unpublished studies are reviewed and evaluated according to the same criteria and 
standards as published evidence. 
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Search methods implemented for unpublished evidence included the following steps: 
1. Obtained the support and endorsement of key stakeholder organizations to 
encourage clinical laboratories and healthcare organizations to participate in 
the pilot test. During Phase 3, endorsements were obtained from and 
presentations or materials soliciting participation were made available to the 
following organizations, their newsletters, and at the following meetings: 
a. Clinical Laboratory Management Association‘s ThinkLab 
b. American Society for Microbiology 
c. American Association for Clinical Chemistry 
d. American Society for Clinical Laboratory Science 
e. Clinical Laboratory Improvement Advisory Committee 
2. Identified facilities likely to have completed relevant assessments, based on: 
a. Conference papers or other public presentations 
b. Relevant publications that implied the author might have additional data 
beyond what was reported (e.g., more recent data, or data more 
encompassing in scope or care setting) 
c. Personal knowledge of our Workgroup members. 
3. For those facilities which had likely completed relevant assessments, 
identified and contacted a senior laboratory scientist, laboratory director, or 
other appropriate representatives (e.g., involved in patient safety, quality 
management, clinical research, regulatory/accreditation compliance) to 
describe the aims of the project and explore the circumstances under which 
the organization would consider participating in the pilot test. 
4. Provided additional information about the pilot test to the facility point-of-
contact to share with colleagues and obtain a preliminary assessment from 
the organization‘s Institutional Review Board (IRB) chair for release of 
previously completed studies with de-identified data. 
5. Extended a formal invitation to the organization, providing more general 
guidance about the type of information needed for unpublished studies. 
6. Established any formal confidentiality safeguards or conditions under which 
the information would be provided for the purposes of the pilot test of 
systematic review methods. 
7. Reviewed study information and other material received, and follow-up with 
additional information requests as needed. 
To minimize the burden on pilot test participants and maintain the consistency with 
published evidence, only previously completed studies were requested (i.e., no new 
data), and it was suggested that these studies may be derived from multiple sources, 
including internal assessments, case studies, Failure Mode and Effects Analyses 
(FMEA), and quality improvement studies. Facilities were also requested to provide data 
that contained no personal health information concerning patients. A commitment was 
made to de-identifying all data and studies submitted, and each facility offered the option 
to remain anonymous in the summaries describing pilot test findings. All organizations 
that requested anonymity when providing unpublished studies remained anonymous in 
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the final evidence summaries (Appendix E) used by the Expert Panels and the 
Workgroup. 
Using this approach in Phase 3, initial exploratory discussions were held with 
representatives from 37 facilities (Step 3). Following these initial discussions, formal 
invitations were issued to 9 organizations (Step 5) to provide studies for each of the 
three topic areas (27 invitations in total), and 23 submissions were received. Ultimately, 
after subjecting the submissions to the same exclusion and inclusion criteria applied to 
published literature as detailed in the previous section, this approach resulted in about 
half (12) of the unpublished studies being included in the systematic review evidence 
base for the three topic areas (Patient Specimen Identification: 6; Critical Value Test 
Result Reporting: 4; Blood Culture Contamination: 2)  
3.3 STEP 3: APPRAISE – SCREEN, ABSTRACT AND STANDARDIZE  
LMBP review methodology includes the screening of all information obtained in the 
ACQUIRE step by two independent reviewers.  
Two reviewers independently screened information acquired from literature searches 
and from submitted unpublished studies by applying inclusion and exclusion criteria as 
detailed below. A pre-abstraction reference list of literature meeting the initial inclusion 
criteria was generated, indicating references that would be considered for full-text 
review.   
3.3.1 EXCLUSION CRITERIA 
Upon review of the title and abstract of an article or an unpublished submission, it was 
excluded if one or more of the following exclusion criteria were applicable.  
 No practice was assessed (i.e., no outcome measures were identified) 
 The practice was not sufficiently described 
 The content was a commentary or opinion piece 
3.3.2 INCLUSION CRITERIA 
An article or unpublished submission was included for a full-text review if at least one 
practice was described that appeared to satisfy all of the following inclusion criteria.  
 Relevant to the review question 
 Satisfied practice-specific criteria (characteristics and requirements) 
 In use and available for adoption 
 Reproducible in other comparable settings 
 Addresses a defined/definable group of patients 
 Has a potential impact on an outcome related to at least one of the following 
IOM healthcare quality aims: effectiveness, efficiency, patient-centeredness, 
safety, timeliness or equity 
Figures 5 a-c provides a summary of search and screening results for the LMBP Phase 
3 pilot test three topic areas. The list of 598 references included in the initial screening 
for Patient Specimen Identification, Figure 5a,  resulted in a total of 16 articles that met 
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the inclusion criteria for use in the systematic review and ultimately 9 that were included 
in the body of evidence. The list of 540 published references included in the initial 
screening for Communicating Critical Values, Figure 5b, ultimately resulted in a total of 5 
articles included in the body of evidence. 1677 published references concerning blood 
culture contamination ultimately yielded 14 articles that could be used (Figure 5c). While 
this rate of reduction may seem restrictive, it is quite consistent with rates observed in 
other systematic reviews (Horvath and Pewsner 2004:25-26). 
All studies meeting the screening criteria are then subject to full-text appraisal by 
abstracting and standardizing study information to prepare evidence summaries.  This 
compilation of individual studies related to a practice generates a body of evidence that 
is used by review staff and expert panelists to complete the ANALYSIS step. For each 
study, this process consists of (1) data abstractions to standardize study information, 
independently conducted by at least two reviewers; (2) a reconciliation and consensus of 
data abstractions where there was not complete agreement; (3) when appropriate, 
calculation of a standardized effect size for each individual study‘s observed effects 
(typically using either an Odds Ratio or Cohen‘s-d statistic, depending on the nature of 
the data), and (4) summarization and synthesis of the practice body of evidence in a 
standardized evidence summary table for used by the expert panelists to complete the 
practice evidence reviews and evaluations. Once each study was abstracted and the 
evidence rated, a summary Body of Evidence Table and graphic representation using 
forest plots of study results for each practice was created that summarized an overall 
summary effect across studies and overall consistency of studies included in the body of 
evidence (See Appendix E). 
FIGURE 5A-C. SEARCH RESULTS FOR PHASE 3 TOPIC AREAS  
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Figure 5b. Topic Area: Critical Value Reporting Literature Search Results 
 
 
Figure 5c. Topic Area: Blood Culture Contamination Literature Search Results 
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3.3.3 DATA ABSTRACTION AND EVIDENCE SUMMARY 
Published and unpublished studies are not reported in a uniform format, making it 
necessary to consistently abstract from each one the relevant information in a 
standardized form for the data elements required for evaluation of study quality and 
effect size. A primary goal of the data abstraction tool is to guide the systematic rating of 
study results so that standardized information is used to develop consistent, transparent 
and well-supported ratings for each study. To avoid biases, two reviewers are assigned 
to complete this abstraction task independently using a standardized abstraction form, 
and then compare their results. If any divergence appears, the reviewers discuss their 
rationale and arrive at a consensus result, at times with assistance from additional 
independent reviewers. Typically, such differences are due to ambiguous reporting on 
the part of the study authors, or that the study was completed to satisfy some objective 
other than answering the review question.  
In Phase 2, an electronic standardized data abstraction tool was developed to produce 
standardized data abstractions of the information required to make judgments of the four 
dimensions of study quality and evaluate effect size. In Phase 3, this data abstraction 
tool was refined to make the abstraction process more consistent across reviewers, the 
information abstracted more standardized and efficient and with respect to completion of 
the evidence summary tables and application of the study quality rating criteria. Detailed 
information on the data abstraction tool is provided in Appendix H – Data Abstraction 
Codebook. These improvements resulted in greater consistency of data abstraction 
results across studies, and a more transparent process of rating study quality and 
findings.  
The abstraction tool consists of five parts, one providing bibliographic information, and 
the others for assessing dimensions of study quality. These dimensions, and their 
component measures, were adapted from existing study quality rating instruments and 
theory to best capture the study and reporting conventions in typical laboratory medicine 
quality improvement studies. As such, they focus less on the internal validity of the study 
with respect to causal inference, and put greater weight on the accuracy of the evidence 
obtained from the methods and measures, assessment of sources and potential for bias 
from sources outside the practice being tested, and documentation of the generalizability 
of quality improvement study results. The items and guidance for recording and rating 
study quality data are reported in Appendix F. The main parts include: 
 Bibliographic information for published studies and other source information for 
unpublished studies 
 Study characteristics (design, sample, time period, care setting) that may be 
important for contextualizing the results, identifying study quality limitations, and 
for assessing the practice‘s applicability to a wide range of care settings 
 Practice characteristics, including what may be important for assessing the 
adequacy of practice description with respect to content, implementation, 
population / practice setting, staff, training, resource, process and functional 
requirements, and costs associated with implementing the practice.  
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 Outcome measure characteristics, that capture the accuracy and completeness 
of the evidence collected to estimate the impact of a practice on one or more 
outcomes. As studies often report more than one outcome associated with 
implementing a practice, in Phase 3 the convention of using statistical meta-
analysis to evaluate only the outcome(s) that most directly address the review 
question related to the IOM domains of healthcare quality (i.e., safe, timely, 
effective, patient-centered, efficient, and equitable) was employed. 
 Results, including findings for all applicable outcome measures reported, 
including both practice effectiveness/quality outcomes associated with IOM 
domains and findings related to practice applicability, cost, feasibility and 
implementation issues, and other harms and benefits. 
Once the data from each study were abstracted in detail, a less detailed Evidence 
Summary Table and draft ratings of the quality of evidence in each study part (along with 
a justification for the rating if points were deducted) for each was prepared to facilitate 
communication of study quality ratings. These Evidence summary tables are presented 
in Appendix E. 
3.3.4 STANDARDIZING THE EFFECT SIZE 
Little if any of the evidence available for the included practices was based on 
randomized designs. The typical LMBP study uses a pre-post one-group design. That is, 
the study provides an estimate for the outcome that resulted from a previous standard or 
―comparison‖ practice and an after-implementation estimate of the new or ―tested‖ 
practice on the same measure. Typical outcome measures include the practice error 
rate, the proportion meeting a timeliness threshold, receipt of appropriate care, time to 
acknowledge critical information. 
In contrast with controlled research, the comparison practice against which a new 
practice is tested likely varies across studies. This can affect the difference score (the 
finding) obtained as much as the new practice. When interpreting magnitude of effect, 
consideration is given to the actual practices being compared as well as the potential 
that other sources of influence (e.g., implementation, changes in practice setting, 
staffing, training, etc.) may distort the difference observed in a finding. In comparative 
effectiveness research, the findings represent the difference between practices as 
implemented in an uncontrolled natural setting. If there are great differences in the 
comparator practices contributing to an evidence summary the results obtained from the 
trial may not be representative of the impact of the new practice over a common base. 
This typically presents as a lack of consistency in findings given a common new practice. 
To facilitate comparability in evaluating diverse outcome measures and practice 
comparators, and aid reviewers in judging the magnitude of effect between a new/tested 
practice and a comparison practice, study results were transformed to a common metric 
(know generally as an ‗effect size‘). When outcome measurement represented a 
dichotomous outcome (e.g., presence or absence of a blood culture contaminant), odds 
ratios (or occasionally logged odds ratios) were calculated. When results from 
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continuous measures were being recorded (such as time to an event), Cohen‘s d was 
adopted to represent the findings.6  
(1) Odds Ratio (OR) compares the chance of an event occurring in one group versus 
another group (e.g., new/post-practice versus standard/pre-practice) for dichotomous 
outcomes (i.e., 2 possible outcomes such as yes/no; error/no error) and has the 
following interpretation: 
 OR > 1: new practice is more successful than the standard practice; the larger 
the number, the greater the relative success 
 OR = 1: new practice is equal to the standard practice,  
 OR<1: new practice is less successful than the standard practice; the smaller the 
number, the worse its relative success 
For example, OR = 1.5 means the tested practice is half again as successful as the old 
practice, OR = 2.0 means the tested practice is twice as successful as the standard 
practice, and OR 0.66 means the tested practice is two thirds as successful as the 
standard practice. The logged odds ratio is simply the log of the odds ratio and centers 
on zero instead of 1 (i.e., 0 = no difference, > 0 favors the tested practice, < 0 favors the 
standard (comparison) practice). 
(2) Cohen‘s d (d-score) is an estimate of the standardized mean difference between two 
practices when the underlying data are continuous. Many formulae exist to convert or 
transform reporting indices into Cohen‘s d, providing a common index on which to 
compare study results. The resulting effect size centers on zero and has the following 
interpretation:  
 d-score > 0: new practice is more successful than standard practice 
 d-score = 0: no differences between new practice and standard practice 
 d-score < 0: new practice is less successful than standard practice 
The further the d-score is from zero the more successful the practice is relative to the 
comparison practice when positive and the less successful when negative.  
3.3.5 RATING INDIVIDUAL STUDY QUALITY 
The evidence summary format is designed to provide the relevant content corresponding 
to the evaluation methods piloted in Phase 2 for rating individual study quality using four 
dimensions listed below. If all four dimensions receive the maximum number of points, 
the overall study quality rating for an individual study would be a ―10‖. Principles for 
making judgments and guidance on each of the rating criteria, including specific reasons 
for deducting points from the maximum, are provided for each dimension in the Guide to 
Rating Study Quality in Appendix F. 
Study (maximum of 3 points) 
                                                                
6 See Appendix G for the detailed formulas used to calculate effect sizes. 
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 Study design 
 Facility / setting 
 Time period 
 Sampling limitations (selection biases) 
 Appropriateness of comparator 
 
Practice (2 points maximum) 
 Description 
 Duration 
 Requirements (equipment, staff, training, costs) 
 
Outcome measure(s) (2 points maximum) 
 Description, relevance, and validity 
 Recording method reliability  
 
Findings/Results (3 points maximum) 
 Type of findings 
 Findings/effect size  
 Potential biases (uncontrolled deviations and results/conclusions bias) 
For each individual study concerning a particular practice, these dimensions can be 


















Study 1      
Study 2      
Study 3      
…      
Study N      
This 10-point scale supports the following categorical study quality ratings 
 Good: 8-10 points total (all four dimensions) 
 Fair: 5-7 points total 
 Poor: ≤ 4 points total 
 
A ―poor‖ quality rating indicates a study has significant flaws, implying biases that may 
invalidate results. Thus, individual studies with a ―poor‖ quality rating are excluded from 
consideration as evidence. 
 
3.4 EVALUATION METHODS AND USE OF EXPERT PANELS   
With the published and unpublished evidence collected, screened, abstracted, 
standardized and summarized by the CDC/Battelle LMBP Review Team, responsibility 
for completing the evaluation of the aggregate body of evidence was assigned to 
multidisciplinary Expert Panels selected for each review topic (see Appendix B for each 
panel‘s roster). The LMBP Expert Panels were asked to review the standardized practice 
evidence summary tables, individual study ratings, and forest plot figures for each study 
documenting the effectiveness of practices associated with their panel‘s topic area. They 
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used this information to reach consensus ratings for effect size, overall consistency and 
overall strength of evidence ratings.  From their evidence evaluations, the Expert Panels 
were then asked to draft an evidence-based recommendation regarding the adoption of 
the practice. The practice-specific evidence reviews, evaluations and draft 
recommendations for each practice were then reviewed by the Workgroup in their 
capacity as the pilot test recommending body. 
The Expert Panels included subject matter experts in the topic area, as well as experts 
in evidence review methods and in laboratory management. Experts were identified 
based on their publication record as well as involvement and leadership in relevant 
organizations and initiatives, particularly those considered key stakeholders for 
laboratory practice recommendations. In addition, for the purposes of the pilot test, like 
other evidence-based recommending organizations‘ methods, experts among the 
Workgroup were included as panelists to ensure support and continuity between the 
work of the Expert Panel and the Workgroup. By inviting individuals with expertise that 
were also associated with laboratory and professional organizations to serve as Expert 
Panelists, another objective was to increase and broaden the participant-observers in 
this stage of the pilot test. This facilitated making the development and testing of the 
methods transparent and accessible to a wider audience that can provide useful 
feedback about refinements that will benefit implementation planning for the evidence 
review process. 
3.5 STEP 4: ANALYZE – RATE THE BODY OF EVIDENCE 
The aggregate body of evidence generated in Step 3.  APPRAISE was analyzed after 
the abstracted and standardized information for individual studies were entered into a 
practice‘s Body of Evidence Table which includes each studies quality ratings across 
four quality dimensions (study characteristics, practice characteristics, outcome 
measures used and results observed).  Figure 6 provides a schematic of the overall 
approach that was used to analyze evidence from both the published and unpublished 
sources for a single practice. The approach involves four main steps leading to one of 
three practice implementation recommendations (i.e., for, against, and no 
recommendation for or against): 
1. Rating individual study quality (good, fair, poor), based on evaluating four 
dimensions (using a 10-point scale) 
a. Study characteristics 
b. Practice characteristics 
c. Measure(s) used 
d. Result(s) observed 
2. Rating the observed individual study effect size(s) categorically on magnitude 
(substantial, moderate, minimal/none) and relevance to the review question 
(direct, less direct, indirect)
FIGURE 6. INDIVIDUAL STUDY QUALITY AND EFFECT SIZE RATINGS ARE TRANSLATED INTO AN OVERALL RATING FOR 
EVIDENCE OF EFFECTIVENESS AND PROVIDE THE BASIS FOR A BEST PRACTICE RECOMMENDATION 
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3. Assessing the consistency of all studies’ (body of evidence) observed effect 
sizes based on direction and magnitude.  
4. Rating the overall strength of a body of evidence based on the total number of 
studies by their quality ratings and effect size ratings. 
Detailed guidance was provided to the Expert Panelists on how to characterize individual 
study quality according to the four analytical dimensions listed above (see Appendix F). 
3.5.1 EFFECT SIZE RATINGS 
Expert Panel members were asked to confirm the summary judgment for each observed 
effect size for each individual study in one of three categories: ―Substantial,‖ ―Moderate,‖ 
―Minimal/None.‖ In Phase 2, it was assumed that because these ratings are specific to 
topic areas, Expert Panel input would be necessary for specifying the value ranges 
associated with each category for the relevant outcome measures. In practice, this 
approach proved unwieldy as there are not necessarily evidence-based or otherwise 
available standards for estimating a clinically relevant impact of laboratory medicine pre- 
and post-analytic practices associated with a given topic area. Therefore, meta-analytic 
graphical displays (forest plots) of effect size magnitude and the 95% confidence 
intervals for that point estimate were adopted in Phase 3 and were used to make effect 
size rating decisions. In general, magnitude of the effect size was used to determine if 
the effect size was substantial, moderate, or minimal/none. The general guidelines for 
making this determination was: if the confidence interval did not include null (1 if logged 
odds ratios or d scores, 0 if odds ratio), then the finding was considered to be 
‗substantial;‘ If the confidence interval included zero, but the probability of impact was 
substantially positive, then the finding was considered to be ‗moderate;‘ effect sizes that 
centered on or near zero were considered ‗minimal/none.‘ An example of an effect size 
rating graph is provided in Figure 7. 
3.5.2 CONSISTENCY RATING 
As established by AHRQ (2007), consistency across individual studies for a given 
practice is measured as a dichotomous variable (i.e., ―consistent‖ or ―not consistent‖) 
based on similarity in reported effect sizes from studies included in a body of evidence 
for a given practice. A body of evidence for a given practice is considered ―consistent‖ if 
the evidence is all in the same direction and within a reasonably narrow range. For the 
evaluation methods, ―reasonability‖ is determined by consensus expert judgment as 
informed by the effect size meta-analysis results and graphic representation (forest plot). 
3.5.3 OVERALL STRENGTH OF A BODY OF EVIDENCE 
Four overall strength rating categories were established: ―High,‖ ―Moderate,‖ ―Suggestive 
(Low),‖ and ―Insufficient‖. Initially, these rating categories were defined in terms derived 
from Guyatt et al. (2008), which expressed the strength ratings in terms of how likely it is 
that additional evidence would change the confidence in the direction and general 
magnitude of the observed effect. The LMBP Workgroup recommended that the 
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category definitions be changed to reflect the quality of the evidence and effect size 
observed, rather than attempting to anticipate the impact of future potential evidence. 
FIGURE 7: EXAMPLE OF AN EFFECT SIZE RATING GRAPH: DEDICATED PHLEBOTOMY 
TEAMS 
Model Study name Subgroup within study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit
Weinbaum 1997 ** Combined 5.78 3.64 9.16
Sheppard 2008 ** N/A 4.83 1.53 15.28
Geisinger 2009 ** N/A 2.52 2.18 2.91
Gander 2009 ** N/A 2.51 1.84 3.43
Providence 2009 ** Combined 2.44 1.56 3.82
Surdulescu 1998 * N/A 2.09 1.68 2.61
Random 2.76 2.17 3.51
0.1 0.2 0.5 1 2 5 10
Favours ComparisonFavours DPT
Boxes proportional to weights
 
The revised definitions for these categories, modeled after the US Preventive Services 
Task Force (2008) are as follows: 
High: An adequate volume of evidence is available and includes consistent evidence of 
substantial healthcare quality changes from studies without major limitations. 
Moderate: Some evidence is available and includes consistent evidence of substantial 
healthcare quality changes from without major limitations. 
Suggestive: Limited evidence is available and includes consistent evidence of moderate 
healthcare quality changes from a small number of studies without major limitations; OR 
the quality of some of the studies‘ design and/or conduct is limited.  
Insufficient: Any estimate of an effect is very uncertain. Available evidence of 
effectiveness is:  
– Inconsistent or weak; OR 
– Consistent but with a minimal effect; OR 
– Contained in an inadequate volume to determine effectiveness 
As shown in Table 1 below, in Phase 3 the overall strength rating was derived from a 
minimum required number of studies with the various categorical ratings for individual 
study quality and effect size assigned by consensus of the Expert Panelists. Note that 
the ―High,‖ ―Moderate,‖ and ―Suggestive‖ effect size ratings require ―consistency‖ across 
studies included in a practice evidence base as discussed above. For example, to 
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achieve an overall strength rating of ―high,‖ a body of evidence would have to include at 
least three studies with a quality rating of ―good‖ that also have an effect size rating of 
―substantial‖ for the relevant outcome measures. To achieve a ―moderate‖ strength 
rating, a body of evidence would have to include EITHER (1) at least two studies with a 
quality rating of ―good‖ that also have an effect size rating of ―substantial,‖ OR (2) at 
least three studies with a quality rating of ―good‖ and an effect size rating of ―moderate.‖ 
TABLE 1. OVERALL EVIDENCE OF EFFECTIVENESS STRENGTH RATING 
 
Strength Ratings Combined Evidence Minimum Criteria 










































3.5.4 ROLE OF EXPERT OPINION 
While it is acknowledged that judgment is necessary for the evaluation and interpretation 
of all evidence regardless of quality, rating systems that classify ―expert opinion‖ as a 
category of evidence create confusion. Simple evidence grading systems facilitate 
incorporating the expert judgment of multiple perspectives, ideally representing all 
relevant stakeholders, by applying detailed and explicit criteria for rating or grading 
evidence quality, effect size, net impact, and overall strength to make the judgments 
transparent (Guyatt et al. 2008). For the purposes of the LMBP Phase 3 practice 
evidence reviews, ―expert opinion‖ about the effectiveness of a given practice is not 
considered evidence, and is excluded from a practice‘s evidence of effectiveness; only 
measured effectiveness is explicitly considered as evidence. The LMBP methods in their 
entirety and the exclusion from evidence of expert opinion of practice effectiveness in 
particular, are consistent with making the LMBP evidence review findings, and hence 
recommendations based on those findings, satisfying a transparent standard of being 
―evidence-based.‖ It is acknowledged that there may be some instances in which 
systematic measures are simply unavailable, in which case structured interpretive 
decision-making models (e.g., the Delphi process) may be used (Thomson et al. 2009). 
However, the results of applying such models are qualitatively different from evidence 
based on systematically organized observations and measurements.  
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3.6 METHODS FOR BEST PRACTICE RECOMMENDATIONS & ADDITIONAL 
CONSIDERATIONS 
Each overall LMBP rating category for the overall strength of a body of evidence 
translates into one of three rating categories.  In Phase 2, the LMBP Methods 
Development Team initially proposed four categories of recommendations: ―Strongly 
recommend,‖ ―Recommend,‖ ―No recommendation for or against,‖ and ―Recommend 
against.‖ However, it was found in practice that based on available evidence from both 
published and unpublished sources, it is difficult to distinguish between the first two 
(―Strongly recommend‖ and ―Recommend‖). It was also found that a number of different 
conditions could result in a ―No recommendation for or against‖ finding (e.g., too few 
studies with substantial or moderate effect size, or the available studies are of relatively 
modest quantity and/or quality, or the available studies consistently show an effect size 
of ‗minimal/none‘). To make the recommendations more useful and informative, and less 
ambiguous, the LMBP Workgroup recommended further refinements to simplify the 
recommendation categories by limiting the number to three, with constructive 
explanations detailing multiple categorical yet distinct reasons supporting its application. 
3.6.1 RECOMMENDATION CATEGORIES 
Following the Workgroup‘s guidance, the recommendation rating categories, consistent 
with the GRADE group findings (2008), reflect the extent to which the available evidence 
gives one confidence that a practice will do more good than harm: 
Recommend: The practice should be identified as a best practice for implementation in 
appropriate care settings, taking into account variations in implementation and/or care 
settings. This recommendation results from consistent and high or moderate overall 
evidence of effectiveness strength rating of desirable impacts. 
No recommendation for or against: The potentially favorable impact on care outcomes 
and/or error reduction is not sufficient, or not sufficiently supported by evidence to 
indicate that it should be identified as a best practice for implementation in appropriate 
care settings. Additional studies may be warranted to strengthen the relevant evidence 
base. This recommendation results from insufficient evidence to determine 
effectiveness. 
Recommend against: The practice should not be identified as a best practice for 
implementation because of consistent evidence of adverse effects. 
 
3.6.2 ADDITIONAL CONSIDERATIONS 
An important distinction can be made between evidence of effectiveness and evidence 
concerning other aspects of implementation, such as feasibility, costs, applicability to 
specific care settings, and other harms and benefits. In Phase 2 if studies were eligible 
for inclusion in the systematic review, implementation-related evidence was included in 
the Recommendation when it was available. In Phase 3, however, these additional 
considerations were not included in the Recommendation as it was observed that the 
evidence review did not systematically search for or record evidence on these additional 
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considerations beyond what was documented in the effectiveness literature, It is 
recommended in future reviews that such evidence be systematically included and 
incorporated in practice recommendations. Such evidence may be reported as: 
- Feasibility of Implementation: Whether the practice is in current use and 
available for immediate application, whether it is able to be used in a variety of 
inpatient and/or outpatient settings, and whether significant barriers to 
implementation have been identified. 
- Economic Evaluation: The cost of implementing a practice, the savings that are 
achieved with implementation, and the results of any cost-effectiveness and/or 
cost-benefit assessments that have been completed. 
- Applicability to Specific Care Settings: Whether the practice is suitable for use 
across a range of inpatient and outpatient care settings, targeted for point-of-care 
testing, or other information relevant to the practice‘s applicability. 
- Associated Harms and Benefits: Whether implementing the practice has had 
observed impacts for patient satisfaction, provider satisfaction, ability to measure 
and monitor quality and process improvement, standardization of protocols 
across a healthcare network or system, or other outcomes that contribute to 
improvements in patient safety and healthcare quality. 
3.7 STEP 5: APPLY THE FINDINGS   
Step 5 of the LMBP methods refers to the dissemination of systematic review findings for 
translation of evidence-based findings into practice.  Dissemination plans for LMBP 
findings include peer-reviewed publications, press releases and presentations at 
scientific and professional meetings.  Access to LMBP evidence review summaries will 
also be available online.    
4.0 EVIDENCE REVIEW RESULTS 
Preliminary evidence reviews were completed in Phase 3 for Patient Specimen 
Identification, Critical Values Reporting and Communication, and Blood Culture 
Contamination. The following discussion summarizes the recommendations and 
preliminary evidence review findings for each practice meeting the review inclusion 
criteria, while Appendix E provides a more detailed evidence summary table for all 
studies included in the preliminary evidence review. 
4.1 PATIENT SPECIMEN IDENTIFICATION 
As noted earlier, practices associated with this topic area are designed to reduce patient 
specimen identification errors and assure positive patient specimen identification. 
Practices for which enough evidence was available from unpublished and published 
sources to be included in the evidence review are: 
 Point-of-Care Testing Bar Coding Systems - Automated patient and 
sample/test result identification system using bar-coded patient armbands 
and bar code scanners when using a testing device at or close to the patient. 
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 Bar Coding Systems - Electronic bar-coding on both patient and specimen 
used to establish positive identification of specimen as belonging to patient. 
This involves the use of scanners and capability to print labels. 
Table 2 summarizes the preliminary findings from the evidence review, including best 
practice recommendations. 
TABLE 2. EVIDENCE-BASED PRACTICE RECOMMENDATIONS: PATIENT 
SPECIMEN/TEST RESULT IDENTIFICATION  
 
Practice Recommendation Statement Preliminary Findings 
Point-of-Care Testing 
Bar Coding Systems 
(3 published studies and 
2 unpublished studies) 
The Laboratory Medicine Best Practices 
Workgroup recommends identifying the use 
of a bar coding process to consistently link 
patients and their specimen test results in 
point-of-care testing settings as a best 
practice to reduce or eliminate Patient 
Specimen/Test Result Identification errors.  
This is based on the strength of evidence for 
this practice and consistency of observed 
effects 
An adequate volume of 
evidence is available and 
includes consistent evidence 
of substantial healthcare and 
safety changes from studies 
without major limitations. (5 
studies, Odds Ratio =6.55, 
95% CI 3.1-14.0). 
Bar Coding Systems 
(4 published studies and 
4 unpublished studies) 
The Laboratory Medicine Best Practices 
Workgroup recommends identifying the use 
of a bar coding process to consistently link 
patients and their specimen through the 
entire testing process as a best practice to 
reduce or eliminate Patient Specimen 
Identification errors.  This is based on the 
strength of evidence for this practice and 
consistency of observed effects 
An adequate volume of 
evidence is available and 
includes consistent evidence 
of substantial healthcare and 
safety changes from studies 
without major limitations. (8 
studies, log odds ratio = 2.45, 
95% CI 1.6-3.3). 
 
4.2 CRITICAL VALUES REPORTING AND COMMUNICATION 
As noted earlier, practices associated with this topic area are designed to assure timely 
and accurate communication of critical value laboratory test results to the licensed 
responsible caregiver who can act on these results. Practices for which enough 
evidence was available from unpublished and published sources to be included in the 
evidence review are: 
 Automated Notification – Automated alerting system or computerized 
reminders using mobile phones, pagers, email or other personal electronic 
devices to alert clinician of critical laboratory test results. 
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 Call Center – Critical value notification process centralized in a unit 
responsible for communication of critical value laboratory test results to the 
licensed caregiver. 
Table 3 summarizes the preliminary findings from the evidence review, including best 
practice recommendations. 
 
TABLE 3. EVIDENCE-BASED PRACTICE RECOMMENDATIONS: CRITICAL VALUE 
TEST RESULT COMMUNICATION  
 
Practice Recommendation Statement Preliminary Findings 
Automated Notification 
(3 published studies) 
No Recommendation for or Against:  The 
Laboratory Medicine Best Practices 
Workgroup cannot recommend for or against 
identifying the use of automated notification 
as a best practice to improve the timeliness 
and accuracy of critical value reporting due 
to limited number of studies with good quality 
rating that would be necessary to make a 
recommendation. 
An insufficient volume of 
evidence is available of 
adequate quality showing a 
moderate or substantial 
improvement attributable to 
using this practice. (3 studies, 
Standard difference of means 
= 0.51, 95% CI -0.4 – 1.4) 
 
Call Center 
(1 published study, 2 
unpublished studies) 
No Recommendation for or Against:  The 
Laboratory Medicine Best Practices 
Workgroup cannot recommend for or against 
identifying the use of Call Centers as a best 
practice to improve the timeliness and 
accuracy of critical value reporting due to 
limited number of studies with good quality 
rating that would be necessary to make a 
recommendation. 
An insufficient volume of 
evidence is available of 
adequate quality showing a 
moderate or substantial 
improvement attributable to 
using this practice.  (3 studies, 
Standard difference of means 
= 0.81, 95% CI -0.52 – 2.15) 
 
4.3 BLOOD CULTURE CONTAMINATION 
As noted earlier, practices associated with this topic area are designed to reduce blood 
culture contamination. Practices for which enough evidence was available from 
unpublished and published sources to be included in the evidence review are: 
 Dedicated Phlebotomy Teams: Use of certified phlebotomists to draw blood 
specimens for laboratory tests. 
 Pre-packaged Prep Kits: Pre-packaged aseptic supplies that are prepared in-
house or commercially purchased. 
 Venipuncture vs. Intravenous catheter collection:  Puncture of a vein through 
the skin vs. use of a thin flexible tube inserted into the body to withdraw blood 
for analysis. 
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Table 4 summarizes the preliminary findings from the evidence review, including best 
practice recommendations. 
TABLE 4. EVIDENCE-BASED PRACTICE RECOMMENDATIONS:  BLOOD CULTURE 
CONTAMINATION  
Practice Recommendation Statement Preliminary Findings 
Venipuncture 
(7 published studies) 
Recommend: The Laboratory Medicine Best 
Practices Workgroup recommends 
identifying the use of venipuncture as the 
preferred technique for sample collection 
where the option exists in the clinical setting 
as a best practice to reduce or eliminate 
blood culture contamination. This is based 
on the strength of evidence for this practice 
and consistency of observed effects 
 
An adequate volume of 
evidence is available and 
includes consistent evidence 
of substantial healthcare and 
safety changes from studies 
without major limitations.  (7 
studies, Odds Ratio = 2.63, 
95% CI 1.85-3.72) 
Dedicated Phlebotomy 
Teams 
(4 published studies, 2 
unpublished studies) 
Recommend: The Laboratory Medicine Best 
Practices Workgroup recommends 
identifying the use of dedicated phlebotomy 
teams for sample collection where the option 
exist in the clinical setting as a best practice 
to reduce or eliminate blood culture 
contamination. This is based on the strength 
of evidence for this practice and consistency 
of observed effects 
 
An adequate volume of 
evidence is available and 
includes consistent evidence 
of substantial healthcare and 
safety changes from studies: 6 
studies without major 
limitations. (Odds Ratio = 2.76, 
95% CI 2.2-3.5) 
Pre-packaged Prep 
Kits 
(4 published studies) 
 
No recommendation for or against: The 
Laboratory Medicine Best Practices 
Workgroup cannot recommend for or against 
identifying the use of Commercial Prep Kits 
as a best practice to reduce blood culture 
contamination due to the limited 
improvement in effectiveness observed 
among the reported evidence. 
 
An adequate volume of 
evidence is available and 
includes consistent evidence 
of minimal healthcare and 
safety changes from studies 
without major limitations. (4 




The preliminary evidence reviews resulted in recommendations for identifying as ―best 
practices‖ two practices for Patient Specimen Identification, and two practices 
associated with reducing Blood Culture Contamination. No recommendation for or 
against one practice associated with reducing blood culture contamination based on an 
adequate amount of evidence suggesting this practice is not observed to represent a 
substantial improvement over standard practices. No recommendation for or against 
identifying two practices associated with critical values reporting could be reached due to 
insufficient evidence available. Plans for moving the systematic review process towards 
ongoing implementation will tackle directly an enhanced approach to collecting relevant 
evidence from unpublished sources, and will carry forward the practices from Phase 3 to 
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complete the evidence reviews for publication.   Only limited work to date has been 
completed on developing a process for reviewing implementation-related evidence 
(―additional considerations‖ in the Recommendation write-up).  Plans for moving the 
review process forward will also need to attend to enhancing and /or limiting the review 
of available evidence or information related to practical aspects as well. 
 
5.0 CONCLUSIONS 
Evidence review and evaluation methods developed and tested during this phase were 
substantially refined from the simplified approach that had been formulated in earlier 
project phases. Efforts to recruit facilities and healthcare organizations to participate in a 
network to provide unpublished evidence provided helpful insight into the factors that 
constrain and encourage participation. Phase 3 network efforts have demonstrated that 
recruitment success depends upon several critical factors, including contacts with facility 
representatives who are both knowledgeable and invested with appropriate decision-
making authority; appropriate formal letters of invitation and endorsement; information 
that meets the needs of relevant IRB chairs and other administrative review offices; 
assurances of confidentiality when requested. Characterization of the roles and 
responsibilities of the Workgroup, Expert Review Panels, and the staff support team 
evolved over the course of the Pilot Phase, helping CDC to further specify organizational 
requirements that must be met to support systematic evidence reviews and the 
production of best practice recommendations on an ongoing basis.  Validated LMBP 
systematic review methods are expected to be published in the peer-review literature. 
In moving towards sustained implementation, it is recommended that refinements and 
enhancements in the systematic evidence review process include some or all of the 
following activities. 
5.1 METHODS: TOPIC AREA SELECTION 
Refine and standardize the process by which systematic review topic areas are selected 
and associated candidate practices are nominated. Topic selection criteria established 
early in the Initiative‘s development still apply (burden of problem/quality gap; 
preventability, availability of existing knowledge, potential effectiveness, operational 
management, and potential economic benefit), but further refinements are needed in 
soliciting and responding to suggestions from the field. 
5.2 METHODS: ANALYTIC FRAMEWORK 
Refine and standardize methods for schematic representation of a topic area analytic 
framework for each review question including: 
 Formalize a process for establishing functional requirements for practices 
associated with a selected topic area. A ―process mapping‖ approach may 
help to outline work flows and common points of intervention at which 
practices can achieve improvements in healthcare quality outcomes.  
 Identify processes from domains of application outside of laboratory medicine 
that meet the same functional requirements, increasing the likelihood that 
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evidence of effectiveness from these other domains will be regarded as 
relevant to laboratory medicine practices. 
 
5.3 METHODS: SEARCH, SCREENING AND DATA ABSTRACTION METHODS 
Make further improvements to the review methods and electronic data abstraction tool 
including:   
 Refine, standardize, and document literature search strategy to generate 
relevant published materials in a broader array of journals and published 
conference proceedings. 
 Develop standardized search and reporting functions for reference and study 
databases 
 Improve guidance and standardization for screening and abstraction methods 
for reviewers 
 Refine reviewer/user interface enhancements for data abstraction 
 Structure and formatting of data abstraction template more directly linked with 
evidence summary templates and individual study evaluation criteria,  
 Further standardization of outcome measures, definitions, and their 
categorization to minimize topic area-specific programming and maximize 
comparability 
 Develop and implement standardized methods for screening and capturing 
non-effectiveness evidence related to feasibility of implementation, 
applicability, economic evaluation and harms and benefits and/or other newly 
developed criteria. 
5.4 METHODS: EVIDENCE SUMMARY AND EVALUATION 
 Finalize evidence summary presentation formats along with development of 
standardized content and terms to facilitate and ensure consistent 
evaluations, and when applicable statistical meta-analyses, and 
recommendation statements (for the LMBP topic area Expert Panels and 
Workgroup), and for publishing and disseminating evidence reviews and 
evidence-based recommendations. 
 Specify methods for including, evaluating and synthesizing additional non-
effectiveness evidence related to implementation feasibility, economic 
evaluation, applicability (settings, populations, contextual variables) and 
harms and benefits, incorporating concepts of external validity and internal 
validity. 
 Further refine protocols for nominating, selecting, and guiding the work of 
expert panelists so that panelists have a clear idea of their roles and 
responsibilities relative to the Recommending Body and support staff, and 
panel composition is adequately diversified to represent key stakeholders‘ 
perspectives to produce unbiased and scientific evidence reviews. 
 Further refine protocols for guiding the work of the LMBP Workgroup (or if not 
overlapping a Recommending Body) so that members of this body have a 
clear idea of their roles and responsibilities relative to the expert panelists 
and support staff. 
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5.5 NETWORK DEVELOPMENT FOR UNPUBLISHED EVIDENCE 
 Further develop the network as the principal source for unpublished 
evidence. Expanding and maintaining this network is essential to the future 
sustainability of an evidence-based laboratory medicine practice 
recommendations process, as the main challenge to its success remains 
insufficient published evidence. 
 Further refine guidance to network participants on informational requirements 
for submitting evidence. 
 Develop and implement an education / curriculum strategy that familiarizes 
laboratory managers with methods for improving the quality of unpublished 
process improvement / quality assurance studies so that data from these 
studies are consistently available to inform ―best practice‖ recommendations. 
 Expand strategies to extend the breadth and depth of the network to provide 
greater opportunities for identifying participating organizations and individuals 
within those organizations responsible for relevant practice evaluations and 
quality improvement initiatives. 
 
 Maintain a network tracking database with strategic information to facilitate 
contacts, targeted follow-up as well as routine communication with network 
affiliates. 
5.6 ORGANIZATIONAL DEVELOPMENT AND SUSTAINABILITY 
 Create a specific business plan for implementation and funding alternative models 
based on collaboration with key stakeholders 
 Develop and implement communication, publication and other dissemination 
strategies based on collaboration with key stakeholders to optimize impact of 
evidence reviews and further the implementation of evidence-based methods and 
standards for quality improvement in laboratory medicine. 
 Develop a process for assuring a pipeline of future topic areas and priorities for 
evidence reviews based on broad stakeholder engagement, including identification of 
appropriate evidence. 
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 Robert Christenson, PhD, DABCC, FACB (U Maryland Medical Center 
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 Lee Hilborne, MD, MPH (RAND / UCLA Medical School) 
 Kent Lewandrowski, MD, PhD (Harvard Medical School) 
 Mary Nix, MS, MT(ASCP)SBB 
(AHRQ)  
 Rick Panning, CLS(NCA), MBA (American Red Cross) 
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APPENDIX C. ROLES AND RESPONSIBILITIES OF WORKGROUP AND EXPERT 
PANELISTS 
The Laboratory Medicine Best Practices Workgroup 
Composition: 13 invited members, and two ex officio representatives from federal 
agencies (CMS and FDA); members are clinicians, pathologists, 
laboratorians, and specialists in systematic evidence reviews 
Main Functions: Provides overall guidance and feedback on developing review and 
evaluation methods for making evidence-based best practice 
recommendations.  As the ―Recommending Body‖ for the LMBP pilot 
test, the Workgroup reviews, provides guidance and makes 
recommendations on: 
– evaluation methods for producing evidence-based best practices 
recommendations  
– systematic evidence review methods used  by Expert Panel and 
CDC/Battelle Review team to synthesize published and 
unpublished studies  
– a format for evidence summaries and draft best practice 
recommendations prepared by Expert Panels and CDC /Battelle 
Review Team staff   
– strategies and methods for presenting and disseminating 
recommendations  
– strategies and alternatives for implementation of an 
organizational support for Laboratory Medicine Best Practices 
methods 
– recruitment of Laboratory Medicine Best Practices Network 
affiliates for unpublished studies 
– topic area selection and criteria for practice reviews  
Expert Panels 
Composition: Each topic area Expert Panel will have 7-9 panelists, including: 
– 2-3 Work Group members with relevant topic area content 
expertise 
– 2-3 topic area content experts who are not Work Group 
members 
– 1 specialist in evidence review methods 
– 2 specialists in laboratory management, including administrative 
and laboratorian specialties 
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Main Functions: The Expert Panels are assembled for the specific purpose of providing 
completing evidence reviews, although during the pilot test they are also 
asked to provide guidance and feedback on the systematic review 
methods for the collection and synthesis of published and unpublished 
evidence for a given topic area. The members of each panel will: 
- review and provide guidance on pilot test strategy prepared by the 
CDC/Battelle Review team  including topic area analytic framework 
and review questions, inclusion and exclusion criteria, search, 
abstraction, review and evaluation methods applied to the published 
and unpublished evidence  
- select practices and formulate descriptions and parameters for the 
evidence review including identification of relevant outcome 
measures for evaluating practice effectiveness and feasibility of 
implementation with support from the CDC/Battelle Review  Team 
staff  
- review the preliminary practice evidence summaries  developed 
using the evidence collection, screening, abstraction and review 
methods 
- apply and provide feedback on evaluation methods developed  by 
the CDC/Battelle Review Team to produce ratings for individual 
study quality and effect size 
- reach consensus on topic area evidence review quality and effect 
size rating categories, consistent with the evidence summary format  
- evaluate individual practices‘ overall strength of evidence, effect size 
consistency (i.e., direction and magnitude)   
- develop final draft practice evidence summaries and draft 
recommendations to be presented to the LMBP Workgroup   
- provide feedback to the Review Team concerning limitations of the 
evidence review process and possible improvements 
CDC / Battelle Team 
Composition: CDC Project Director, Task Leader for LMBP Methods Development, 
Task Leader for Network Development and Organizational 
Requirements, evidence review specialists, communications specialist – 
each CDC role has a Battelle counterpart. 
Main Functions: The Team‘s work spans several functions, including: 
Methods Development 
- developing protocols for  identification and selection of topics 
and associated practices 
- developing analytic frameworks linking outcomes with practices 
and the healthcare quality issues / patient safety problems they 
are intended to address 
- developing protocols for collecting published and unpublished 
practice-related evidence  
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- developing protocols for systematically collecting, reviewing and 
synthesizing  published and unpublished evidence  
- developing criteria for evaluating and rating practice-specific 
evidence  including individual study quality, effect size, consistency 
of individual study findings, overall strength of a body of evidence, 
and other implementation considerations such as cost and feasibility  
Literature Search 
- Developing and presenting search strategies, review criteria and 
work plans to conduct a systematic literature search and review 
of search results  
- Conducting the literature search and results review  
- Summarizing and maintaining a record of the literature search 
results  
Network Recruitment & Unpublished Evidence Harvest 
- Identifying and contacting potential facilities and organizations  
willing to share relevant unpublished practice 
studies/assessments 
- Providing sufficient information about the purpose and conduct of 
the evidence reviews to facilitate a network candidate‘s internal 
administrative review of CDC‘s invitation to participate 
- Maintaining a complete database of recruitment efforts, including 
a record of recruitment outcomes 
- Obtaining and cataloguing unpublished materials received  
 
Evidence Screening and Review 
- Applying screening (inclusion and exclusion) criteria to published 
search results and unpublished information received  
- For unpublished evidence, obtaining additional information and 
clarification as needed when documentation is incomplete 
- Maintaining an accurate record of screening dispositions 
- Completing a standardized format summarizing information from 
published and unpublished sources 
- Abstracting relevant information from document sources for 
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Expert Panel Facilitation 
The CDC/Battelle Team facilitates the work of each topic area Expert 
Panel: 
- ensuring that the panelists have the materials they need to 
complete the evidence review  
 
- facilitating Panel discussions 
 
- preparing written summaries of Panel discussions  
 
- drafting evidence summary, recommendations, and other 
supporting documentation  
 
- providing other coordination activities as needed to promote a 
transparent, systematic, and objective review of available 
evidence 
Workgroup Facilitation 
The CDC/Battelle Team facilitates the Workgroup‘s involvement by: 
- ensuring that the Workgroup members have the materials 
they need to provide timely feedback and recommendations 
on methods development and implementation strategy 
- keeping the Workgroup apprised of the LMBP work plan and 
progress on methods development and pilot test 
implementation 
- scheduling, coordinating, and preparing written summaries 
of regular Workgroup meetings 
Organizational Development Planning 
The CDC/Battelle Team is evaluating organizational development needs 
for implementing the LMBP evidence review and evaluation methods for 
making evidence-based recommendations 
- Attributes and Features of Similar Efforts 
- Organizational Structure and Governance 
- Requirements for getting started 
- Requirements for long-term sustainability 
- Effective approaches to disseminating recommendations 
Documentation and Dissemination 
The CDC/Battelle Team is responsible for 
- documenting the implementation and outcomes of the pilot 
test 
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- creating and disseminating information about the systematic 
evidence review and evaluation methods used and the 
evidence-based recommendations formulated 
- receiving and summarizing feedback from key stakeholders 
about LMBP methods and best practice recommendations. 
60 
 
APPENDIX D. LITERATURE SEARCH STRATEGIES 
Topic Area:  Patient/Specimen Identification Errors 
Purpose: To identify candidate practices for accurate patient/specimen identification 
and characterize specific process attributes. 
Review Question: What are effective interventions/practices for reducing 
patient/specimen identification errors? 
Search Strategy:   Focus on identifying relevant published literature that 
categorizes/defines identification errors and/or identifies potential interventions/practices 
to reduce identification errors.  Information sources are to be screened by the CDC 
Review Team to select articles/other literature for full-text review.   
A comprehensive search of English language literature published during or after 1995 
using multiple databases and other strategies.  These include: 
a. PubMed, MedLine, CINAHL, and Cochrane databases 
b. Professional guidelines electronic databases (CLSI, ISO, NACB) 
c. Hand searching journals of relevance to the review topic, reports, conference 
proceedings, and technical reports.  
d. Reference lists of relevant reviews 
e. Key informants: consultation with sub workgroup for relevant information sources  
The title/abstract of the article should address: 
a. A bar-coding technology implemented to establish positive identification 
of patients, and/or laboratory test orders and results,  
b. Technology system components that interface with electronic medical 
and/or laboratory information systems, 
c.  Assessment or monitoring of bar-coding system,   
d. Identified outcome measure.  
At least two reviewers will independently screen the search results by applying exclusion 
criteria.    
A pre-abstraction reference list of literature will be generated. 
Initial Search Terms (results) 
 Laboratory identification errors (187)* 
 Identification errors AND patient AND specimen (25)*** 
 Laboratories AND identification systems AND specimen misidentification (0)* 
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 Specimen labeling errors (11)*** 
 Information systems AND hospitals AND reduce identification errors (4)*** 
*date/language exclusion criteria applied 
**duplicate records removed 
***both date/language exclusion and duplicate records removed 
 
Additional Search Terms 
 Patient specimen identification ((260)*** 
 Patient specimen identification errors (0)*** 
 Laboratory interventions to reduce identification errors (0) 
 Laboratory methods to reduce identification errors (0)** 
 Laboratory practices to reduce identification errors (0)** 
 Laboratory strategies to reduce identification errors (0)** 
 Reduce patient specimen identification errors (0)** 
 Reducing patient specimen identification errors (0)** 
 Practices for reducing patient specimen identification errors (0)** 
 Strategies to reduce patient specimen identification errors (0)** 
 Methods to reduce patient specimen identification errors (0)** 
 Practices AND strategies to reduce patient specimen identification errors (0) 
 Strategies to reduce identification errors (10)*** 
 Practices AND strategies to reduce identification errors (0) 
 Practices to reduce identification errors (6)** 
 Practices to reduce patient specimen errors (2)** 
 Strategies to reduce patient specimen errors (0)** 
 Practices to reduce patient identification errors (0)** 
 Strategies to reduce patient identification errors (0)** 
 Practices to reduce specimen identification errors (0)** 
 Strategies to reduce specimen identification errors (0)** 
 
Phase 3 Final Report 62 
 Reducing patient identification errors (16)*** 
 Reducing specimen identification errors (2)** 
 Information systems AND laboratories AND reduce identification errors (0)** 
*date/language exclusion criteria applied 
**duplicate records removed 
***both date/language exclusion and duplicate records removed 
Exclusion Criteria 
 Upon review of the title/abstract, exclude the article only if  it can be determined 
that: 
o No practice was assessed (i.e., no outcome measures are identified) 
o The practice is not sufficiently described 
o The article is  a commentary or opinion piece  
Note to reviewers: It may not be apparent from the title and abstract if the exclusion 
criteria apply to the article. 
Reviews: Reviewers will screen full-text references and apply exclusion criteria to 
identify those to be included in full-text reviews. 
Reviewers will meet for consensus on references to be entered into the data abstraction 
database. 
Inclusion Criteria 
 The specific intervention/ practice identified in the literature: 
o Is in use and available for application 
o Can be performed and reproduced in other comparable patient care 
settings 
o Impacts a defined group of patients 
o Identifies a potential improvement in an outcome that can be related to at 
least one of the following aspects of patient care: effectiveness, 
efficiency, patient-centeredness, safety, timeliness or equity  
Data Abstraction: References identified for abstraction will be entered into the data 
abstraction database. 
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Topic Area: Communicating Critical Values 
Purpose: To identify peer-reviewed publications that assesses candidate practices for 
communication of critical values for laboratory tests. 
Review Question: What practices are effective for communicating laboratory critical 
value results to the licensed caregiver who can act on them? 
Search Strategy:   A comprehensive search of English language literature published 
during or after 1995 using multiple databases and other strategies.  These include: 
a. PubMed, MedLine, CINAHL, and Cochrane databases 
b. Professional guidelines electronic databases (CLSI, ISO, NACB) 
c. Hand searching journals of relevance to the review topic, reports, conference 
proceedings, and technical reports.  
d. Reference lists of relevant reviews 
e. Key informants: consultation with sub workgroup for relevant information sources  
The title/abstract of the article should address: 
a. A critical value reporting practice, 
b. Reporting or Communication of laboratory critical values/ critical test 
results, 
c. Technology to improve critical values reporting/improve processes in 
result reporting, 
d. Assessment/Monitoring of critical values reporting. 
At least two reviewers will independently screen the search results by applying initial 
inclusion/exclusion criteria.    
A pre-abstraction reference list of literature meeting the initial inclusion criteria will be 
generated indicating references for full-text review. 
Initial Search Terms 
 Communication of critical values in laboratory tests (29)  
 Communicating critical values in laboratory tests (0)*  
 Communicating critical values (12)***  
 Critical value reporting (95)***  
 Critical value identification (364)***  
 Critical value identification AND reporting (0)**  
 * date/language exclusion criteria applied 
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**duplicate records removed 
***both date/language exclusion and duplicate records removed 
 
Initial Inclusion/Exclusion Criteria  
Initial inclusion criteria 
 The title/abstract of the article addresses: 
o A critical value reporting practice 
o Reporting or Communication of laboratory critical values/ critical test 
results 
o Technology to improve critical values reporting/improve processes in 
result reporting 
o Assessment/Monitoring of critical values reporting  
Inclusion Criteria: 
 At the minimum, the published information source should be an observational or 
descriptive study that describes pre-analytic practices of reporting and/or 
communicating critical values from laboratory tests to patient care setting. 
 The specific intervention/ practice identified in the literature: 
o Is in use and available for application 
o Can be performed and reproduced in other comparable patient care 
settings 
o Impacts a defined group of patients 
o Identifies a potential improvement in an outcome that can be related to at 
least one of the following aspects of patient care: effectiveness, 
efficiency, patient-centeredness, safety, timeliness or equity  
 
Initial exclusion criteria 
 Upon review of the title/abstract, exclude the article only if  it can be determined 
that: 
o No practice was assessed (i.e., no outcome measures are identified) 
o The practice is not sufficiently described 
o The article is  a commentary or opinion piece  
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Note to reviewers: It may not be apparent from the title and abstract if the exclusion 
criteria apply to the article. 
Reviews: Reviewers will screen full-text references and apply inclusion/exclusion criteria 
to identify those to be included in the data abstraction database. 
Reviewers will meet for consensus on references to be entered into the data abstraction 
database. 
Inclusion/Exclusion Criteria  
References are to be excluded IF: 
 The reference is a commentary/opinion piece about critical values reporting 
 A post-analytic practice is not specified  
 The practice is not sufficiently described ( service, materials or policy 
implemented not described, how delivered/implemented not described)  
 No practice assessed ( no outcome measure is reported) 
 
Data Abstraction: References identified for abstraction will be entered into the data 
abstraction database. 
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Topic Area: Blood Culture Contamination 
Purpose: to identify candidate interventions/practices that are effective at reducing 
blood culture contamination. 
Review Question: What interventions/practices are effective at reducing blood culture 
contamination? 
Review Search Strategy: Focus on identifying relevant published and unpublished 
literature that categorizes/defines blood culture contamination and/or potential 
interventions/practices that reduce blood culture contamination. Information sources are 
to screened by the CDC Review Team to select articles/other literature for full-text 
review. 
A comprehensive search of English language literature published after 1995 to present 
using multiple databases and other strategies. These include:  
a. PubMed and Cochrane databases that often linked to related articles 
b. Professional guidelines electronic databases (Cumitech, CLSI, ISO, NACB) 
c. Hand searching journals of relevance to the review topic, reports, conference 
proceedings, and technical reports.  
d. Reference lists of relevant reviews 
e. Key informants: consultation with sub workgroup for relevant information sources  
The title/abstract of published articles should address: 
a. A blood culture contamination reduction practice, 
 
b. Reporting of blood culture contamination test results, 
 
c. Blood culture collection techniques aimed at reducing the blood culture 
contamination rates, 
 
d. Assessment/Monitoring of patient infection rate due to collection 
site/technique. 
Initial Search Terms 
 Blood culture contamination (1677)  
 Blood culture contamination rates(117) 
 Blood culture contamination laboratory tests results (9)*  
 Blood culture contamination indicators(50)***  
 Causes of blood culture contamination (0)***  
 Strategies to reduce blood culture contamination (15)*** 
 Proper site preparation procedure for blood culture collection (0)*** 
* date/language exclusion criteria applied 
**duplicate records removed 
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***both date/language exclusion and duplicate records removed 
 
Exclusion Criteria  
Upon review of the title/abstract, exclude the article if: 
- The title is not applicable to blood culture contamination   
- No practice was assessed (i.e., no outcome measures are identified) 
- The practice is not sufficiently described (service, materials or policy 
implemented not described, how delivered/implemented not described) 
- The article is a commentary or opinion piece that contains no specific 
information on costs, benefits, and/or implementation. 
Reviews: Reviewers will screen full-text articles, apply exclusion criteria and meet for 
consensus on references to be entered into the data abstraction database. 
Inclusion Criteria 
 At the minimum, the published information source should be an observational or 
descriptive study  
 The specific intervention/ practice identified in the literature: 
o Is in use and available for application 
o Can be performed and reproduced in other comparable patient care 
settings 
o Impacts a defined group of patients 
o Identifies a potential improvement in an outcome that can be related to at 
least one of the following aspects of patient care: effectiveness, 
efficiency, patient-centeredness, safety, timeliness or equity  
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
TOPIC AREA: Patient Specimen Identification 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 




Systems Study Practice Measures Results Total Rating       
Bologna 2002 2 2 2 2 8 Good Substantial 
Yes 
  
Hayden et al. 
2008 3 2 2 3 10 Good Substantial   
Killeen et al. 
2005 2 2 2 3 9 Good Substantial   
Sandler et al. 
2005 1 1 2 0 4 Poor n/a data insufficient   
Turner et al. 
2003 1 1 1 1 4 Poor n/a     
Zarbo et al. 
2009 2 2 2 3 9 Good Moderate   
Unpub A 
2009 3 1 1 2 7 Fair Substantial 5 Studies = Good/Substantial 
U of MN 
2009 1 2 1 1 5 Fair Substantial 1 Study = Good/Moderate 
U of WA 2 2 2 2 8 Good Substantial 2 Studies = Fair/Substantial 
LBJ 2009 2 2 2 2 8 Good Substantial 2 Studies = Poor/na 
                  
            High 
Evidence Summaries: Patient Specimen Identification 
Phase 3 Final Report 71 
Patient Specimen Identification: Bar Coding Systems 
 
Model Study name Statistics for each study Log odds ratio and 95% CI 
Log  Lower  Upper  
odds ratio limit limit 
U WA 2009 * 4.99 4.01 5.97 
U MN 2009 *+ 3.41 0.26 6.56 
Bologna 2002 ** 3.37 1.38 5.36 
Unpublished PSID A * 2.49 0.44 4.53 
Hayden 2008 ** 1.88 1.66 2.11 
LBJ General 2009 * 1.87 -1.02 4.77 
Killeen 2005 ** 1.65 0.89 2.41 
Zarbo 2009 ** 0.99 0.44 1.53 
Random 2.45 1.57 3.33 
-8.00 -4.00 0.00 4.00 8.00 
The sample size is reflected by the size of the rectangle; uncertainty (95% confidence interval) is represented by horizontal lines. 
The diamond is the overall effect size from pooling of the evidence.  Boxes are proportional to weights. 
**=”Good” Study Quality rating  
*=”Fair” Quality rating 
+=Variance Uncertain  Favors comparator   Favors barcoding   
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Bologna LJ (1) and Mutter M 
(1)  
- 2002 
- J Healthcare Information 
Manag. 
- [1] The Valley Hospital, 
Ridgewood NJ 
and 
Bologna LJ (1), Lind C (1), and 
Riggs RC (2) 
- 2002 
- Clin Leadersh Manag Rev.  
- [1] The Valley Hospital, 
Ridgewood NJ; 
[2] BD Strategies for Becton 
Dickinson, Franklin Lakes, NJ   
- Funding not reported 
- Design: Before-After 
- Facility/Setting: Valley Hospital, 
Ridgewood, NJ, >400 bed 
community hospital  
- Time period: 7/97-7/98 and 
1/2000-9/2000 (non-consecutive 
periods) 
- Population/Sample: Number of 
phlebotomies for 10 care centers: 
Before practice (1999): 69,432   
After practice (1– 9/2000): 59,490 
- Comparator: Combination of  
print and hand-written labels used 
- Study bias: none 
-Description:  Barcoding system; 
labels print at bedside;  
- Duration: 10 months (12/1999 – 
9/2000) 
- Training: not discussed 
- Staff/Other resources: Nursing 
supervisor, licensed medical 
practitioners, phlebotomists; 
portable label printers, BD System 
Software; bar-coded wristbands 
- Cost: not reported 








 - Recording Method: 
Internal Quality Control 
instrument 
- Pretest-Posttest  
- Findings/Effect Size:  
Error Rates for the 10 care centers: 
(1)  Incorrect/ incomplete label:  59%  
reduction 
pretest:  0.017% (12/69,432) 
posttest: 0.003% (1/59,490)  
 OR = 5.75 
 (2) Misidentified patients:  94% 
reduction, 
pretest:  0.049% (34/69,432) 
posttest: 0.003% (1/59,490) 
 OR = 29 (CI, 4 – 212) 
(3) Unnecessary phlebotomy:  89%  
reduction 
pretest:  0.027% (19/69,432) 
posttest: 0.003% (2/59,490) 
 OR = 16.01  
 
-  Statistical Significance/Test(s): 
not discussed 
-  Results/conclusion biases: None 
Quality Rating:  8 (Good) 
 (10 point maximum) 
 




Study (3 pts maximum): 2;  
-  Data collected during notably 
different time periods  
Practice (2 pts maximum): 2 
 
Outcome measures (2 
pts.  maximum): 2 
 
Results/findings (3 pts maximum): 
2;  
- No statistical test results provided  
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Hayden RT, Patterson DJ, Jay 
DW, Cross C, Dotson P, 
Possel RE, Srivastava DK, 
Mirro J, and Shenep JL. 
- 2008  
- Journal of Pediatrics 
- [St. Jude's Children's 
Research Hospital (multiple 
departments), Memphis, TN, 
USA 
- Funding: Partly self-financed; 
and supported by the 
American Lebanese Syrian 








- Design: Before-after 
- Facility/Setting: St. Jude 
Children's Research Hospital, 
pediatric cancer center with a high 
percentage of acutely ill patients; 
Memphis, TN 
- Time period: 36 months  (9/03-
8/06) 
- Sample:  
Pre-practice:  19,247 accessions 
(test order events) per month for 
12 mos. (9/03 – 8/04) 
Post-practice:  17,793 accessions 
per month for 12 mos. (9/05 -8/06)   
- Comparator: Not reported  
- Study bias: none 
- Description: Barcoding system 
using handheld data terminals 
(personal digital assistants, PDAs) 
with built in scanner that track and 
verify orders at the point of 
collection located in each inpatient 
room, each clinic and procedure 
room. 
Full implementation – 8/05.  
- Duration: 24 months   
- Training: Education provided 
using the ―train-the-trainer‖ 
approach 
- Staff/Other Resources: Nurses.  








- Outcome Measures: 
PSID Error Rate: 
Mislabeled samples (%) - 
mismatches between 
patient name and. 
specimen (wrong label or 
specimen collected from 
wrong patient). 
 
- Recording Methods: 






- Findings/Effect Size: 
84% reduction in PSID monthly mean 
error rate: 
Pre:   0.032% 
Post: 0.005%  
 OR = 6.58 (CI, 5.26 – 8.22) 
- Statistical Significance/Test(s):  
P<.001  
Nonparametric test, Post-hoc analysis 
with Wilcoxon rank sum test analysis.   
 
- Results/conclusion biases: 
Conclusions focus mostly on findings 
favorable to the practice described.  
 
 
Quality Rating: 9 (Good)  
(10 point maximum) 
 
Effect Size Magnitude 
 Rating: Substantial 
 
(Relevance:  Direct) 
 
Study (3 pts maximum): 2;   
-No comparator information 
provided 
Practice (2 pts maximum): 2 Outcome measures (2 
pts  maximum): 2 
 
Results/findings (3 pts maximum): 
3 
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Killeen JP, Chan TC, Jones K, 
and Guess DA 
- 2005 
- Academy of Emergency 
Medicine 
- University of California, San 
Diego, CA, USA 
- Funding: Self-financed  
 
 
- Design: Before-after 
- Facility/Setting: UCSD Medical 
Center, San Diego CA  
–Time Period: Two 6-month 
periods: 6 mos. pre-practice and 6 
mos. post-practice (dates not 
reported)  
- Sample: All Emergency 
Department (ED) patients seen 
during study period (annual 
census: 40,000) 
Total ED laboratory specimens: 
Pre-practice:   22,243 
Post-practice: 22,574 
- Comparator: Imprint stamp 
sticker labels on specimens and 
paper requisitions 
-Study bias: Unclear if the 6-
month periods being compared 




- Description: Barcoding system  
- Duration: 6 months duration; no 
dates provided  
-Training: not discussed 
- Staff/Other Resources: not 
discussed 
- Cost: not reported 
- Outcome Measure: 
PSID Error Rate - Number 
of misidentified, 
unlabeled, or mislabeled 
specimens / number of 
specimens (per 1000 
specimens) 
 




- Findings/Effect Size: 
Pretest : 2.56 per 1000 [CI: 1.94 to 
3.32]  (0.00256%); 57/22,243; ID 
errors: 41 mislabeled and 16 
unlabeled 
Posttest: 0.49 per 1000 [CI: 0.24 to 
0.87], (0.00049%); 11/22,574; ID 
errors:  8 mislabeled and 3 unlabeled. 
 
- Statistical Significance/ Test(s):  
p <.05 ; Chi-square test 
 OR = 5.21 (CI, 2.44 – 11.11) 
 
- Results/conclusion biases: 
 None reported 
Quality Rating:  9 (Good)  
(10 point maximum) 
 
Effect Size Magnitude 
 Rating: Substantial 
(Relevance: Less Direct) 
Study (3 pts maximum): 2;     
- Study/practice dates not 
provided 
 
Practice (2 pts maximum): 2 Outcome measures (2 
pts  maximum): 2 
 
Results/findings (3 pts maximum): 
3  
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Sandler SG, Langeberg A, and 
Dohnalek L. 
- 2005 
- Developmental Biology  
- Georgetown University 
Hospital (multiple 
departments), Washington DC, 
USA 
- Funding: Partially from the 
Greenspring Financial 
Insurance Limited (GFIL) 
- Design: Non-comparative study 
- Facility: Georgetown University 
Hospital, Northwest Washington, 
DC; 609-licensed bed, not-for-
profit, acute care teaching and 
research facility.  
- Study Setting:  "18-bed 
hematology-oncology-bone 
marrow transplant unit staffed by 
approximately 20 licensed 
registered nurses‖. 
- Time Period: 10/02- no end date 
provided 
- Sample: 125 tests, all blood 
samples and blood components 
for transfusions. 
-Comparator: Not reported 
- Study bias: Small sample size, 
no comparison data or complete 
time period provided.  The number 
of patients represented by 
transfusions is not reported. 
- Description: Barcoding system 
for transfusion linking patients’ 
wristbands with blood component 
labels. Consists of the hand-held 
PC/bar-code scanner with radio 
frequency port to a portable printer.  
Software checks for: (i) the 
operator's electronic signature 
(personal ID badge bar code); (ii) 
the patient's name and medical 
record # (wristband); (iii) the blood 
component (compatibility bar 
code); and (iv) the blood centre's 
whole blood # (blood bag bar 
code). 
- Duration: 10/02 - ?(no end date) 
- Training: provided during 1-hour 
session including written and 
instruction review on how to use 
the system. 
- Staff: Nurses  
- Cost: not reported 
- Outcome Measures: 
(1) Positive Identification 
rate Percentage  of 
patients, blood samples 
and blood components for 
transfusion positively and 
accurately identified 
(2) Number of correctly 
labeled samples - labels 
for blood sample tubes & 
certification forms legible 
with complete information 
 
- Recording Method: 
electronic medical record 
- Non-comparative Study, Time series 
(average): 
- Findings/Effect Size:  
(1) ―All (100%) patients, blood 
samples, and blood components for 
transfusion were positively and 
accurately identified.‖ 
(2) ―All (100%) bar-code-labeled blood 
sample tubes and certification forms 
were legible with complete 
information.  
- Stat. Significance/Test(s): None  
 
- Results/conclusions biases: The 
stated purpose was to focus on 
nurses who transfuse blood 
infrequently, yet no statistics 
presented for these results (suggest 
that these nurses perform more poorly 
than nurses who transfuse frequently).  
Results focused on subjective ratings. 
Quality Rating: 3 (Poor) 
 (10 point maximum) 
 
Effect Size Magnitude 




Study (3 pts maximum): 1;         
 - Complete study time period not 
reported 
- Transfusion study may be too 
distinctive to be generalizable  
Practice (2 pts maximum): 1; 
No practice duration specified  
Outcome measures (2 
pts  maximum): 1; 
Recording method is not 
adequately described. 
Results/findings (3 pts maximum): 
0 
-  Insufficient sample:  Statistical 
power not discussed and sample size 
too small 
- Data insufficient to allow effect size 
calculation(non comparative study)  
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Turner CL, Casband AC, 
Murphy MF [1] 
- Yr Published:  2003 
- Publication: Transfusion 
- [1] National Blood Service, 
John Radcliffe Hospital Oxford, 
UK 




- Design: Observational study  
- Facility/Setting Oxford Radcliffe 
Hospital, 1500 bed teaching 
hospital, Oxford, UK; Setting:  
Hematology outpatient clinic (later 
extended to hematology inpatient 
ward) 
- Study Period: Not reported 
- Sample: 
First unit RBC transfusions: 
Pre:  51  (48 blood prescribed) 
Post: 51. (45 blood prescribed)  
Sample collection: 
Pre:  30; Post: 30 
- Comparator: Standard system 
without barcoding (checking and 
administering blood total process 
of 27 defined steps; sample 
collection process 17 steps); 
manual checking/verification of 
patient information on patient 
wristband and patient chart  
- Barcoding system using hand-
held computers for scanning pdf 
barcodes, generates barcoded 
wristbands and labels via portable 
printer for crossmatch with blood 
administration and sample 
collection process verification steps 
at the patient bedside.  Checking 
and administering blood total 
process of 16 defined steps; 
sample collection process 8 steps.   
- Duration: Not provided  
- Training: Education/training on 
transfusion safety and use of the 
barcode system was provided to 
staff 
- Staff: Phlebotomists, blood bank 
receptionists, IT, the blood bank 
(Note:  Staff preferred the new 
technology once familiar with it) 
- Cost: Initial equipment/support ~ 
$1.2 million (US$ 2003) 
- Outcome Measures: 
Blood administration (pre-
transfusion) – Percent 
correct performance of 
blood pack bedside 
check: (1) Patient’s ID 
(surname, first name, date 
of birth, sex, and hospital 
number).  
(2) Cross ref. of blood 
group, unit #,compatibility 
label, expiration date, 
patient’s prescription & 
transfusion report form 
special requirements  
(3) Sample collection: 
Percent sample tubes 
labeled immediately with 
hospital number,  
surname, first name, date 
of birth, sex, sample date 
- Recording Method: 
Audits/direct observations  
- Pretest-Posttest: 
- Findings/Effect Size:  
(1) Blood admin. patient ID  check: 
Pre:   100% (51 /51)   
Post:  100% (51 /51) 
0% improvement 
(2) Blood admin. cross reference 
check: Pre:   9.8% ( 5/51)   
Post:  41.2% (21 /51) 
30.4% improvement 
p-value : 0.0005 (Table 2, p. 1205) 
(3) Sample collection labels - patient 
ID -Pre:  50% (15/30) 
Post:  100% (30/30) 
50% improvement 
p-value:  <0.0001  (Table 4, p. 1206) 
- Stat. Significance/Test(s):  
Stat. analysis using exact tests of 
independent proportions 
-Biases: Study period not reported, 
small sample, barcoding system 
reinforced with education and training 
Quality Rating: 4 ( Poor) 
 (10 point maximum) 
 
Effect Size Magnitude 
 Rating: N/A 
 
(Relevance: Indirect)  
Study (3 pts maximum): 1;     
- Transfusion study may be too 
distinctive to be generalizable 
- Study design, time period and 
sample selection methods may 
introduce bias affecting results  
Practice (2 pts maximum): 1; 
-  Important 
practice/implementation 
characteristic (dates/duration) not 
identified 
Outcome measures (2 
pts maximum): 1; 
-  Process compliance 
outcome measures only 
modestly related to 
evidence review question 
Results/findings (3 pts maximum): 
1; 
- Potentially insufficient sample: 
measurement period; # of subjects not 
reported; sample size 
 - Staff training may impact effect size; 
not clearly attributable to barcoding 
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Zarbo RJ, Tuthill JM, D'Angelo 
R, Varney R, Mahar B, 
Neuman C, Ormsby A. 
-  2009 
- Am J Clin Pathol 
- Department of Pathology, 
Henry Ford Hospital, Detroit, 
MI. 
- Funding: Not reported  
 
  
- Design: Before-after 
- Facility: Henry Ford Hospital, 
Detroit, MI. 
- Study Setting: Surgical 
Pathology lab gross room  
- Time Period: Two 3-week 
periods:  Pre: 7/06; Post:  8/07 
- Sample:  
Cases: 
Pre:   2,694; Post: 2,877 
Specimen parts: 
Pre: 4,413; Post: 4,725 
Tissue cassettes: 
Pre: 8,776; Post: 9,167 
Histology slides: 
Pre: 14,270; Post:17,927  
 - Comparator:  Simple-logic, bar-
coded slide label only (2006); 
specimen accessioning and 
processing completed by manual 
entry of information and hand 
written labels on specimen 
cassettes and slides. 
- Barcoding system and process 
redesign to standardize workflow  
using a complex-logic, bar-coded 
pathway tying together 4 work cells 
to provide computer-readable 
encoding for identification of parts, 
and accession, gross dissection, 
histology/microtomy, and pathology 
sign-out stations.  Also includes 
manual quality control checks at 
each station to ensure case 
integrity before processing, and 
barcoding  in all subsequent 
processes (2007 implementation) 
- Duration: 3 weeks - July 2007 
  - Training:  Group education 
session, ensuring all staff members 
were in unison on the goals and 
time frame of the data collection 
and how to use the visual data 
display 
- Staff: Surgical pathology, 
histology and informatics staff 
- Cost: Not reported 
- Outcome Measures: 
Patient specimen 
identification (PSID) error 
rates  
(1) Surgical cases 
(2) Specimen parts – 
mismatch between 
pathology requisition and 
patient information 
(3) tissue cassettes – 
mismatch between 
cassette ID and lab tag 
information  
(4) histology slide labels 
 
- Recording Method:  
Data collected, recorded 
and defects categorized 
by 59 surgical pathology 
personnel ( 21 senior staff 
and 38 technical staff), 
using a visual data display 
collection tool (details on 
page 469) 
- Pretest-Posttest 
- Findings/Effect Size: PSID error 
rates(1) Surgical cases: 
Pre (2006): 1.67% (45/2,694) 
Post: (2007):0.63%  (18/2,877) 
 62.3% reduction; p-value:  <.001 
 OR = 2.68 (CI, 1.55 – 4.63) 
(2) Specimen parts  
Pre ( 2006): 0.23% (10 /4,413)  
Post ( 2007): 0.38%, (18 /4,725)  
Not statistically significant  
(3) Tissue cassettes  
Pre (2006): 0.057% (5 errors/8,776)  
Post (2007): 0.055% (5 errors/9,167) 
3.5% reduction; Not statistically sign.  
(4) Histology slide labels 
Pre( 2006): 0.21%, (30 errors/14,270)  
Post ( 2007): 0.01% (2 errors/17,927)  
95% reduction; p-value  <.001 
- Stat. Significance/Test(s):  
χ2 tests (Fisher exact test adjusted for 
small counts and Mantel-Haenszel 
test) to 2 data sets  
Quality Rating: 9 (Good) 
(10 point maximum) 
 
Effect Size Magnitude 
 Rating: Moderate 
(Relevance: Direct) 
Study (3 pts maximum): 2;     
- Workflow process (surgical 
pathology) may be too distinctive 
to be generalizable to other 
barcoding practices 
Practice (2 pts maximum): 2 Outcome measures (2 
pts  maximum): 2 
Results/findings (3 pts maximum): 
3 
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Unpublished Study A –  
 
Barcoding System    
 - 2009 
- LMBP Network 
- In-house audit or quality 
control initiative 
- Western USA 
- Funding: Self-financed  
 
 
- Design: Before-after 
- Facility: Academic medical 
center in Western U.S.; >300 
beds; > 1,000,000 lab tests/yr.  
- Setting:  After 1 mo. med./surg. 
unit pilot (11-12//2006) 
implemented on other non-ICU 
units with laboratory phlebotomy 
team 
- Time Period:  
1/1/06 -7/31/2009  
- Sample: All patient blood 
specimens (sample size not 
reported); approx. 33% of 
29,000/mo. collected by 
phlebotomy team (units served: 
neurology, med./ surg., transplant, 
ob/gyn, oncology,  neuropsych, 
emergency, pediatric, and nicu)   
Estimated sample: 9,570/mo.  
(.0.33 x 29,000); 114,840/year  
- Comparator:  Status Quo (no 
barcode labeling system) 
- Description: Barcoding system 
consists of phlebotomists using 
patient bedside barcode specimen 
labeling with wireless handheld 
device and an attached mini-
barcode label printer.  The device 
can access the patient test orders 
in real time, collect orders, and 
print test labels at the patient 
bedside.   
- Duration: 11/06-7/09, ongoing 
-Training:  3 trainers provided 
directly from system vendor; no 
details on person-time or intensity. 
- Staff: 2 FTEs from clinical lab IT; 
1 FTE phlebotomy supervisor; 20 
FTEs around-the-clock (24/7) 
blood draws 
- Cost: Start-up software: $30,000; 
hardware: $72,000; Annual 
maintenance: $32,000 (US$ 2006) 
- Outcome Measure:  




Note: error rate estimated 
from data provided by 
authors:  
 
- Recording Methods: 
Event reporting system 
and occurrence 
management  reports log 
 
- Pretest-Posttest 
- Findings/Effect Size: 
Total (annual) PSID errors reported 
Pre: 
2006:  12 errors 
Post: 
2007: 1 error 
2008: 0 errors;  
2009: 0 errors (through 7/09). 
PSID Error Rate (calculated using 
above PSID errors using estimated 
sample size of 114,840/ yr.):  
Pre-: 12/114,840 = 0.010%   
Post-: 1/114,840 = 0.0008% 
 
OR = 12.00 (CI,1.56 – 92.3) 
 
- Stat. Significance/ Test(s):  
None reported 
 
Results/conclusion bias:   
None reported  
Quality Rating: 7 (Fair) 
 (10 point maximum) 
 
Effect Size Magnitude 
 Rating: Substantial 
(Relevance: Direct) 
 
Study (3 pts maximum): 3 
 
 
Practice (2 pts maximum): 1;  
- Description lacks detailed 
specifications on how system 
interfaces with hospital & 
requirements for implementation 
Outcome measures (2 
pts  maximum): 1; 
- Recording method may 
not accurately capture all 
instances of the outcome 
Results/findings (3 pts maximum): 
2;  
- Small number of errors reported  
yields unstable effect size estimate 
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Unpublished 
 
Univ. of Minnesota Medical 
Center Fairview, Acute Care 
Laboratory, Minneapolis, MN, 
USA 
-  2009 
- LMBP Network 
- In-house audit or quality 
control initiative 
- Funding: Self-financed  
 
 
- Design: Case-Control  
- Facility/ Setting: UMN Fairview, 
Minneapolis, MN; >300 bed 
academic medical center; > 
1,000,000 tests/yr.  
- Study Setting: Clinical lab, ED, 
Adult and Pediatric ICUs 
- Study Period: Multiple study 
arms/start dates in various units:  
Clinical lab: 06/2006 -08/2009; ED 
07/2006- present; 
PCU pilot only: 11/2006-2/2007; 
Adult ICUs:  02/2008-08/2009; No 
end date reported. 
- Sample: Includes 100% of 
specimen (container)s and all 
error types. Specimen types, 
numbers and dates not reported. 
Total volume: 39,300  / month.  
- Comparator:  No details 
reported  for practice 
- Study bias:  Time period and 
sample selection methods may 
introduce bias affecting results 
- Description:  Barcoding system  
for patient id using hand-held PC  
to verify specimen labels match 
wristband prior to labeling 
specimen tubes at the bedside 
- Duration: 3 years, first 
implemented in the clinical lab 
(06/2006- present, ongoing), then 
campus ED (07/2006-present),  
PCU pilot only (11/2006-2/2007) 
Adult ICUs (02/2008-08/2009); 
practice is ongoing. 
- Training: ~30 min. for users 
- Staff:  Lab in collaboration with 
nursing and IT staff to implement 
0.5 FTE maintaining, auditing, 
problem-solving, validation, etc. 
- Cost: Start-Up:  Design & 
programming cost:  $600,000; 
hardware : ~ $425,000 
 Post Start-Up: ~$425,000 for new 
installations;  ~$300,000 for 
replacement hardware  
- Outcome Measure:  
Patient specimen 
Identification (PSID) error 
rate: Number of 
mislabeled specimens, 
wrong specimen in tube 
(WSIT)and  unlabeled 
specimens per 10,000 
collections 
- Recording Methods:  
Pre-implementation:  




system (electronic event 
tracking logs, and 
compared to ―cancel 
comments‖ in lab 
computer system). 
Compliance (scan rate) 
based on monthly 1-day 
audits of each unit where 
barcoding is implemented. 
- Pretest-Posttest 
 
- Findings/Effect Size 
PSID error rate 
Units Without Barcoding system:  
12.1 errors/10,000 collections.  
 
Units with Barcoding system:  
0.4 errors/10,000 collections 
 
- Stat. Significance/Test(s): 
Proportion successful; significance not 
reported 
 
Results/conclusion biases:  Sample 
sizes and specific dates not reported. 
Results not specified by medical unit 
(i.e., with/without barcoding system 
vs. those not reported).  WSIT and 
unlabeled specimens in numerator 
(outcome measure); not relevant to 
review question  
 
Quality Rating: 5 (Fair) 
 (10 point maximum) 
 
Effect Size Magnitude 
Rating: Substantial 
(Relevance: Less Direct) 
Study (3 pts maximum): 1; 
 - Sample not adequately 
described; may not represent 
results of the practice  
  
Practice (2 pts maximum): 2 Outcome measures (2 
pts  maximum): 1; 
- Recording method 
change pre vs. post could 
impact error results 
 
Results/findings (3 pts maximum): 
1; 
- Measurement period not clearly 
defined, results not specified; results 
may not be due to practice 
- Statistical power not discussed 
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Unpublished 
 
Univ. of Washington, 
Pathology Laboratory, Seattle, 
WA, USA 
- 2009 
- LMBP Network 
- In-house audit or quality 
control initiative 
- Funding: Self-financed  
 
 
- Design: Before-after 
- Facility: Univ. of Washington, 
Seattle, WA;,>300 bed academic 
medical center; 
 > 1,000,000 lab tests annually 
-Study Setting: Anatomic 
pathology lab gross room. 
- Time Period: 12/1/2007 – 
09/2009 
- Sample:  Patient specimen 
cassettes/blocks (includes 
outpatient biopsies and inpatient 
surgical specimens).  
Pre: 12/2007– 2/2008; 85,213 
Post: 12/2008- 9/2009, 50,016 
Historical annual baseline volume:  
85,213 cassettes/blocks  
produced 
- Comparator: Not described  
- Study bias: Findings for 
personnel savings based on user 
recall 
-Barcoding system to identify and 
track all specimens from 
accessioning to gross station, and 
just-in-time, single piece workflow 
system for cassette/block labeling, 
with computer printing 2D 
barcoded cassettes at grossing 
station requiring custom software 
and commercial cassette printers.    
- Duration: 9 months (12/1/08-
9/09), ongoing; initial partial 
implementation in 12/2008, full 
implementation 3/2009.  
-Training: End User Training for 
permanent gross room personnel 
and rotating pathology residents 
- Staff: Gross room pathologists, 
path. assistants and residents 
- Cost: Software custom 
~$200,000; 4 cassette printers @ 
$20,000 each = $80,000; 
Hardware:  PCs, barcode readers, 
label printers, mounting arms = 
$8,000 (US$ 2008) 
- Outcome Measures:  
(1) Patient specimen 
identification (PSID) error 
rate:  Number mislabeled 
specimen 
cassettes(includes 
duplicate number, wrong 
specimen, wrong case, 
wrong patient) / total 
number of pathology 
specimen cassettes  
(2) Personnel Savings – 
estimate of how much 
labor hours saved due to 
implemented practice 
 
- Recording Methods: 
(1)Incident Reports (pre 
and post); also counted 
directly post only 
(2) Survey of gross room 
personnel – estimates of 
time saved due to 
barcoding system  
- Pretest-Posttest 
 
- Findings/Effect Size:  
(1) PSID error rate 
Pre Barcode System (12/07 -12/08): 
1.16%  (988/85,213 ) 
Post Barcode System (12/0 – 09/09): 
0.00080%  (4/50,016) 
 OR = 147 (CI, 55 – 391) 
(2)  Post-practice: saved 0.75-1.0 FTE 
gross room personnel (less material 
handling, less error resolution efforts), 
not reported over what time period. 
 
- Stat. Significance/Test(s): 
Proportion successful; no statistical 
analysis/significance reported 
 
- Results/conclusion bias:   
personnel savings based on user 
recall (no point deduction as bias is 
for non-effectiveness measure –
feasibility)  
Quality Rating: 8 (Good) 
 (10 point maximum) 
 
Effect Size Magnitude 
 Rating: Substantial 
(Relevance: Direct) 
Study (3 pts maximum): 2;     
- Workflow process (anatomic 
pathology) may be too distinctive 
to be generalizable to other 
barcoding practices 
Practice (2 pts maximum): 2 Outcome measures (2 
pts  maximum): 2 
 
Results/findings (3 pts maximum): 
2;  
- No statistical analysis/significance  
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Lyndon B Johnson General 
Hospital Core Laboratory, 
Houston, TX, USA 
- 2009 
- LMBP Network 
- In-house audit or quality 
control 
- Funding: Self-financed  
 
 
- Design: Before-after 
- Facility: Lyndon B Johnson 
hospital, Houston, TX, >300 bed 
teaching hospital.; > 1,000,000 lab 
tests annually 
Study Setting: All nursing units 
except ER, ICU, NICU and 
Outpatients; Lab collects 8,500 
specimens monthly, 280/ daily 
- Time Period: 1/1/2009 – 
8/31/2009 
Pre:  :1/2009 – 4/2009 (4 mos.) 
Post:  6/2009 –8/2009 (3 mos.) 
- Sample: Inpatient  blood 
samples by venipuncture  
Pre:  41,815   Post: 24,789  
- Comparator: Phlebotomists use 
of a printed draw list and pre-
printed specimen label to enter 
collection information (date/time & 
ID of patient) 
- Study bias: Low baseline error 
rates may underestimate 
effectiveness in general use.  
- Barcoding system used by 
laboratory department only; 
laboratory phlebotomists print 
labels from wireless handheld 
printer and label specimen tubes 
by the patients’ bedside; in use 
24/7. 
- Duration: 6/1/2009- 10/1/2009  
- Training: Staff training takes 3 
hours to learn equipment use   
- Staff: 20 phlebotomists, IT facility 
staff for installs and training  
- Cost: Cost related to training 
phlebotomists: $14.20 * 3 hours * 
20 FTEs =$852. Cost of Collection 
Manager (hardware, installation, 
support, and training) = $1 million 
for district (2 hospitals; 650 and 
330 beds respectively). (US$ 2009) 
- Outcome Measures:  
Patient specimen 
identification (PSID) error 
rate: Number of 
mislabeled 
specimens/total number of 
specimens  
 
- Recording Methods: 
Incident reports  
Pre: review of occurrence 
log based on manual 
forms 




PSID error rate 
Pre:   1.012%, ( 5/ 41, 815) 
Post :  0.00% (0/24,789) 
100% positive identification; 
OR = 6.50 (CI,0.36 – 117.61) 
 
Stat. Significance/Test(s): 
Proportion successful/ significance not 
reported 
 







Quality Rating: 8 (Good) 
 (10 point maximum) 
 
Effect Size Magnitude 
Rating: Substantial 
(Relevance:  Direct) 
Study (3 pts maximum): 2;    
-  Study bias – phlebotomists only 
with low initial error rates 
Practice (2 pts maximum): 2  Outcome measures (2 
pts  maximum): 2 
 
Results/findings (3 pts maximum): 
2; 
- Statistical analysis/power not 
reported 
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
 
POINT OF CARE TESTING BAR-CODING SYSTEMS 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 




Systems Study Practice Measures Results Total Rating       




2004 3 2 1 2 8 Good Substantial   
Rao et al. 
2005 1 2 1 2 6 Fair Substantial 3 Studies = Good/Substantial 
Geisinger 
2009 2 2 2 2 8 Good Substantial 1 Study = Fair/Substantial 
Unpub B 
2009 2 2 2 1 7 Fair Moderate 1 Study = Fair/Moderate 
                  
            High 
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**=”Good” Study Quality rating  
*=”Fair” Quality rating 
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Colard, DR [1] 
- 2005 
- Point of Care 
[1] Department of Pathology, 
Saint Luke’s Hospital; Kansas 
City, MO 
- Funding: not reported  
 
- Design: Before-after 
- Facility/Setting: Saint Luke's 
Hospital, Kansas City, MO; 629-
bed tertiary care teaching hospital 
for the Univ. of Missouri-Kansas 
City School of Medicine. 
- Time Period: 10/2000 - 5/2004 
Pre:  10/2000 – 11/2002 (25 mos.) 
Post:  12/2002 – 5/2004 (17 mos.) 
- Sample: The point-of-care 
glucose program at St. Luke's 
Hospital, Kansas City, MO, 
performs 12,000 tests per month.  
All glucose POCT taken within 
given time period. No data 
provided on number of tests or 
tests per month for study sample.   
- Comparator: Manual entry of 
patient information and test results 
into the laboratory information 
system. 
- Study Bias: unexplained sample 
size increase; gap in outcome 
data ((12/2003 – 5/2004) 
- Description: POCT Barcoding   
- Duration: 19 months (12/2002-
5/2004) 
- Training: training provided to all 
nursing staff; nurses with high scan 
errors received additional training.  
Due to modifications post-
implementation, additional training 
required. 
- Staff/Other Resources: nursing 
staff (operators); POCT coordinator 
implement new process change 
- Cost: not reported 
  
- Outcome measures: 
(1) Patient ID Error Rate - 
% patient identification 
error rate for point of care 
blood glucose tests 
(2) Number unidentified 
point of care blood 
glucose tests  





(1) Monthly error rates- 
Pre-barcoding:   9.4%  
Post-barcoding:  0.7%; 
 OR = 14.72 (CI, 11.95 – 18.12) 
 
(2) Monthly unidentified test counts –  
Pre-barcoding (11/2002): 404 
Post-barcoding (5/2004): 6 
 OR = 69.6444; d = 2.340) 
 
- Stat. Significance/Test(s): Not 
discussed 
 
- Results/Conclusion Bias:  
-Data presented as reported above 
with corresponding monthly "process 
changes"  
- Sample size not explicitly reported; 
effect size calculated based on 
estimate from authors’ data. 
Quality Rating (10 point 
maximum):  8 (Good) 
Effect Size Rating: 
Substantial  
(Relevance: Direct) 
Study  (3 pts maximum): 2 
 
 
Practice (2 pts maximum): 2 
 
Outcome measures (2 
pts maximum): 2 
 
 
Results/findings (3 pts maximum): 
2; 
- Appropriateness of statistical 
analysis;   
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Nichols JH [1,2]; Bartholomew 
C [2]; Brunton M [2]; Cintron C 
[2] ; Elliott S [2], et al 
- 2004 
- Clinical Leadership 
Management Review 
[1] Tufts University School of 
Medicine. [2] Baystate Health 
System in Springfield, MA. 
- Funding: Self-financed  
- Design: Before-After 
- Description: Baystate Health 
System,  integrated delivery 
network, in western MA; 3 
hospitals; > 850 beds; (Baystate 
Med. Ctr., Franklin Med. Ctr., Mary 
Lane Hospital); almost 1 million 
point-of-care tests/yr   
- Time Period: 1/ 2002 – 1/2004 
Pre: 1/2002 – 10/2002 
Post:  11/2002 – 1/2004 
- Sample: Intensive Care Unit 
(ICU) blood gas and glucose 
POCTs, system wide volumes of 
nearly 600,000 glucose and blood 
gas tests annually for each year of 
the study period. All tests in 
sample (all 3 hospitals) 
 - Comparator: Status quo (POCT 
without barcoding) and operator 
lock out ―3-Strike Rule‖ 
- Study Bias: operators continued 
to have intermittent problems 
reading bar-coded wristbands. 
- Description: POCT Barcoding  
5-digit operator code and 9-digit 
patient account number  
- Duration:  15 months (11/ 02 – 
1/04) 
- Training: Not reported 
- Staff/Other Resources: Nursing 
and pathology departments 
- Cost: Not reported 
 
- Outcome measure: 
Patient ID errors : monthly 
number (count):  
(1) Glucose meter  
(2) Blood gas POC 
devices  
- Recording method:  
Internal quality control 
instrument 
- Pretest-Posttest: 
- Findings/Effect Size: 
Identification errors 
(1) "Rates of identification errors 
decreased significantly over time 
for…glucose devices after 
implementation of bar coding (p = 
0.0007)..."* decreased from average 
26/month to 1/month 
(2) ―Rates of identification errors 
decreased significantly over time 
for…blood gas...devices after 
implementation of bar coding (p = 
0.048)*, from avg. of 4.6 to 1.7/month 
 OR = 14.92 (CIO,7.66 – 29.07)  
- Stat. Significance/Test(s): Not 
reported; p-values provided 
- Biases: *Sample sizes or monthly 
volumes not provided.  Unclear from 
the data presented whether compare 
bar coding to the lock-out program 
only (June-Oct. 02) or to cumulative 
data from both the lock-out program 
and previous period – Jan-Oct. 02.) 
Quality Rating (10 point 
maximum):  8 (Good) 
Effect Size Rating: 
Substantial (Relevance: 
Direct) 
Study  (3 pts maximum): 3   
 
Practice (2 pts maximum): 2  Outcome measures (2 
pts  maximum): 1;   
- Face validity: Monthly 
errors without monthly 
test volume not error 
rates 
Results/findings (3 pts maximum): 
2;  - Appropriateness of statistical 
analysis:  Does not provide data 
sufficient to allow/verify calculation 
of an effect size (sample size not 
reported) 
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Rao, AC; Burke, DA; and 
Dighe, AS [1] 
- 2005 
- Point of Care  
[1] Massachusetts General 
Hospital 
- Funding: Self-financed  
- Design: Before-after 
- Facility/Setting: Massachusetts 
General, Boston, MA; 900-beds; 
largest teaching hospital of 
Harvard Medical School and 
hospital-based research program 
in the U.S. 
- Time Period: No dates reported;  
1 month Pretest 
1 month Pilot test – bar coding 
1 month Posttest 
- Sample: 35 inpatients included in 
the pilot test of bar coding only - 
462 total glucometry tests: 
- Pre: 170  
- Pilot: 134  
- Post: 150  
- Comparator: Usual Care - POC 
device with keypad for manual 
data entry for patient identification  
- Study Bias: none 
 
 
- Description: POCT Barcoding 
2D bar code for patient wristbands; 
only the medical record number 
included in the ID bar code which 
is a unique identifier for each 
patient. 
- Duration: 1 month (pilot test only) 
- Training:  Provided to teach 
nurses, operations coordinators, 
operations assistants on how to 
print wristbands and troubleshoot. 
- Staff/Other Resources: Not 
reported. 
- Cost: Not reported 
- Outcome Measure: 
Patient ID error rate - % 
errors in Medical Record 
Number (MRN) 
 
- Recording method: 





- Findings/Effect Size:  
1 month preceding test: 1.2% (2/170) 
1 month pilot test:  1.5% (2/134) 
1-month test: 0% (0/158) 
 
 
- Stat Significance/ Tests: Difference 
in error rates was statistically 
significant by Chi-squared analysis 
(P<0.005). 
 OR = 4.75 (CI, 0.25 – 88.73) 
(results for 2 comparator periods 
pooled) 
 
- Results/Conclusions Biases: Study 
period is short, 1 month; relatively 
small sample sizes.  
 
Quality Rating (10 point 
maximum):  6 (Fair) 
 
Effect Size Magnitude  
Rating: Substantial  
(Relevance: Direct) 
 
Study (3 pts maximum): 1;  
- The sample may not be 
representative of the results of 
the practice. The study time 
period and sample selection 
methods may introduce a study 
bias that could affect results 
Practice (2 pts maximum): 2; 
 
Outcome measures (2 
pts  maximum): 1;  





Results/findings (3 pts maximum): 
2;  
- Measurement period insufficient 
and sample may be too small to 
allow a robust estimate of the 
impact of a practice 
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Unpublished  
- Geisinger Medical Center: 
Schuerch, C [1]   
- 2009 
- LMBP Network 
[1] Department of Laboratory 
Medicine, Geisinger Medical 
Center, Danville, PA 
- Funding: Self-funded 
- Design: Observational study 
- Facility/Setting: Geisinger 
Medical Center, Danville, PA; a 
teaching hospital; > 300 beds; > 1 
million tests annually. 
- Time Period: 1/2004 -6/2009 
Baseline (initial barcoding 
implementation):  1/2004 (1 mo) 
Barcoding practice (full 
implementation): 1- 6/2009 (6 
mos)* 
- Population/ Sample: Point-of-
Care glucose tests for hospital 
inpatients.  On average, 
approximately 18,000 inpatient 
POC glucose tests/month; total 
glucose tests during 6 months 
2009: 106,780  
- Comparator: Initial stage of 
barcode POCT implementation 
(2002-2004) compared to full 
practice implementation (2007-
2009). Improvement Committee, 
investigation, reporting; monitoring 
after low scan rates (< 1/3) and 
high ID errors  
- Study Bias: Data used do not 
reflect pre-barcoding and based 
on 1 month following 2 years of 
implementation. 
- Description:  POCT Barcoding 
with ongoing reporting of barcoding 
procedure compliance (scan rate) 
and patient ID errors to nursing 
management. 
- Duration: 1/1/2009- 6/30/2009 
- Training: Education of nursing 
staff on new practice guidelines 
includes one-on-one nursing 
educators; placing ―scan only‖ on 
each meter, and laminated 
scanning guidelines cards were 
attached to each meter tote. 
- Staff/Other Resources: Not 
reported 
- Cost: Not reported 
- Outcome Measure:  
Patient ID error rate:  
Monthly # of misidentified 
patients/ total glucose 
POCTs 
 
* Monthly avg. scan rate: 
# of patient wristbands 
scanned / Total POCT 
glucose" 
Avg scan rate 1-6/2009) = 
96.7%  
Avg  scan rate (1/2004) = 
31.8% 
 
- Recording method:  
Occurrence log 
- Pretest-Posttest 
- Findings/Effect Size: 
Patient ID error rate  
Baseline (1/2004):  2.9% 
Post (6 mos. 2009): 0.5% 
 OR = 5.94 (CI,5.26 – 6.71) 
 
- Stat. Significance/ Tests:  Not 
reported 
 
- Results/ Conclusion Bias: Pre and 
post comparison  practices include 
POCT barcoding; results show effect 
of improving implementation of POCT 
barcoding as reflected in average 
scan rates 
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Quality Rating (10 point 
maximum): 8 (Good) 
 
Effect Size Magnitude Rating 
: Substantial 
(Relevance: Direct) 
Study (3 pts maximum): 2; 
- Study design/time period may 
introduce bias affecting  results 
Practice (2 pts maximum): 2  Outcome measures (2 
pts maximum): 2  
 
Results/findings (3 pts maximum): 
2;  
- Appropriateness of statistical 
analysis:  Does not provide data 
sufficient to allow/verify calculation 
of an effect size (sample size not 
reported) 
- Unpublished  
 
POCT - Barcoding A [1]: 
Anonymous 
- 2009 
- LMBP Network 
- LMBP Submission Form 
- [1] Midwest Academic 
Medical Center, Minnesota, 
USA 
- Funding: In-house, quality 
management project 
- Design: Before-after 
- Facility/ Setting: Midwest- MN 
Pathology Laboratory, Teaching 
Hospital; >n 300 beds; >1 million 
tests/yr.  
- Time Pd: 1-5/2009; Pre: 1/1/09 - 
3/31/09; Post: 4/1/09 – 4/28/09   
- Population/Sample:  all inpatient 
and outpatient bedside glucose; 
Annual glucose POCT performed 
(2008): 247,000  
- Comparator: Manually verify 
patient armband to glucose work 
list 
- Study bias: Short measurement 
pd of candidate practice (4/1/09 – 
4/28/09) 
- Description:  POCT Barcoding 
- Duration: 4/1/2009 – 10/1/2009 
- Training: Training needs are 
modest – time to train all glucose 
users on new process; support for 
barcode accessories; on-going 
training on policy and process 
updates. 
- Staff/Other Resources: Time to 
identify & test new armband-
materials barcodes, develop 
barcodes for user-id and maintain 
process 
- Cost: Not reported 
Outcome Measure: 
Patient ID error rate – % 
of POCT glucose results 





- Recording Method: 
Occurrence log  
Pretest-Posttest Findings/Effect Size: 
Patient ID error rate  
Pre (Jan – Mar 2009):  0.097%; Post 
(April 2009): 0.061% 37% reduction  
 OR = 1.59 (CI, 1.06 – 2.39) 
 
(Note: Denominator of rate estimated from data 
provided by author—not explicitly stated.)  
 
- Stat. Significance/ Test(s): No report 
 
- Results/Conclusions Bias: Authors 
state Std Dev and means reported – 
none provided; denominator info not 
provided to replicate results. No power 
or stat. test reported  
Quality Rating (10 point 
maximum): 7 (Fair) 
 
Effect Size Magnitude 
Rating: Moderate 
(Relevance: Less Direct) 
Study (3 pts maximum): 2;  
- Study time period may not be 
representative of practice 
results 
Practice (2 pts maximum): 2  Outcome measures (2 
pts maximum): 2  
Results/findings (3 pts maximum): 
1;  
- Measurement period insufficient  
- Appropriateness of statistical 
analysis:  Sample size estimated by 
reviewers.  
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Practices associated with timely and accurate CRITICAL VALUE REPORTING 
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
 
TOPIC AREA: Accurate and Timely Reporting of Critical Values 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 
Overall Strength of Body of 
Evidence 
Practice: Call 
Centers Study Practice Measures Results Total Rating       
Saxena et al. 2005 2 2 2 1 7 Fair Substantial 
Yes 
  
Unpublished A 2008 2 2 2 1 7 Fair Moderate 2 Studies = Fair/Substantial 
Providence-Everett 
2009 0 1 2 0 3 Poor Minimal/None 1 Study = Fair/Moderate 
Geisinger 2009 3 2 1 1 7 Fair Substantial 1 Study = Good/Minimal 
Unpublished B 2009 3 2 2 1 8 Good Minimal/None 1 Study = Poor/Minimal (excluded) 
                  
              Suggestive 
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Critical Value Reporting: Call Centers 
 
 
Model Study name Time point Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit
Geisinger 2009 * Blank 1.684 1.635 1.733
Unpub Call Ctr A 2 * Blank 0.697 -0.149 1.543
Saxena 2005 * Blank 0.047 0.000 0.094
Random 0.814 -0.520 2.148
-2.00 -1.00 0.00 1.00 2.00
Favours Comp Favours Call Center
Boxes proportional to weights
 
**=”Good” Study Quality rating  
*=”Fair” Quality rating 
Boxes proportionate to study size 
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- Author (s)   
- Yr Published  
- Publication  
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias 
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Saxena, S (1,2); Kempf, R 
(1,2); Wilcox, S; Shulman, 
IA; Wong, L; Cunningham, 
G; Vega, E, and Hall, S. (2) 
- 2005 
- Joint Comm J Qual Patient 
Saf. 
[1] Keck School of Medicine, 
University Southern 
California, 
[2] Los Angeles County + 
University of Southern 
California Healthcare 
Network 
- Funding: Self-financed 
 
- Design: Cross-sectional 
- Facility/Setting: LA 
County and Southern Calif 
Mel Ctr.; Urban, acute care 
teaching hospital; >700 beds 
- Time Pd: 11/03 – 12/04  
Pre:  11/2003 -4/2004 
Post:  5/2004 – 12/2004 
- Population/Sample:  
All CV lab test notifications 
for selected inpatient wards 
and outpatients (not micro); 
range: 334-700/ mo.  
Pre:  Not reported 
Post:  4,042 
 - Comparator:  Identical 
standardized call center 
system w/o IT practice 
(integrated electronic form)  
- Study Bias: Both practice 




center system - Lab tech calls 
customer service center (CSC) 
which is responsible for directly 
communicating CV test result to 
designated physician by 
telephone.  Utilizes an integrated 
IT application/database with 
electronic telephone abstract form 
filed in the patient record with test 
results. Physician required to 
―read-back‖ patient information for 
verification.   
-  Duration: 14 months (11/03-
12/04) 
- Training: 10 hrs. training CSC 
staff  to use system 
- Staff/Other Resources: 
Interdisciplinary team 
- Cost:  230 hours IT time over 5-
month period for development  
 Outcome measures: 
(1) Time to receipt of CV result 
in minutes 
 
(2) Timeliness of reporting - % 
CV results reported within 1 
hour 
 
(3) Timeliness of reporting –% 
CV results reported within 15 
min 
 
- Recording method: 
Automated data tracked 
through IT interface 
Pretest-Posttest & Descriptive 
- Findings/Effect Size: 
(1): Monthly average CV  lab test notification 
time: 
Pre:    38 minutes 
Post:  10 minutes  
(2)  Noncomparative:  "For May 2004-December 
2004, almost all (99%-100%) notifications were 
completed within one hour"* 
(3) Noncomparative:  ―For May 2004-December 
2004, 79%-83% of notifications were completed 
within 15 minutes.‖* 
 
* cited directly from source document; no 
additional data provided.  
 
- Stat. Significance/Test(s):  Not reported. 
 
- Results/Conclusion Bias:  No data sources 
provided for outcomes reported; no comparison 
period sample size reported. 
Quality Rating (10 point 
maximum):  7 (Fair) 
Effect Size Magnitude 
Rating (Relevance: Direct): 
Substantial 
Study (3 pts maximum): 2; 
- Study design may introduce 
bias that would affect results. 
  
Practice (2 pts maximum): 2 Outcome measures (2 pts 
maximum): 2  
 
Results/findings (3 pts maximum): 1;  
- Appropriateness of statistical analysis: Does 
not provide data sufficient to allow/verify 
calculation of an effect size (sample size not 
reported)   
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Bibliographic 
Information 
- Author (s)   
- Yr Published  
- Publication  
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias 
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Unpublished - Call Center: 
Study  A 
- 2008 
- LMBP Network 
- Eastern USA 





- Design: Before-after 
- Facility/Setting: Large urban 
academic medical center in Mid-
Atlantic U.S.; > 600 beds; > 
32,000 inpatients/yr. and 
300,000 outpatients 
- Time Period: 3/08-5/08 
Pre: 3/26/2008-4/27/08 
(33 days) 
Post: 4/28/2008- 5/28/2008 (31 
days) 
- Population/Sample:  No 
sample size reported.  
Approximately 200 CV calls/day 
– likely inpatient only - includes 
all CV test results within time 
period 
- Comparator:  Computer call 
queue software tracks time to 
report CVs to licensed 
caregivers without using call 
center. 
- Study Bias: None 
- Description: Call center Operates 
24 hrs./7 days/wk. with a 1 hour 
target threshold for all CV calls.  Lab-
certified CV test results go into call 
center computer queue for its staff to 
call licensed caregivers.  Call Center 
staff asks caregiver to read-back the 
results, and documents the read-back 
in the computer system. Utilizes 
escalation procedure to identify 
patient caregiver. 
 - Duration: 1 month (Practice 
initiated on 4/28/08) 
- Training: Not discussed 
- Staff/Other Resources:  Staffed by 
1-3 medical technologists per shift  




(1) Timeliness of reporting  
- % daily CV results reported within 
1 hour 
 
(2) Time to receipt of result -
Average daily time (min.) per CV 
test result notification (i.e., to 
report  to licensed caregiver)  
 
- Recording method:  Person 
making call asks caregiver to read-
back results.  The read-back is 
recorded in the computer system, 
which tracks time from when result 






- Findings/Effect Size: 
 
(1) % CV results reported within 1 hour: 
Pre: 76.7%  daily average 
(SD: 13.74; Variance: 188.69; Range: 37.5 - 95.3% 
daily)   
Post:  92.1% daily average  
(SD: 5.35; Variance: 28.62; Range: 71.6 – 99% daily). 
 
(2) Noncomparative:  
Pre-Call Center only (3/26–4/21/08):  
Avg. daily CV notification time: 46.5 minutes (SD: 
25.53; Range: 21 – 157); removing the single  157 
min. outlier: 42.1 minutes (SD 12.25) 
 
- Stat. Significance/Test(s): Not reported. 
- Results/Conclusion Bias:   No comparisons 
available on differences between areas where call 
center was and was not implemented. 
 
 
Quality Rating (10 point 
maximum):  7 (Fair) 
 
Effect Size Magnitude 
Rating (Relevance: Direct): 
Moderate 
 
Study (3 pts maximum): 2; 
- Study sample may not be 
representative of practice; - 
call center not implemented 
hospital-wide, no information 
on population 
Practice (2 pts maximum): 2  
 
Outcome measures (2 pts 
maximum): 2  
 
 
Results/findings (3 pts maximum): 1; 
- Sample sufficiency:  Measurement period may 
be insufficient to allow robust estimate of impact  
- Appropriateness of statistical analysis:  Does 
not provide data sufficient to allow/verify 
calculation of an effect size (sample size)   
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Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
Providence Regional 
Medical Center, Everett, WA, 
USA 
- 2009  
- LMBP Network Submission 
- Funding: Self-financed 
- Design: Observational 
- Facility/Setting: Providence 
Regional Medical Center in 
Everett, WA; > 300 beds; >1 
million tests/yr. 
- Time Period:10/08 -6/09 (3 
consecutive calendar 
quarters) 
2008- 4th qtr: 10/08-12/08 
2009 -1st qtr: 1/09-3/09 
2009- 2nd qtr: 3/09-6/09 
- Population/Sample:  
Call center: 108 outpatient 
only hospital CV calls   
Comparator:  1,162 inpatient 
only hospital CV calls 
- Comparator: Inpatient CV 
test results communicated by 
laboratory techs 
-Study Bias:  
- Description: Critical values 
results communicated by client 
services call center to designated 
physician or clinic staff. 
- Duration: 10/08-6/09 
- Training: Client services staff 
trained on call center 
management software 
- Staff/Other Resources:  Not 
reported 
- Cost: Not discussed 
 
Outcome Measures: 
Timeliness of reporting - % CV 
results reported within 15 min. 
 
- Recording Method: 
Occurrence log 
Comparison: Call Center (outpatient) v. Techs 
(inpatient) 
 
- Findings/Effect Size: 
Timeliness within 15 min-  
2008-4th qtr: 
Call Center: 97% (n=29); Techs: 99.8% (n=427) 
2009 – 1st qtr 
Call Center: 97% (n=32); Techs: 98% (n=329) 
2009- 2nd qtr: 
Call Center: 60% (n=47); Techs: 99% (n=406) 
 
- Stat. Significance/Test(s): Not discussed 
 
- Results/Conclusion Bias: Sample selection 
may explain unfavorable direction of results 
Quality Rating (10 point 
maximum):  3 (Poor) 
 
 




Study  (3 pts maximum): 0;   
- Samples for the practices 
are sufficiently different to 
clearly nullify generalizability 
of the results – small number 
of outpatient only CV calls 
for call center vs. large 
number of inpatient only  CV 
calls for comparator 
Practice (2 pts maximum): 1; 
- An important aspect of 
implementation not well-
described; staffing not reported 




Results/findings (3 pts maximum): 0; 
- Sample sufficiency:  Statistical power is not 
discussed AND the sample is likely too small to 
allow a robust estimate of the impact of a 
practice 
- Appropriateness of statistical analysis:  Does 
not provide data sufficient to allow/verify 
calculation of an effect size  
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- Author (s)   
- Yr Published  
- Publication  
- Author Affiliations  
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- Study bias 
Practice 
- Description   
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- Training  
- Staff/Other Resources  
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Outcome Measures 
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Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
Geisinger Medical Center, 
Danville, PA, USA 
- 2009 
- LMBP Network Submission 
- Funding: Self-funded  
- Design: Before-After 
- Facility/Setting: Geisinger 
Medical Center, Danville, 
PA; teaching hospital with > 
300 beds; >1 million tests/yr. 
- Time Period: 1/2006--6/09 
Pre: 2006 (12 mos.) 
Post: 1- 6/2009 (6 mos.) 
- Population/Sample: Avg. 70 
CV calls/day to inpatient 
units and ER. All CVs 
excluding Anatomic 
Pathology reported for GMC 
testing population; Post:  
12,306 CV calls;  
Pre:  sample size not 
reported. 
- Comparator: Passive 
system used by bench 
technologists using a written 
call log with no readback 
verification. 
- Study Bias:  None noted  
- Description:  
Call center operates 24 hrs./7 
days/wk. and is staffed by21 
FTEs.  A centralized Client 
Service Contact Center with an 
integrated software application 
make critical value calls directly to 
a licensed practitioner who can 
take action on critical values. The 
Call Center must also verify and 
document readback of the critical 
value. The time interval is 
measured from the identification 
of the verified critical value to the 
receipt by the responsible 
licensed care giver. 
 - Duration: 1/07 - practice 
ongoing 
- Training: Education materials 
provided 
- Staff/Other Resources:  Call 
Center staff 
- Cost: Not discussed 
Outcome Measures: 
(1) Timeliness of reporting - % 
CV results reported within 30 
min interval from identification 
of the verified critical result to 
acknowledgement by 
responsible licensed caregiver. 
 
- Recording Method: Vendor 
occurrence/monitoring; No 
reliable method of tracking 
comparator rates (2006) as   
no monitoring system was in 
place to ensure that the results 
were given to care providers 
nor was there documentation of 
the readback of results. 
Pretest-Postest 
 
- Findings/Effect Size: 
(1) % CV results reported within 30 min to 
responsible licensed caregiver 
Pre (2006):  50% 
Post (2009): 95.5% 
 
- Stat. Significance/Test(s): Not reported 
 
- Results/Conclusion Bias: 
Data collected during notably different time 
periods (2006 and 2009); data not provided to 
support findings or statistical analysis  
Quality Rating (10 point 
maximum):  7 (Fair) 
Effect Size Magnitude 
Rating (Relevance: Direct): 
Substantial 
 
Study  (3 pts maximum): 3  
 
Practice (2 pts maximum): 2  Outcome measures (2 pts 
maximum): 1  
Results/findings (3 pts maximum): 1;  
- Appropriateness of statistical analysis:  
Compares two practices with estimates 
based on data from notably different time 
periods 
- Data insufficient to allow/verify calculation 
of an effect size (no sample sizes reported) 
Evidence Summaries: Critical Value Reporting 
Phase 3 Final Report 96 
Bibliographic 
Information 
- Author (s)   
- Yr Published  
- Publication  
- Author Affiliations  
- Funding  
Study 
- Design  
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- Population/Sample  
- Comparator  
- Study bias 
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Unpublished - Call Center: 
Study B 
- 2009 
- LMBP Network Submission 
- Western USA 
- Funding: Self-financed  
 
- Design: Time-series 
- Facility/Setting: Western 
USA, Large Health 
Maintenance Organization 
(HMO) Laboratory; > 300 
beds; >1 million tests/yr.  
- Time Period: 4-7/2009 
April-May & June-July 2009 
- Population/Sample: A 
sample of 500-750 CV test 
results/mo; study population 
was CVs for routine 
outpatient laboratory work. 
Inpatient or STAT excluded. 
No sample sizes reported. 
- Comparator: None: 
Note:  Original CV protocol: 
Regional Lab notified 
collection laboratory which 
then notified provider. 
-Study Bias: None 
- Description: Call center operates 
24 hrs./7 days/wk. 24/7 Adult & 
Advice Call Center that was 
already staffed with Advice RNs 
and Call Center MDs who were 
rotating Emergency Physicians. 
Two tracks were created, one for 
INR CVs and one for all other lab 
CVs  
- Duration: 3/09 - ongoing 
- Training: Not discussed 
- Staff/Other Resources:  Staffing 
level unknown; skilled nursing 
staff call center; lab assistants 
occasionally assist in notification. 
- Cost: Not discussed 
 
Outcome Measure: 
Timeliness of reporting – % CV 
results reported within 1 hour 
 
- Recording Method: Internal 
quality control instrument; audit 
of electronic medical record 
Time series 
 
- Findings/Effect Size: 
Timeliness of reporting (within 1-hr) 
N = 550-750 CVs monthly (2009) 
 
Time 1 (April-May 2009): 647 CVs notified  
within 1 hour/ 650 CVs monthly = 99.5% 
(*estimate - based upon range: 1-6 not reported) 
 
Time 2 (June-July 2009): 650 CVs notified within 
1 hour/ 650 CVs monthly = 100% 
 
- Stat. Significance/Test(s): Not reported 
 
- Results/Conclusion Bias: ‖Workflow change 
does not account for rare  human factor incident 
where lab personnel may forget to notify CV 
immediately (within 1 hr) and the CV is caught at 
the end-of-shift‖ 
Quality Rating (10 point 
maximum):  8 (Good) 
 
Effect Size Magnitude 
Rating (Relevance: Direct): 
Minimal/None 




Results/findings (3 pts maximum): 1;  
- No statistical significance/tests performed 
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
Critical Value Reporting: Automated Notification 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 




Notification Study Practice Measures Results Total Rating       
Kuperman et al. 
1999 2 2 2 1 7 Fair Minimal/None 
Yes 
1 Study = Good/Substantial 
Park et al. 2008 0 2 2 2 6 Fair Minimal/None 2 Studies = Fair/Minimal 
Tate et al. 1995 3 2 2 1 8 Good Not Available 1 Study = Good/n.a. 
Piva et al. 2009 3 2 2 1 8 Good Substantial   
                  
               Suggestive 
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Critical Value Reporting: Automated Notification 
Study name Outcome Statistics for each study Std diff in means 
and 95% CI
Std diff Lower Upper 
in means limit limit
Piva 2009 ** %  reported < =1 hr 1.269 1.167 1.371
Park 2008 * Clinical Resp Rate 0.184 -0.168 0.535
Kuperman 1999 * Time to Resolution 0.058 -0.228 0.344
0.513 -0.397 1.423
-2.00 -1.00 0.00 1.00 2.00
<==Favors Comp Favors AN==>
Std Effect Est -- Automated Notification to Reduce Lab CV Notification Time
* "Fair" Study Quality; ** "Good" Study Quality.  Boxes proportional to study size.
 
 
**=”Good” Study Quality rating  
*=”Fair” Quality rating 
Boxes proportionate to study size 
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- Author (s)   
- Yr Published  
- Publication  
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
  - Study bias  
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
-Results/Conclusion Bias   
Kuperman GJ [1,2]; Teich 
JM [1,2]; Tanasijevic MJ 
[2]; Ma'Luf N [2]; 
Rittenberg E [2]; Ashish 
Jha MA [2]; Fiskio J [1]; 








[1] Partners HealthCare 
Systems, [2] Harvard 
Medical School 
 
- Funding: Partly from 
research grant (R01 -
Agency of Health Care 
Policy and Research) 
- Design: Randomized 
Controlled Study  
- Facility /Setting:  Brigham & 
Woman’s Hospital; 720 bed 
tertiary-care hospital in Boston, 
MA,  
- Time Period: 12/1994-
10/1995 (Medical: 12/1994– 
1/1995: 2 months; Surgical: 
9/1995 – 10/1995: 2 months) 
- Population/Sample: 178 
subjects; 192 tests; 4 
laboratory tests with critical 
values and/or alert situations 
- Comparator:  Same as 
practice without alert to 
physician pager (i.e. alert goes 
to patient floor computer 
screens) and with CV results 
telephoned by lab technologists 
to patient floor (nursing staff).  
- Study Bias: None 
 
- Description: Automated 
notification -  system generates 
an alert to a digital pager of the 
patient’s covering physician 
results  
- Duration: 6 months 
- Training:  Not discussed 
- Staff/Other Resources:  
Computer technicians, physician, 
nurses, unit secretary, telephone 
operator, reviewers  and lab 
supervisor/manager; clinical 
alerting system, digital pager, 
computer workstation 
- Cost: Not reported 
Outcome Measures: 
(1) Time to Treat (TTT) - Time 
interval from the filing of the 
alerting result  to the ordering 
of appropriate treatment 
 
(2) Time to Resolution (TTR)  - 
Time interval from  the filing of 
alerting result to the arrival time 
in the laboratory of a bedside 
test demonstrating the alerting 
condition was no longer 
present 
 
- Recording method:  
Occurrence log, Chart review 
 
- Comparison (RCT)  
- Findings/Effect Size:  
(1) TTT: Total N = 97;  
Practice Mean time:  3.4 hours 
(SD = 8.0; Median =.07; n = 43).  
Comparator Mean time:  3.3 hours  
(SD = 7.4; median = 1.1; n = 54)  
(2) TTR: Total N = 94 
Practice Mean time: 12.8 hours 
(SD = 15.4; median = 7.0; n = 40). 
Comparator Mean time: 13.7 hours 
(SD = 14.5; median = 8.1; n = 54) 
 
- Stat. Significance/Test(s):  
(1) TTT:  Student T-test P-value = 0.59; d 
= -0.013; statistical power < 80% 
(2)  TTR: Student T-test P-value = 0.68; d 
= 0.060; statistical power < 80%  
 
- Results/Conclusion Bias: Favorable 
conclusions not supported; but instead 
are contradicted by reported findings. 
Authors note that differences are not 
significant but focus on direction of effect.  
Quality Rating (10 pt 
max):  7 (Fair); Effect 
Size Magnitude Rating: 
Minimal/None  
(Relevance: Direct) 
Study  (3 pts maximum):  2 
- Results may not be 
generalizable: Tertiary-care 
population 
Practice (2 pts maximum): 2 Outcome measures (2 pts  
maximum): 2 
 
Results/findings (3 pts maximum): 1 
- Results not clearly attributable to the 
practice (p-values); conclusions not 
supported by work 
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- Recording method  
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- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
-Results/Conclusion Bias   
Park H [1]*, Min WK [1], 
Lee W [1], Park H [2], 
Park CJ [1], Chi HS [1], 
Chun S [1] 
- 2008 
- Annals of Clinical & 
Laboratory Science. 
[1] Asan Medical Center, 
University of Ulsan 
College of Medicine, 
Seoul, Korea; 
[2] Kangbuk Samsung 
Hospital,Sungkyunkwan 
University School of 
Medicine, Seoul, Korea;  
* Current affiliation: 
Catholic University of 
Korea, College of 
Medicine, Seoul, Korea 
- Funding: Korea Health 
Industry Dev Institute. 
-  Design: Before-after 
- Facility/Setting: 2,200 bed 
tertiary care urban, academic 
medical center, Seoul Korea 
- Time Period: Two 12-month 
study periods 1/01 – 12/05:  
Pre:1/1/01 -12/31/01 
Post: 1/1/05 - 12/31/05 
- Population/Sample: Serum 
potassium alert values –  
Pre:  121 alert calls for 2001: 
ICU:  56; general wards 65 
Post:  96 alert calls for 2005 
ICU: 31; general wards 65 
- Comparator:  Lab tech 
phones nurses on inpatient 
floor to notify of patient CV. 
Nurse then informs physician of 
patient of CV result.  Call 
documented in lab & rcvng loc 
- Study Bias: None 
An automated alerting system 
which involves the use of a 
computerized database (i.e., HIS; 
LIS) -Text messages w/ patient 
information and test result is 
transmitted to appropriate 
physician via PDA phones.   
 
- Duration: 1/1/05 -12/31/05 
 
- Training: Not discussed 
 
- Staff/Other Resources:  Lab 
technicians, nurses, physicians; 
Computer software and PDA 
phones for all physicians 
 
- Cost: not reported 
Outcome Measures: 
(1) Time to receipt - Time 
interval in minutes from 
dispatching critical value result 
alert to acknowledgement by 
responsible caregiver 
 
(2)  Clinical response rate 
(CRR) - response rate defined 
as the frequency of clinical 
responses divided by total # 
critical value alerts 
 
-  Recording method: 
Occurrence log – (1)  





Pretest-Posttest   
- Findings/Effect Size: 
(1)Time to receipt 
 Overall mean decreased by 40.8% 
Pre (2001): 343.3 min (SD = 369.6) 
Post (2005): 203.2 min. (SD = 294.1).  
―Median mean‖ (2001): 213.0 min;  
―Median mean‖ (2005): 74.5 min 
P<.001;   d=-0.419 
(2)CRR - Overall increase:  
Pre: 73.3%  
Post: 79.3% 
General wards - No change (82.3%) 
 ICU - increase: 65.1% (2001) to 73.8% 
(2005) 
- Stat. Significance/ Test(s): 
(1)  p= 0.190 (overall Mean); p <0.001 
(―median Mean‖);  
(2) Overall rate: p=0.265, d = 0.184, OR 
= 1.40 
- Results/Conclusion Bias:  None 
Quality Rating (10 point 
maximum):  6 (Fair) 
 
Effect Size Magnitude 
Rating: Moderate 
(Relevance: Direct) 
Study  (3 pts maximum): 0 
- The time period and sampling 
methods likely to introduce a 
study bias substantially 
affecting results; 4–yr gap with 
relatively small sample 
- Results are unlikely to be 
generalizable to other settings 
given large proportion ICU  
Practice (2 pts maximum): 2 
 
Outcome measures (2 pts  
maximum): 2 
 
Results/findings (3 pts maximum): 2 
- Appropriateness of statistical analysis:  
Compares two practices and their 
estimates are based on data collected 
during notably different time periods 
(2001 v. 2005) 
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Tate KE [1], Gardner RM 




- Proceedings from the 
ANNUAL SYMPOSIUM 
on COMPUTER 
Applications in MEDICAL 
CARE 
 
[1] LDS Hospital, Salt 
Lake City, Utah 
 








- Design: Observational 
 
- Facility/Setting: Private 520-
bed tertiary-care facility part of 
Intermountain Health Care 
Hospital System; LDS Hospital, 
Salt Lake City, Utah; 48-bed 
adult unit nursing division  
 
- Time period:  13-weeks 
(10/1/93-1/21/94)  
 
- Population/Sample:  CV 
alerts for 335 inpatients 
(representing 497 critical 
values or tests) 
 
- Comparator:  None  
(Previous practice:  laboratory 
staff call nursing unit by 
telephone when critical test 
results appear.) 
 
- Study Bias: None 
- Description: Automated 
notification system  
 
- Duration:10/1/1993 – 1/21/1994 
 
- Training: Not discussed 
 
- Staff/Other Resources: 
Laboratory staff and nurses 
 




(1) Time to receipt -Time 
interval (in min.) from 
dispatching CV result alert to 
acknowledgement by 
responsible caregiver (76% of 
all alerts acknowledged by 
primary care nurses) 
 
(2) Timeliness of reporting - % 
CV results reported within 
various time intervals 
 
 
- Recording method: HIS – 








- Findings/Effect Size:  
(1) Time to receipt:  Average weekly alert 
acknowledgment time:  38.6 min.  
 
 (2) Timeliness of CV reporting: 
51% within 12 min. (4.2 min avg.), 
81% within 1 hr.  
95% within 2 hrs.  
 
- Stat. Significance/ Test(s): None 
reported 
 
- Results/Conclusion Bias: None  
Quality Rating (10 point 
maximum):  8 (Good) 
Effect Size Magnitude 
Rating: Not available  
(Relevance: Direct) 
Study  (3 pts maximum): 3 
 
Practice (2 pts maximum): 2 
 
Outcome measures (2 pts  
maximum): 2 
 
Results/findings (3 pts maximum): 1 
- Appropriateness of statistical analysis:  
Does not provide data sufficient to 
allow/verify calculation of an effect size 
- Statistical power not discussed; sample 
may be too small for a robust estimate  
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Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
-Results/Conclusion Bias   
Piva, E [1], Sciacovelli, L 
[1], Zaninotto, M [1], 
Laposata, M [2], Plebani, 
M [1]- 2009 
 
- American Journal of 
Clinical Pathology 
 
[1] Department of 
Laboratory Medicine, 
Padua University School 
of Medicine, Padua, Italy; 
[2] Vanderbilt University 
Hospital, Nashville TN  
 
- Funding: not reported 
 
 
- Design: Before-after 
 
- Facility/Setting: University of 
Padua, Academic medical 
center, > 300 bed inpatient 
hospital; Annual test volume: 
>1,million 
 
- Time period: 1/1/07 – 
2/28/08; 
Pre: 1/1/07-12/31/07 (1 year) 
Post: 1/1/08-2/28/08 (2 mos.) 
 
- Population/Sample: All 
critical values 
Pre: 7,320 CVs (4,394 routine 
inpatient; 2,926 emergency; 
1,323 outpatient) 
Post: Not reported 
- Comparator: Telephone-only 
CV notification system 
- Study Bias: None 
- An automated alerting system 
which involves the use of a 
computerized database (i.e., HIS; 
LIS) of test results. The alert 
message flashes on the monitor 
until the physician or a nurse in 
charge of notification confirms 
that the message has been 
received; the flashing alert is 
stopped after 60 minutes.  
 
- Duration: 1/1/08 – 2/28/08 
 
- Training: Not discussed 
 
- Staff/Other Resources:  
physicians, clinical pathologist, 
nurses, laboratory 
 




(1) Timeliness of reporting - % 
CV results reported within 1 hr:; 
#  unsuccessful notifications 
w/in 1 hr / total # of CVs  
 
 (2) Time to receipt: - Time 
from detection of CV in minutes 
to acknowledgement by 
responsible clinician 
 
- Recording method: register 
(pre-implementation) and HCIS 
(health care information 




- Findings/Effect Size:  
(1)  % Reported  within 1 hour 
Pre: >50% ―unsuccessful‖  
Post: 10.9% 
 
(2)  Time to receipt 
Pre:  Average 30 min;  
Post: Average 11 min 
 
- Stat. Significance/ Test(s): None 
reported 
 
- Results/Conclusion Bias: No post 
sample data (numerator or denominator); 
sample size only for pre-practice period.   
Quality Rating (10 point 
maximum):  8 (Good) 
 
Effect Size Magnitude 
Rating: Substantial  
(Relevance: Direct) 
Study  (3 pts maximum):  3 
 
Practice (2 pts maximum): 2 
 
Outcome measures (2 pts  
maximum): 2 
 
Results/findings (3 pts maximum): 1 
- Appropriateness of statistical analysis:  
Does not provide data sufficient to 
allow/verify calculation of an effect size  
- Sample sufficiency:  Number of post 
period subjects not reported. 
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Practices associated with reduction of BLOOD CULTURE CONTAMINATION 
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
 
TOPIC AREA: Blood Culture Contamination Consensus Ratings 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 





Teams Study Practice Measures Results Total Rating       
Gander et al. 




al. 2008 1 2 2 3 8 Good Substantial   
Surdulescu et 
al. 1998 1 1 1 2 5 Fair Substantial   
Weinbaum et 
al. 1997 2 2 2 3 9 Good Substantial 5 studies = good/substantial 
Providence-
Everett 2009 2 2 2 2 8 Good Substantial 1 study = fair / substantial 
Geisinger 
Wyoming 
2009 2 2 2 3 9 Good Substantial   
            High 
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DEDICATED PHLEBOTOMY TEAMS 
Model Study name Subgroup within study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit
Weinbaum 1997 ** Combined 5.78 3.64 9.16
Sheppard 2008 ** N/A 4.83 1.53 15.28
Geisinger 2009 ** N/A 2.52 2.18 2.91
Gander 2009 ** N/A 2.51 1.84 3.43
Providence 2009 ** Combined 2.44 1.56 3.82
Surdulescu 1998 * N/A 2.09 1.68 2.61
Random 2.76 2.17 3.51
0.1 0.2 0.5 1 2 5 10
Favours ComparisonFavours DPT
Boxes proportional to weights
 
**=”Good” Study Quality rating  
*=”Fair” Quality rating 
Boxes proportionate to study size 
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Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Gander RM (1,2), Byrd L (2), 
DeCrescenzo M (3), Hirany S 
(2), Bowen M (2), Baughman 
J (2)  
- 2009 
-  Journal of Clinical 
Microbiology 
- [1] Dept of Pathology, 
University of Texas 
Southwestern Medical Center, 
Dallas Texas 
  [2] Dept of Pathology, 
Parkland Health and Hospital 
System 
  [3] Dept of Performance 
Improvement, Parkland Health 
and Hospital System 
- Funding not reported 
- Design:  Cohort Study (Groups 
defined by predictor) 
-  Facility/Setting:  Parkland Memorial 
Hospital - 968 bed tertiary care 
teaching hospital,  Dallas, Texas 
-  Time Period: 12/1/2006-12/31/2007 
(data collected for 5 separate months 
over  a 13- month period) 
- Population/Sample: 3,662 blood 
cultures from 2,642 adult patients in ED 
west: 2,012 blood cultures by 
phlebotomists; 1650 blood cultures by 
nonphlebotomy staff  
  -*Comparator: Venipuncture by 
Nonphlebotomy staff  
- Study bias:  
  - ED setting/samples only 
  - Students and other limited 
experience/skill staff used for 
comparator  
Description: Dedicated 
phlebotomy team assigned to 
manage all blood collection 
and specimen activities 
- Duration:   13 months 
(12/1/2006- 12/31/2007; 
ongoing afterward) 
- Training: not discussed, but 
phlebotomist must be certified. 
-Staff/Other Resources:  
 Cultures collected by 
phlebotomy teams Aerobic and 
anaerobic bottles with media. 









-Recording method:  
 Blood culture data 
reviewed for 5 separate 
months (at 3 month 




- Comparison (cross-sectional)  
 
- Findings/Effect Size: 
BCCR 
Dedicated phlebotomy practice: 
Overall:  3.1%  (62/2012); 
monthly range:  2.4 to 3.6   
Nonphlebotomy:  
 Overall:  7.4% (122/1650); 
 monthly range 6.2 to 10.2% 
 
Effect Size: OR = 2.51 (CI,1.84 – 
3.43) 
- Statistical significance/Test(s): 
chi-square =34.41 df=1, p<.0001 
 





Quality Rating (10 point 
maximum):  9 (Good) 
Effect Size Magnitude 
Rating: Substantial 
( Relevance: Direct) 
Study  (3 pts maximum): 2 
- Only ED setting/patients/tests; not 
generalizable due to higher ED BCCRs  
Practice ( 2 pts maximum): 2  Outcome measures (2 
pts. Maximum): 2 
 
Results/findings (3 pts maximum): 
3 
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- Type of Findings  
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-  Sheppard C (1), Franks N 
(2), Nolte F(1), Fantz C (1). 
- 2008  
- Am J Clinical  Pathology  
 [1] Department of Pathology 
and Laboratory Medicine, 
Emory University, Atlanta, GA. 
 [2] Department of Emergency 
Medicine, Emory University, 
Atlanta, GA.  
- Funding: Self-funded 
- Design:  Cohort Study 
Facility/Setting: Emory Crawford Long 
Hospital; Academic Medical Center 
Atlanta, GA, USA 
Time Period: No dates reported – 9 
months (6 months comparator; 3 
months practice) 
-  Population/Sample: Total 2,854 
blood cultures collected in the ED; 
nonphlebotomist comparator 6-month 
sample = 2,576; phlebotomy practice 3-
month sample 278 
 Note:  1/4 - 1/3 of all blood cultures in 
hospital from the ED 
- Comparator: Nonphlebotomy staff 
working 2:00 pm to 10:00 pm collected 
6 months before the intervention. 
- Study bias: Potential patient selection 
bias – higher acuity for phlebotomist. 
ED only 
Description: Phlebotomist 
dedicated to the ED randomly 
collected specimens on the 
weekday evening shift (2:00 
pm-10:00 pm)  
Duration:  3 months. – no 
dates reported  
- Training: Not reported 
- Staff:  
 1 dedicated lab phlebotomist  
-Cost/Other Resources:   
Proposed implementation- 
annually for dedicated 
phlebotomist in ED (annual 
blood culture volume of 
approximately 6,000):  8.4 
FTEs  at $13.49/h (2.0 FTEs 
each for day, evening, and 
night shifts and 2.4 FTEs for 





- Recording method: 
BCC data collected 
quarterly and reported by 







Phlebotomist: 1.1% (3/278 cultures) 
Nonphlebotomist::  5.0% (129/2576 
cultures) 
Note:  1.1% for phlebotomist 
collection was not significantly 
different from the average 
phlebotomy rate for the hospital of 
1.3%. 
 






-Results/conclusion biases: none 
 
Sheppard 2008 
Quality Rating (10 point 
maximum):  8 Good  
Effect Size Magnitude 
Rating: Substantial 
( Relevance: Direct) 
Study  (3 pts maximum): 1 
- Study/practice dates not provided 
- ED setting only 
- Practice sample "random" but small 
relative to total volume 
Practice ( 2 pts maximum): 2 Outcome measures (2 
pts. maximum):  2 
 
Results/findings ( 3 pts 
maximum): 3 
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- Type of Findings  
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-Ramsook C (1,2), Childers K 
(2), Cron SG (3), Nirken M (2) 
- 2000 
- Infect Control Hosp 
Epidemiology 
[1] Eric Williams Medical 
Sciences Complex 
 [2] Emergency Medicine, 
Texas Children's Hospital, 
Baylor College of Medicine, 
Houston, TX  
[3] Academic General 
Pediatrics, Baylor College of 
Medicine 
- Funding not reported 
 
-  Design: Observational Study  
- Facility/setting: Texas Children's 
Hospital; Houston University-affiliated 
pediatric emergency room Houston, 
Texas, USA 
- Time period: 2/1/1999-7/31/1999  
- Population/Sample: Single blood 
cultures drawn by phlebotomists from 
1,073 patients  
- Comparator:  Venipuncture by nurses 
using three sequential Betadine swabs 
followed by three sequential alcohol 
swabs for skin antisepsis 
-Study biases:  
-Pediatric ED setting 
- Limited experience/skill staff used for 
comparator 
Description: Laboratory 
phlebotomists using one 
Betadine swab followed by one 
alcohol swab for skin 
preparation   
- Duration: 6 months 
- Training: not discussed, but 
phlebotomist must be certified. 
- Staff/Other resources: 
Cultures processed by 
laboratory phlebotomist,  
swabs, and alcohol swabs 






Blood culture data 
reviewed for 6 month 
period. 
 





Overall: 2.0% (17/646); 2.6%  
Nonphlebotomy:  
Overall: (5/427); 1.2%  
 
 - Statistical significance/Test(s): 
-  Phlebotomist versus not-
phlebotomist relation not tested 
- Statistical power is not discussed 
Effect Size: OR = 0.44 (CI,0.16 – 
1.20) 
- Results/conclusion biases: 
Potential confound if phlebotomists 
are used to collect samples from 
younger patients (documented 
relationship of patient age with 
BCCR); potential confound from 
different skin preparation 
 
Ramsook 2000 
*Quality Rating ( 10 point 
maximum): 5 Fair  
Effect Size Magnitude 
Rating: Adverse 
 (Relevance: Direct) 
Study (3 pts maximum): 2  
- Only Pediatric ED setting; not 
generalizable due to high ED BCCRs 
Practice (2 pts maximum): 2  
 
Outcome measure (2 pts. 
Maximum): 1 
Clinical histories not 
obtained, patients on 
antibiotics not excluded   
*Results/findings (3 pts 
maximum): 0 
- More rigorous skin prep technique 
applied by nurses is a potential 
confounder for lower BCCR rates   
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-  Surdulescu S(1), Utansingh 
D(1), Shekar R(1) 
- 1998 
- Clinical Performance and 
Quality Healthcare 
- Dept. of Internal Medicine, 
The Division of Infectious 
Disease, St. Luke's Medical 
Center, Case Western 
Reserve University, 
Cleveland, Ohio 





- Design: Retrospective cohort 
study/Natural experiment with nested 
case-control study (Groups defined by 
outcome). 
Facility /Setting: St. Luke's Medical 
Center, Case Western Reserve 
University, Cleveland, Ohio 
- Time period: 1/1/1993-12/1/1995 
-  Population/Sample: Observational 
study: Sample size not explicitly stated. 
6900 phlebotomy venipunctures in 
1995. Case-control study  23 patients 
contaminated blood cultures matched 
with 23 patients with negative blood 
cultures1    Comparator: Non-
phlebotomy staff blood draws with prep 
kit 
- Study bias: none noted  
Dedicated phlebotomy team 
assigned to manage all blood 
collection and specimen 
activities.  Blood draws with 
prep kit. 
Duration: 24 months 
- 1/1/1993-12/1/1995 
- Training: not discussed, but 
phlebotomist must be certified. 
- Staff: not discussed  









- Recording method: Not 
described for cohort study.  
 
Case-Control: Chart 











Dedicated Phlebotomy practice: 
2.6 %From Jan 1993-Oct 1993  
Nonphlebotomy:  
5.6%From Jan 1993-Oct 1993  
Phlebotomy teams were eliminated  
From Nov 1993-Dec 1995 
Overall: 4.5 % to 5.8% in 1994 and 
5.3% in 1995; p=.001  
 
Effect Size: OR = 2.09 (CI,1.68 – 
2.61) 2 
- Statistical test: Chi-square, 2 df. 
- Statistical power is not discussed. 
- Results/conclusion biases: none 
noted 
*Quality Rating (10 point 
maximum: 5 Fair 
Effect Size Magnitude 
Rating: Substantial 
( Relevance: Direct) 
Study (3 pts maximum): 1 
-Cohort sample size not explicitly stated 
- Use of commercial prep kit potentially 
limits generalizability  
Practice (2 pts maximum): 1 
-Staffing qualifications for 
practice and comparator not 
well-described. 
Outcome measure: ( 2 
pts maximum): 1 
-  As QC, it is unknown 
whether same physicians 
drawing the cultures were 
reviewing the charts. 
Results/conclusion Biases: (3 pts 
maximum) 2 
- Denominators for proportions not  
reported  
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- Weinbaum FI (1, 2), Lavie S 
(3), Danek M (2), Sixsmith D 
(4), Heinrich GF (5), Mills SS 
(5). 
- 1997 
-  Journal of Clinical 
Microbiology 
- New York Hospital Medical 
Center of Queens, Flushing, 
New York 
[1] Dept of Surgery  
[2] Dept of Quality 
Management 
[3] Dept of Pathology 
[4] Dept Emergency Medicine  
[5] Administration 
- Funding not reported  
- Design: Nonrandomized prospective 
intervention trial 
- Facility/Setting: New York Medical 
Center Hospital of Queens; 487 bed  
Community Hospital Center Flushing, 
NY, USA 
- Time period: No dates reported- 9 
months ( 6 months comparator; 3 
months practice)  
-  Population/Sample: 956 Blood 
cultures drawn by Blood Culture 
Collection Team (BCT) with prep kits 
- 2 Comparators: (1) House staff 
conducting draws without prep kits. (2) 
House staff conducting draws with prep 
kits. 
- Study bias: none noted  
- Description: 
Blood Culture Team (BCT) 
made up of three full-time 
phlebotomists with prep kits. 
- Duration: 9 months- no dates 
reported 
- Training: not discussed, but 
phlebotomist must be certified 
- Staff/Other resources: 
Three full-time phlebotomists 
using prep kits; aerobic and 
anaerobic bottles  






- Recording method: 














House staff with prep kit 4.8%, (.016) 
House staff without prep kit  8.4% 
(.014) 
DPT with prep kit 1.1% (.004) 
 
Effect Size: OR = 4.34 (CI,1.82 – 
10.36) 
- Statistical significance/Tests: 
Mantel Haenszel Chi-square = df=1, 
p<0.001; For house staff with prep kit 
vs. house staff without prep kit, 
P=.173. 
 
- Results/conclusion biases: none 
Noted 
Quality Rating ( 10 point 
maximum): 9 Good 
 
Effect Size Magnitude 
Rating:  Substantial 
 
( Relevance: Direct) 
Study (3 pts maximum): 2 
-No dates for time period specified, 
however duration of practice described; 
concomitant use of second practice 
(commercial prep kit) potentially limits 
generalizability.  
Practice ( 2 pt maximum): 2 
 
Outcome measures( 2 
pts maximum): 2 
Results/findings ( 3 pts 
maximum): 3 
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Unpublished  
 
-  Providence Regional 
Medical Center – Everett 
-2009 
-LMBP Network 
-  Funding: In house - as part 
of ongoing Patient 
Safety/Quality Indicators from 








- Design: Before-after 
- Facility/Setting: Providence Regional 
Medical Center – Everett; Non-teaching 
hospital; >300 beds Everett, 
Washington, USA 
- Time period: 1/1/2005-7/31/2009 
-  Population/Sample: Currently 
process ~1900 blood cultures per 
month. In 2005 the volume was ~1100. 
- *Comparator: Venipuncture and line 
draws by  Non-phlebotomy staff 
- Study bias:  
- ED and CCU setting/Samples 
Based on data points for 2 months – 
cannot assess long-term variation 
 
- Description: 
Blood cultures collected by Lab 
phlebotomists; training coupled 
with individualized feedback to 
personnel performing blood 
draws. 
- Duration: 1/1/2005; ongoing 
afterward 
- Training: Data sharing with 
Nursing and medical staff; 
education on collection 
technique. 
-Staff/Other Resources: ~400 
hours of phlebotomy support to 
draw 700+ BC/mos collected 
by nursing staff.  





- Recording method: 
Internal quality control 















Jan – Mar, 2005    
-Lab Phlebotomy Team     3.0%    
-Non Lab personnel           6.0% 
May – Jul, 2009  
-Lab Phlebotomy Team     0.9% 
-  Non Lab personnel         3.1% 
Effect Size: OR = 2.44 (CI, 1.56 – 
3.82)1 
 
- Statistical power is not discussed 
- Results/conclusion bias:  
- Possible confound by change in 
prevalence of non-phlebotomist use 
of venous catheters for blood 
specimens over 4.5 year study 
period 
Quality Rating (10 point 
maximum): 8 Good 
Effect Size Magnitude 
Rating: Substantial 
( Relevance: Direct) 
Study (3 pts maximum): 2 
- Generalizability limited because of 
concomitant use of second practice 
(individualized monitoring & feedback). 
Practice (2 pts maximum): 2 Outcome measures (2 
pts maximum): 2 
Results/findings (3 pts maximum): 
2 
- Change in prevalence of line draws 
by non-phlebotomists is a 
confounder for results     
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Unpublished  
 
- Geisinger Wyoming Valley 
Hospital 
- 2009 




- Design: Observational – time series 
- Facility/Setting: Geisinger Wyoming 
Valley Hospital; Inpatients, ER, Urgent Care 
and Outpatients, Wilkes-Barre PA 
- Time period: 1/2006-9/2009 (45 months) 
-Population/Sample: All inpatients, 
Emergency Department, Urgent Care and 
Outpatients. Approximately 98% of the 
blood cultures collected are inpatient and 
Emergency Department 
On average, 780 blood cultures collected at 
site monthly in 2009. 73% by phlebotomists; 
total estimated sample size approximately 
35,100  (45  x 780); 9,360/year 
- *Comparator: Venipuncture and line  
collections (A-line, Pic line, dialysis etc…) 
by nonphlebotomy staff  
- Study bias: Inclusion of line draws in 
comparator may bias estimated difference 
in rates. 
- Description: Blood cultures 
collected by laboratory 
phlebotomists. All lab draws are 
peripheral collections. 
 
- Duration: 45 months 
1/2006-9/2009; ongoing 
 
- Training: not discussed, but 
phlebotomist must be certified. 
 
-Staff/Other Resources: Cultures 
collected by laboratory 
phlebotomist. 
 
- Cost: not reported 
Description: Blood Culture 
Contamination Rate (BCCR) 
Laboratory phlebotomist  
Nonphlebotomy 2 
- Recording method: All 
blood cultures designated by 
Microbiology to be 
contaminants. 
 
Observational – time series 
Findings/Effect Size: BCCR  
Laboratory phlebotomist:  




2009 (9 months): 1.5% 
Overall monthly average: (45 months): 
1.8% 
Non-phlebotomy: 
Annual monthly averages 
2006:  4.9% 
2007: 4.3% 
2008:  3.9% 
2009 (9 months): 3.9% 
Overall monthly average (45 months):   
4.3% 
Effect Size: OR = 2.52 (CI, 2.18 – 2.91)4 
- Statistical significance/Tests(s): 
Monthly averages reported; statistical 
analysis/testing not reported, but analysis 
by reviewers obviates need. 
 Results/conclusion biases: None 
Geisinger 2009 
Quality Rating ( 10 point 
maximum): 9 (Good) 
Effect Size Rating: 
Substantial 
 (Relevance:  Direct) 
 
Study ( 3 pts maximum): 2 
- lack of monthly sample size data 
Practice(2 pts maximum): 2 Outcome measure (2 pts 
maximum): 2 
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Consensus Ratings 2009 
 
VENIPUNCTURE VS. INTRAVENOUS CATHETER STUDIES 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency Overall Strength of Body of Evidence 
Practice: 
Venipuncture  
(vs. Catheter)  
Collection Site Study Practice Measures Results Total Rating       
Desjardin et 
al. 1999 3 1 2 3 9 Good Moderate 
Yes 
  
Everts et al. 
2001 3 1 1 3 8 Good Substantial   
Martinez et 
al. 2002 3 2 1 1 7 Fair Substantial 3 Studies = Good/Substantial 
McBryde et 
al. 2005 3 2 2 3 10 Good Substantial 1 Study = Good/Moderate 
Ramsook et 
al. 2000 3 2 1 1 7 Fair Moderate 2 Studies = Fair / Substantial 
Norberg et al. 
2003 3 2 1 3 9 Good Substantial   
            High 
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**=”Good” Study Quality rating  
*=”Fair” Quality rating 
Boxes proportionate to study size 
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- Author (s)   
- Yr Published/Submitted  
- Publication  
- Author Affiliations 
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
- Description   
- Duration  
- Training  




- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Beutz M (1), Sherman G (2), 
Mayfield J (3), Fraser VJ (4), 
Kollef MH (1). 
 
- Year: 2003 
 
- Publication: -Chest 
 
- Author Affiliation: 
(1) Pulmonary and Critical 
Care Division, Washington 
University School of Medicine; 
(2) Departments of Nursing, 
Barnes-Jewish Hospital;  
(3) Infection Control, Barnes-
Jewish Hospital  
(4) Division of Infectious 
Diseases, Washington 
University School of Medicine 
 
- Funding: not reported 
- Design: Prospective cohort  
 
- Facility/Setting: Barnes-
Jewish hospital; Teaching 
hospital; ICU > 300 beds St 
Louis, MO, USA. 1,600 ICU 
admissions annually 
- Time Period: 
2/1/2001-10/30/2001 
- Sample: All 119 patients 
admitted to ICU with 
temperatures > 38.3 C and BC 
specimens drawn from a 
central vein catheter (CVC) and 
peripheral venipuncture (PV) 
within 4 hours of each other. 
Multiple pairs allowed if drawn 
> 24 hours apart. 300 BC pairs 
- Comparator: BC drawn by 
PV, 70% isopropyl alcohol 
followed by 2% iodine 
disinfectant 
- Biases: None 
- Description: Blood 
cultures drawn  from Central 
Venous Catheters1 
 
-  Duration: 8 months 
 
- Training: not discussed 
 
- Staff: Blood cultures 
obtained by critical care 
nursing staff. 
 
- Cost: not reported 
 






- Recording method: Two 
study physicians blinded to 
the site of BC classified 
paired cultures.2 
If both BC positive, 
accepted as positive; if both 
BC negative, accepted as 
negative. Disparate results 
resolved for true 
bacteremia. 
- Type of Findings: Paired comparisons 
 
- Findings:  
(1) BCCR: CVC= 20/300 (6.7%); PV =  
11/300 (3.7%). Remainder (269/300) 
correctly identified. 
 (2) PPV: CVC = 58.3% (CI, 44.4% to 
72.2%);  PV = 66.7% (CI, 50.6% to 82.8%). 
(3) Specificity: CVC = 92.5% (CI, 89.4% to 
95.6%); PV = 95.9% (CI, 93.5% to 98.3%) 
 
Effect Size: OR = 1.88 (CI, 0.88 – 3.99) 
- Statistical Significance/Tests: 
- Difference in main effects not tested, CI 
for results 2 & 3 = no significant differences 
Catheter vs. PV 
- Stepwise mult. logistic regression  
- Statistical power is not discussed 
 
- Results/conclusion bias: none 
 
Quality Rating  
(10 point maximum):  9 
Good 
Effect Size Magnitude 
Rating: Moderate  
( Relevance: Direct ) 
Study   
(3 pts maximum): 3 
Practice  
(2 pts maximum): 2 
Outcome measures  
(2 pts  maximum): 2 
Results/findings  
(3 pts maximum):2 
- Difference in main effects not tested 
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- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- DesJardin JA (1), Falagas 
ME (2), Ruthazer R (3), Griffith 
J (3), Wawrose D (4), 
Schenkein D (3), Miller K (3), 
Syndman DR (3) 
 
- Year: 1999 
 
- Publication: Annals of 
Internal Medicine 
 
- Author Affiliation: 
(1) Western Infectious 
Disease Consultants 
 (2) Athens, Greece 
 (3) New England Medical 
Center 
 (4) Nashville, TN 
 
- Funding: In part by National 
Research Service Award T32-
A107329 training grant from 
NIH, 
- Design: Retrospective cohort  
 
- Facility/Setting: New England 
Medical Center; Academic 
Medical Center; 100-300 beds;  
Tertiary oncology ward, 
Boston, MA, USA 
 
- Time Period: 8/1/1994-
6/1/1996 
 
- Sample: 551 paired BC 
cultures obtained from 185 
patients with 306 admissions. 
Paired culture defined as at 
least one BC clearly labeled as 
drawn from a central venous 
catheter and at least one blood 
sample drawn through a 
peripheral venipuncture (PV). 
Blood samples had to be drawn 
within 4 hours of each other. 
- Comparator: PV 
- Study Bias: None noted 
- Description: Blood cultures 
drawn from Central Venous 
Catheters (CVC) paired 
blood cultures. 
 
- Duration: 22 months 
 
- Training: Not discussed 
 
- Staff/Resources: Not 
described 
 
- Cost: Not reported 
- Description: 3Outcome 
measures: 
(1) Blood Culture 
Contamination Rate 
(BCCR) – percentage of all 







Retrospective screening of 
all BCs. Blinded 
assessments of culture 
results done by infectious 
disease experts were used 
as the gold standard.1 
 
- Type of Findings: Paired Comparisons 
 
- Findings:  
(1) BCCR:CVC = 24/552 (4.3%); PV = 
13/552 (2.35%) 
 (2) PPV: CVC= 63% (CI= 50% - 75%); PV    
= 73% (CI=60% - 86%) 
 (3) Specificity CVC 95% (CI =93% - 97%) 
PV =  97% (CI=96%-99%) 
 
Effect Size: OR = 1.88 (CI, 0.95 – 3.74) 
 
- Statistical Significance/Tests: 
- Bootstrap methods used to adjust for 
potential clustering around patient, hospital 
admission, and blood culture.2  
- Statistical power is not discussed/NA 
 
-Results/conclusion bias: None noted 
Quality Rating  
(10 point maximum):  9 
(Good) 
Effect Size Magnitude 
Rating: Moderate 
(Relevance: Direct ) 
Study   
(3 pts maximum): 3 
Practice  
(2 pts maximum): 1 
- Staffing qualifications for 
practice not described. 
Outcome measures  
(2 pts  maximum): 2 
Results/findings  
(3 pts maximum): 3 
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- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- McBryde, ES(1,2), Tilse, M(2), 
McCormack, J(2). 
 
- Year: 2005 
 
- Publication: Journal Hospital 
Infection 
 
- Author Affiliations:  
(1) Queensland University of 
Technology, Brisbane, 
Queensland Australia 
 (2) Department of Medicine and 
Department s of Infectious 
Diseases  and Microbiology, 
University of Queensland, Mater 
Misericordiae Hospital, Brisbane, 
Queensland, Australia. 
 
-Funding: not reported 
 
- Design: Retrospective cohort 
study 
 
- Facility/setting: Mater 
Misericordiae Hospital, 280 beds; 
Teaching hospital; Hematology/ 
oncology Ward, ICU, and General 
wards Brisbane, Queensland 
Australia 
 
- Time Pd: 1/1/1998- 8/1/2002 
 
- Sample: 962 paired peripheral 
and catheter-drawn cultures from 
same patient within 120 min of 
each other. Limited to 1 pair per 
day. 10  mL blood split evenly 
between anaerobic and aerobic 
culture bottles at the bedside. 
 
- Comparator: Peripheral Vein 
Draw (PV) BC drawn from patients 
within 120 min. of central venous 
catheter draw.  
- Skin prep not described 
- Staff not described 
 
- Biases: None noted 
- Description: Central venous 
catheter (CVC); Specimen 
drawn  by ward nursing staff on 
the haematology/ oncology 
ward, by resident doctors in the 
intensive care unit and by 
trained phlebotomists in general 
wards. Interlink catheter system 
cleaned with 70% isopropyl 
alcohol swabs 
 
- Duration: 44 Months 
 
-Training:  Nursing staff on the 
hematology/oncology ward, 
resident doctors in ICU, and 
trained phlebotomists in the 
general wards. 
 
- Staff/resources:  Various staff 
involved with the BC collections; 
Bactec 9240 automated BC 
system  
 
-Cost: Not reported 
 
- Description:  
(1) Blood Culture 
Contamination Rate (BCCR) – 
percentage of all blood 




Retrospective chart review and 
microbiology data.1 
 
- Type of Finding(s): Paired comparison  
 
- Finding(s): 
(1) BCCR:CVC = 125/962 (13.0%); PV = 25/962 
(1.3%) 
(2) Specificity CVC 85% (CI =82% - 87%) PV =  
97% (CI= 95%-98%) 
 
Effect size: OR = 5.60 (CI, 3.61 – 8.69) 
 
- Statistical Significance/Tests:  Not conducted 
for finding, but CI indicates p. <0.05 for 
specificity 
- Statistical power is not discussed 
 
- Results/conclusion bias: None noted 
 
Quality Rating (10 point 
maximum): 10  (Good) 
Effect Size Magnitude 
Rating: Substantial 
( Relevance: Direct ) 
Study   
(3 pts maximum): 3 
Practice  
(2 pts maximum): 2 
Outcome measures  
(2 pts  maximum): 2 
Results/findings  
(3 pts maximum): 3 
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- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Ramsook C (1,2), Childers K 
(2), Cron SG (3), Nirken M (2) 
- Year: 2000 
- Publication: Infect Control 
Hosp Epidemiol 
- Author Affiliations:  
(1) Eric Williams Medical 
Sciences Complex 
 (2) Emergency Medicine, 
Texas Children's Hospital, 
Baylor College of Medicine, 
Houston, TX  
(3) Academic General 
Pediatrics, Baylor College of 
Medicine 
- Funding: not reported 
 
-  Design: Observation: IV 
catheter (IVC) drawn by nurses 
compared with venipuncture 
(V) drawn by nurses and 
phlebotomists 
 
- Facility/setting: Texas 
Children's Hospital; Houston 
University-affiliated pediatric 
emergency room Houston, 
Texas, USA 
 
- Time Period:  
2/1/1999-7/31/1999 
 
- Sample: Single BC drawn 
from 2,431 patients  
 
- Comparator: venipuncture by 
nurse or laboratory 
phlebotomist1 
 
- Bias: None noted 
- Description: Single IV 
catheter (IVC) draw by 
nurses using three 
sequential Betadine swabs 
followed by three sequential 
alcohol swabs from 1295 
patients.  
 
- Duration: 6 months 
 
- Training:  Not discussed 
 
- Staff/resources:  lab 
phlebotomist and nurses; 
aerobic bottles, Betadine 
swabs, alcohol swabs, 
saline, Bactec 9240, 
 
- Cost:  Not reported 
 
 
- Description: Blood Culture 
Contamination Rate 
(BCCR) – percentage of all 
blood cultures growing 
contaminants 
 
-Recording method: Only 
aerobic cultures. Review 
performed during specified 
time period (6 months) of 
age, blood site collection, 
contaminant/ pathogen; 
practice, and skilled staff 
performing blood culture. 
 




(1) BCCR: IVC = 44/1295 (3.4%); V = 
22/1084 (2.0%) 
(2) BCCR: Nurse IVC = 44/1295 (3.4%) 
(3) BCCR: Nurse V = 5/427 (1.2%) 
(4) BCCR: Laboratory phlebotomist V = 
17/642 (2.6%) 
 
Effect Size: OR = 1.70 (CI, 1.01 – 2.85) 
 
- Statistical Significance/Tests: 
-  IVC versus V relations not tested 
- Statistical power is not discussed 
 
- Results/conclusion bias: Possible 
confound by relative skill of person 
performing draw and by skin preparation. 
*Quality Rating  
(10 point maximum): 7 (Fair) 
Effect Size Magnitude : 
Moderate 
Rating: ( Relevance: Direct ) 
Study   
(3 pts maximum): 2 
- Pediatric ED setting may 
not be generalizable 
Practice  
(2 pts maximum): 2 
Outcome measures2 
(2 pts  maximum): 1 
-  Clinical histories not 
obtained patients on 




(3 pts maximum): 2 
- Results may be influenced by different 
preparation systems or age of sample 
for different practices. 
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- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Norberg, A(1,2), Christopher, N. 
C.(1,2),  Ramundo, M. L. (1,2), 
Bower, J. R. (1,2), Berman, S. A. 
(1). 
 
- Year: 2003 
 
- Publication: Journal of 
American Medical Association 
 
- Author Affiliations:  
(1) Divisions of Emergency 
Medicine and Infectious 
Diseases, Dept of Pediatrics 
Children's Hospital Medical 
Center of Akron, Akron, Ohio 
(2) Northeastern Ohio Universities 
College of Medicine, Rootstown, 
Ohio 
 
- Funding: not reported 
 
- Design:  Observational Pre-Post 
study 
 
- Facility/Setting:  Emergency 
Department, Children's Hospital 
Medical Center of Akron, Akron, 
OH   
 
- Time Period: 1/1/1998-
12/31/1999  
 
- Sample: 4,108 Blood culture 
specimens from emergency 
department patients <18 yrs. age  
Venipuncture:  2,000 
Cather:  2,108 
 
- Comparator: Peripheral 
intravenous catheter (PIC): blood 
culture specimens obtained by ED 
registered nurses through newly 
inserted  peripheral intravenous 
catheters (1/1/1998-11/19/1998) ; 
indwelling, vascular catheters 
excluded 
 
- Study bias:  Pediatric 
emergency department setting 
- Description: Venipuncture (V) 
at a dedicated site distant to the 
catheter (if required). 
 
-  Duration: 12 months 
 
- Training: Not discussed 
 
- Staff: ED registered nurses  
 
- Cost: Not reported 
 
- Description: Blood Culture 
Contamination Rate (BCCR) – 
percentage of all blood 
cultures growing contaminants 
 
-Recording method: Blinded 
assessment of pathogenicity or 
contaminant.1 
- Test for isolates not 
discussed 




(1) BCCR: PIC = 191/2108 (9.1%); V = 56/2000 
(2.8%) 
 
Effect Size: OR = 3.46 (CI, 2.55 – 4.69) 
 
Statistical Significance/Tests: 2-sample test of 
proportions P <.001 
 
- Results/Conclusion bias: None noted 
 
*Quality Rating (10 point 
maximum):  8(Good) 
Effect Size Magnitude 
Rating:Substantial 
( Relevance: Direct ) 
Study  
(3 pts maximum):  2 
-  Pediatric emergency 
department setting may not be 
generalizable. 
Practice  
(2 pts maximum): 2 
Outcome measures  
(2 pts  maximum): 1 
- Recording method not 
well described 
Results/findings  
(3 pts maximum): 3 
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- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Martinez JA (1,2), DesJardin JA 
(1,2), Aronoff M (1,2), Supran 
S(1,2), Nasraway SA (1,2), 
Snydman DR (1,2). 
 
- Year: 2002 
 
- Publication: Critical Care Med 
 
- Author Affiliations:  
(1) Departments of Medicine and 
Surgery, New England Medical 
Center 
( 2) Tufts University School of 
Medicine 
 
- Funding: Supported in part by 
National Research Service Award 
T32-AI07329 from NIH 
 
- Design: Retrospective cohort 
study 
 
- Facility/Setting: Surgical and 
cardiothoracic ICU, New England 
Medical Center; Academic Medical 
Center; 100-300 beds; Boston, 
MA, USA 
 
- Time Period: 11/1/1994- 8 
1/1997 
 
-Sample: 271 critically ill surgical 
patients in whom samples for 
paired cultures were drawn by a 
critical care nurse within 4 hours 
through a central venous or arterial 
catheter (C) and peripheral 
venipuncture (PV) = 490 paired 
BC.  
 
- *Comparator: BC drawn through 
a peripheral venipuncture by 
critical care nurses; skin 
disinfected with povidone-iodine.  
 
- Study Bias: None noted 
- Description: Central Venous 
Catheter or Arterial Catheter. 
Catheter ports or stopcocks 
were disinfected with either 
povidine-iodine or 75% 
isopropyl alcohol 
 
- Duration: 33 months 
 
- Training: Not discussed. 
 
- Staff/resources: Critical care 
nurses;  
 
-Cost:  Not reported 
 
- Description: (1) Blood 
Culture Contamination Rate 
(BCCR) – percentage of all 





-Recording method:  Two 
physicians blinded to BC 
source classified paired 
cultures with at least one 
positive result as true 
bacteremia (or fungemia) or 
contamination.1  
-Each undetected contaminant 
counted as a separate 
observation.2  
- A 10-mL blood sample 
inoculated in aerobic and 
anaerobic media and 
processed by using ESP 384 
Blood Culture system. 
 
 
-Type of Finding(s): Paired Comparison  
- Descriptive (one group) 
 
- Findings:  
(1) BCCR:C = 20/499 (4.0%); PV = 8/499 (1.6%) 
(2)  PPV: CVC= 63% (CI= 51% - 76%); PV = 
78% (CI=64% - 91%) 
(3) Specificity C 95% (CI =94% - 97%) PV =  
98% (CI= 97%-99%) 
 
Effect Size: 2.57 (CI, 1.13 – 5.89) 
 
- Statistical Significance/Tests:  
- Authors use bootstrapping to adjust for 
potential clustering around patient, hospital 
admission, and BC since they included multiple 
blood culture pairs from the same patient.3 
- Statistical power is not discussed 
 
- Results/conclusions biases: Discrepancy in 
number of paired cultures 490 in sample 
description 499 in results4 
 
Quality Rating (10 point 
maximum): 7 (Fair) 




(3 pts maximum): 3 
Practice 
(2 pts maximum): 2 
Outcome measures 
(2 pts  maximum): 1 
- Recording method 
provides multiple counts for 
dependent samples 
Results/findings 
(3 pts maximum): 1 
- Discrepancy in number of paired cultures 
490 in sample description 499 in results4 
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Laboratory Medicine Best Practices 
Consensus Ratings 2009 
PRE-PACKAGED PREP KITS VS. NO PRE-PACKAGED PREP KITS 
 
  Study Quality Rating Effect Size Rating 
Overall 
Consistency 




Kits Study Practice Measures Results Total Rating       
Trautner et al. 
2002 2 2 1 2 7 Fair Substantial 
Yes 
  
Wilson et al. 
2000 2 1 2 3 8 Good Minimal/None   
McLellan et 
al. 2008 2 2 2 2 8 Good Minimal/None 1 Study = fair/substantial 
Weinbaum et 
al. 1997 2 2 2 3 9 Good Minimal/None 3 studies = good/minimal 
                  
            High 
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**=”Good” Study Quality rating  
*=”Fair” Quality rating 
Boxes proportionate to study size 
Blood Culture Contamination Evidence Summary Tables (2009) 




- Author (s)   
- Yr Published/Submitted  
- Publication   
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
- Trautner W [1], Jill EC [1, 2], Rabih 
O D[1,3] 
 - 2002   
- Infection Control and Hospital 
Epidemiology 
  [1] Dept of Medicine, Infectious 
Diseases Section, Baylor College of 
Medicine, Houston, Texas 
  [2] Dept of Pathology, Veterans 
Affairs Medical Center and Baylor 
College of Medicine, Houston, 
Texas.   
  [3] Dept of Physical Medicine and 
Rehabilitation, Center for 
Prostheses and Infection. 
Funding: Houston Dept of Veterans 
Affairs and Medi-Flex Hospital 
Products 
 
- Design:   Prospective single-blind clinical 
trial in which each patient received both 
interventions; both interventions compared 
with external referent group [1] 
- Facility/Setting VA Medical Center, 
Houston, Texas; Tertiary-care teaching 
hospital 
Time Period: 11/12/2000- 5/31/2001 
- Sample:  Paired blood culture sets 
collected from two venipuncture sites in 
each of 215 patients,  
Comparator: 383 BC paired specimens (2 
venipuncture sites) using povidone iodine 
swabs or povidone iodine poured onto a 
cloth swab. BC specimens collected during 
1st 6 weeks of the study from patients on 
the same wards as study patients. 
Study bias:  Authors cite 2 potential 
sources: 
- ―Sicker‖ patients, requiring greater skill in 
venipuncture, less likely to be selected to 
participate by house staff. 
- House staff more skilled in phlebotomy 
technique more likely to participate in study. 
- Description: Paired 
specimens collected from two 
venipuncture sites in each pt., 
using commercial prep kits. 3 
  
Duration: 1/1/1998- 12/31/1999 
- Training: Not discussed 
- Staff: House staff (medical 
students/residents) and other 
clinical staff 4  
- Cost: Not reported 
 
Description: Blood Culture 
Contamination Rate (BCCR) 
– number and proportion of 
blood cultures growing 
contaminant organisms 2  
 
-Recording method:  
Practice: Monitoring of BCs 
by researcher blinded to 
collection method 
Comparator: Not specified. 
 
 
 Type of finding: Comparison – RCT 
with external comparator for both 
interventions 
- Findings/Effect Size: 
BCCR: 
(1) BCCR for venipuncture 
specimens collected w/o prep 
kits 25/383 (6.5%) vs. 4/215 
(1.9%) for specimens w/ prep 
kits. 
(2) Difference in BCCR for the 2 prep 
kits not stat signif: 0.5% (1/215) 
with chlorhexidine gluconate kit and 
1.4% (3/215) with tincture of iodine 
plus isopropyl alcohol  
Effect size: OR =3.68 (CI,1.26 – 10.73) 
Statistical Significance/Tests:  
 (1) Fisher exact test, p = .01 5  
 (2) McNemar test of dependent 
proportions, p = .62 
Power to detect 4% difference: 0.45 
Results/Conclusion bias: Staff were 
aware that contamination rates were 
being monitored and may have been 
more careful to follow venipuncture 
protocol in study patients than in non-
participants. Venipuncture technique was 
NOT directly observed by investigators. 
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Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
Quality Rating (10 point 
maximum):  7 Fair 
Effect Size Magnitude Rating: 
Substantial 
( Relevance: Direct ) 
Study  (3 pts maximum):  2 
- Primary study focus comparison of 2 
interventions 
- Potential biases 
Practice (2 pts maximum): 
2 
Outcome measures (2 
pts  maximum): 1 
- Recording method for 
comparator not described 
Results/findings (3 pts maximum): 
2 
Bias; statistical test 
Wilson ML[1], Weinstein MP[2], 
Mirret S[3], Reimer LG[5,6], 
Fernando C[5], Meredith FT[3], 
Reller LB[4]. 
- 2000 
-J Clin Microbiol. 
-[1] Dept of Pathology and Lab 
Services, Denver Health Medical 
Center &  U  Colorado Schl  Med, 
Denver [2] Clinical Microbiology Lab, 
Depts. of Pathology & Medicine, 
Robt Wood Johnson Med Schl, New 
Brunswick, NJ  [3] Clinical Microbiol 
Lab, Duke U Medl Ctr, Durham, NC  
[4] Depts. of Pathology & Medicine, 
Duke U Schl Med, Durham, NC [5] 
Clin Micro Lab, Salt Lake City VA 
Med Ctr, Salt Lake City, UT, [6] Dept 
of Pathology, U Utah Schl  Med, Salt 
Lake City, UT 
 
- Funding: Supported in part by 
Medi Flex (Overland Park, KS) 
Design: Non-randomized multi-center 
comparison study. 
 
Facility/Setting: Academic medical center 
(Robert Wood Johnson University Hospital 
(RWJUH), Duke University Medical Center 
(DUMC) and Denver Health Medical Center 
(DHMC)), and VA/Military/Federal hospital 
(Salt Lake Veterans Affairs Medical Center 
(SLVAMC)). 
 
Time period: Duration, start/end dates NR 
 
Population/Sample: 12,367 blood samples. 
6,362 samples collected after disinfection 
with conventional alcohol pledgets and 
6005 collected following disinfection with 
prep kits.1 Specimens collected via venous 
catheter excluded from analysis. 
 
Comparator: Blood culture specimens 
collected after antisepsis with conventional 
isopropyl alcohol pledgets. In each 
institution, use of prep kits and conventional 
practice alternated by month.  
 
-Biases: none noted 
Practice Description: Prep Kit 
(70% isopropyl alcohol & 2% 
iodine tincture on separate 
sterile applicators).  
 
Duration: Start/end dates NR. 
Use of prepkit alternated by 
month with use of conventional 
pledgets. Order of use not 
described. 
 
Training: Four sites provided 
instructions. (RWJUH)- written 
instructions and verbally (via in-
service training). (SLVAMC and 
DUMC) written instructions 
(DHMC), kit used for routine 
skin disinfectant, phlebotomy 
teams were given verbal 
instructions via in-service 
training.  
- Staff: House staff 
physicians/medical students 
except at DHMC, where 
phlebotomy teams performed 
venipuncture.  
 
- Cost: NR 
Outcome measure: 
Blood culture contamination 
rate (BCCR)—proportion of 
all blood cultures growing 
contaminant organisms.2,3 
 
 Recording method: Isolates 
categorized as clinically 
important, contaminants, or of 
indeterminate clinical 
significance, using std clinical 
microbiology methods.  
 
Type of Finding: Comparison  
Findings:   
Overall contamination rates:  
 Conventional Pledgets -  5.5% (351 
of 6,362 blood cultures; range, 3.7 to 
8.1%). 
 Prep kits: 5.5% ( 328 of 6,005 blood 
cultures; range 3.5 to 7.5%).  
Effect Size:  
Site ORwtd   95% ci 
 DUMC .1.03 .0.81 – 1.31 
RWJUMC .1.08 0.85 -1.39 
DHMC .91 0.62 – 1.34 
SLVAMC . 1.08 .42 – 2.75 
Overall 1.03  0.83 – 1.13  
 
Stat signif/Tests: Χ2, no significant 
differences among study sites, no 
difference in contamination rates 
between prep kit and conventional 
pledget skin disinfection 
 
Statistical power: Not discussed by 
authors. Post facto estimate – Power to 
detect 1.5% overall difference in 
proportions > .90 
 
Results/conclusion biases: none 
Blood Culture Contamination Evidence Summary Tables (2009) 
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Bibliographic Information 
- Author (s)   
- Yr Published/Submitted  
- Publication   
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
Total Rating (10 pts 
maximum): 8  
Good  
Effect Size Magnitude Rating:  
Minimal ( Relevance: Direct) 
Study  (3 pts maximum):  2 
 - Duration data collection, order of 
 - Practice/comparator use not 
stated. 
 
Practice:( 2 pts maximum): 
1 
- Variation in 
implementation of practice 
among institutions 
Outcome measures: 
(2pts maximum): 2 
Results/findings (3 pts maximum): 
3  
Wilson ML[1], Weinstein MP[2], 
Mirret S[3], Reimer LG[5,6], 
Fernando C[5], Meredith FT[3], 
Reller LB[4]. 
- 2000 
-J Clin Microbiol. 
-[1] Dept of Pathology and Lab 
Services, Denver Health Medical 
Center &  U  Colorado Schl  Med, 
Denver [2] Clinical Microbiology Lab, 
Depts. of Pathology & Medicine, 
Robt Wood Johnson Med Schl, New 
Brunswick, NJ  [3] Clinical Microbiol 
Lab, Duke U Medl Ctr, Durham, NC  
[4] Depts. of Pathology & Medicine, 
Duke U Schl Med, Durham, NC [5] 
Clin Micro Lab, Salt Lake City VA 
Med Ctr, Salt Lake City, UT, [6] Dept 
of Pathology, U Utah Schl  Med, Salt 
Lake City, UT 
 
- Funding: Supported in part by 
Medi Flex (Overland Park, KS) 
Design: Non-randomized multi-center 
comparison study. 
 
Facility/Setting: Academic medical center 
(Robert Wood Johnson University Hospital 
(RWJUH), Duke University Medical Center 
(DUMC) and Denver Health Medical Center 
(DHMC)), and VA/Military/Federal hospital 
(Salt Lake Veterans Affairs Medical Center 
(SLVAMC)). 
 
Time period: Duration, start/end dates NR 
 
Population/Sample: 12,367 blood samples. 
6,362 samples collected after disinfection 
with conventional alcohol pledgets and 
6005 collected following disinfection with 
prep kits.1 Specimens collected via venous 
catheter excluded from analysis. 
 
Comparator: Blood culture specimens 
collected after antisepsis with conventional 
isopropyl alcohol pledgets. In each 
institution, use of prep kits and conventional 
practice alternated by month.  
 
-Biases: none noted 
 
Practice Description: Prep Kit 
(70% isopropyl alcohol & 2% 
iodine tincture on separate 
sterile applicators).  
Duration: Start/end dates NR. 
Use of prepkit alternated by 
month with use of conventional 
pledgets. Order of use not 
described. 
Training: Four sites provided 
instructions. (RWJUH)- written 
instructions and verbally (via in-
service training). (SLVAMC and 
DUMC) written instructions 
(DHMC), kit used for routine 
skin disinfectant, phlebotomy 
teams were given verbal 
instructions via in-service 
training.  
- Staff: House staff 
physicians/medical students 
except at DHMC, where 
phlebotomy teams performed 
venipuncture.  
 
- Cost: NR 
Outcome measure: 
Blood culture contamination 
rate (BCCR)—proportion of 
all blood cultures growing 
contaminant organisms.2,3 
 
 Recording method: Isolates 
categorized as clinically 
important, contaminants, or of 
indeterminate clinical 
significance, using std clinical 
microbiology methods.  
 
Type of Finding: Comparison  
Findings:   
Overall contamination rates:  
 Conventional Pledgets -  5.5% (351 
of 6,362 blood cultures; range, 3.7 to 
8.1%). 
 Prep kits: 5.5% (328 of 6,005 blood 
cultures; range 3.5 to 7.5%).  
Effect Size:  
Site ORwtd   95% ci 
 DUMC .1.03 .0.81 – 1.31 
RWJUMC .1.08 0.85 -1.39 
DHMC .91 0.62 – 1.34 
SLVAMC . 1.08 .42 – 2.75 
Overall 1.03  0.83 – 1.13  
 
Stat signif/Tests: Χ2, no significant 
differences among study sites, no 
difference in contamination rates 
between prep kit and conventional 
pledget skin disinfection 
Statistical power: Not discussed by 
authors. Post facto estimate – Power to 
detect 1.5% overall difference in 
proportions > .90 
Results/conclusion biases: none 
Blood Culture Contamination Evidence Summary Tables (2009) 
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- Author (s)   
- Yr Published/Submitted  
- Publication   
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
Total Rating (10 pts 
maximum): 8  
Good  
Effect Size Magnitude Rating:  
Minimal ( Relevance: Direct) 
Study  (3 pts maximum):  2 
 - Duration data collection, order of 
 - Practice/comparator use not stated. 
 
Practice:( 2 pts maximum): 
1 
- Variation in implementation 
of practice among institutions 
Outcome measures: 
(2pts maximum): 2 
Results/findings (3 pts maximum): 
3  
Weinbaum FI [1,2], Lavie S [3], 
Danek M [2], Sixsmith D[4], 
Heinrich GF[5], Mills SS[5]. 
J Clin Microbiol 1997 
 
Affiliations: The New York 
Hospital Medical Center of 
Queens, Departments of 
[1]Surgery, [2] Quality 
Management, [3]Pathology, [4] 
Emergency Medicine, and [5] 
Administration. 
 
Funding: not reported 
Design: Nonrandomized prospective 
intervention trial.  
 
Facility/Setting: General adult medical 
and surgical wards of a community 
teaching hospital, Flushing, Queens, 
New York.  
 
Time Period: 1 year, dates not 
specified. 
Sample: A total of 2562 blood culture 
specimens collected by a dedicated 
phlebotomy team and house staff 
(interns & residents) on two adult in-
patient general medical and surgical 
care units.  
 
Comparator:   
1. Blood specimens collected by house 
staff without use of commercial prep kit 
(N=599) during an initial 3-month 
interval on Unit A and 2 months on Unit 
B.  
 
2. Specimens collected by phlebotomy 
Description: Two practices 
were introduced at the same 
time—a dedicated 
phlebotomy team and use of 
a commercial blood culture 
prep kit with isopropanol and 
tincture of iodine. Prep kits 
were initially available only to 
the phlebotomy team. After 
the phlebotomy team was 
withdrawn from one unit, 
prep kits were provided to 
the house staff who collected 
blood culture specimens. 
Duration:  Dedicated 
phlebotomy team with prep 
kit: 6 mos. House staff with 
prep kit: 3 months. 
Training: not discussed 
Staff: Three FTE 
phlebotomists; house staff. 
 Cost: Incremental cost of 
using the commercial prep 
kit, rather than alcohol and 
povidone iodine swabs not 




Recording method:  Blood 
cultures were evaluated by 
using a BACTEC NR-660 
system. Positive cultures 
were considered 
contaminated if they grew 




Type of finding: Comparison between 
independent  groups  
Findings3:   BCRR (se) 
House staff + prep kit:  4.8 % 
(.016) 
House staff – prep kit
 8.4%(.014) 
DPT + prep kit  1.1 % (.004) 
 
Effect size4:  OR  95% ci  
DPT + PK v HS – PK 6.25
 (.3.58-10.91) 
HS + PK v HS – PK 1.38 (.0.68 – 
2.81) 
(DPT = Dedicated phlebotomy team; 
PK = prep kit; HS = house staff) 
 
Stat tests, significance, & power:  
Test: Mantel Haenszel X2, p < 0.001 
for comparisons between house staff 
without prep kit vs. dedicated 
phlebotomy team with prep kit. For 
house staff with prep kit vs house 
staff without prep kit, p = .173. Power 
not addressed by authors. 
Blood Culture Contamination Evidence Summary Tables (2009) 
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Bibliographic Information 
- Author (s)   
- Yr Published/Submitted  
- Publication   
- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
- Description   
- Duration  
- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
team with commercial prep kit 
(N=1755). 
 
Biases:  Limitations: Contamination 
rate for phlebotomy teams that did not 
use prep kit not collected—
improvement in BCCR attributable to 
prep kit, independent of phlebotomy 
team, not evaluable. 
estimated. 1  
Results/Conclusion biases: none 
 
Total Rating(10 pts 
maximum): 9 Good 
Effect Size Magnitude: 
Minimal 
( Relevance: Direct) 
Study: (3 pt maximum): 2 
.- Study limitations 
Practice: (2 pt maximum): 
2 
Outcome measure( 2pt 
max): 2 
Results/findings(3 pt max): 3  
 
McLellan, E; Townsend R, and 
Parsons HK. 
-2008 
- Journal of Infection 
- Dept of Microbiology, Northern 
General Hospital, Sheffield 
Teaching Hospitals NHS 
Foundation Trust 
- Funding: Enturia Limited 
 
Design:  Prospective observational 
intervention study 
 
Facility/Setting: Northern General 
Hospital , Sheffield Teaching Hospitals 
NHS Foundation Trust,  Sheffield, 
South Yorkshire, UK  
Academic Medical Center 
 
Time Period: Two intervention 
periods— 
1st: Aug-Oct, 2007 compared with 2 
comparator periods: 
1. Aug – Oct, 2006 
2. May – Jul 2007  
2nd: Dec, 2007 – Feb 2008, one 
Description: Blood 
specimens collected via 
venipuncture primarily by 
doctor support workers 
(DSW). Junior doctors 
(house staff) obtain blood 
specimens when DSWs are 
not available or unable to 
obtain a specimen. The 
commercial prep kit, 
comprising an applicator 
impregnated with 2% 
alcoholic chlorhexidine and 2 
alcohol swabs to disinfect 
culture bottle seals, was 
used on both MAU during 1st 
Description: Blood culture 
contamination rate (BCCR) 
(by comparison of several 
time frames)   
 
Recording method:  
All positive blood cultures 
were evaluated as true 
positives or contaminants 
by a medical 
microbiologist. Positive 
cultures identified by 
routine analysis (BACTEC 
9240). Positive cultures 
Gram-stained and 
subcultured to appropriate 
Type of finding: Non-randomized 
comparison 
Findings:  See Table 1 1 
(1) Intervention vs previous year: 
BCCR  6.6% (20/304) on MAU1 
compared with 17.3% during 
previous year (p<0.001) and on 
MAU2 8.5% (21/248) compared with 
13.5% (p=0.11) .   
(2)Intervention compared to 
immediately preceding 3 months 
(May-to July 2007): BCCR for MAU1 
and MAU2 were 8.7% (P=0.38) and 
9.2% (P=0.87), respectively. 
(3) December 2007- February 2008, 
prep kit reintroduced only on MAU1; 
Blood Culture Contamination Evidence Summary Tables (2009) 
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- Author (s)   
- Yr Published/Submitted  
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- Author Affiliations  
- Funding  
Study 
- Design  
- Facility/Setting  
- Time Period  
- Population/Sample  
- Comparator  
- Study bias  
Practice 
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- Training  
- Staff/Other Resources  
- Cost  
Outcome Measures 
- Description (s)  
- Recording method  
 
Results/Findings 
- Type of Findings  
- Findings/Effect Size  
- Stat. Significance/Test(s)  
- Results/Conclusion Bias  
medical admissions unit (MAU1) in 
hospital was compared to another 
(MAU2). 
 
Sample: 1st intervention period: 552 
BCs 2nd int period: 610 BCs. See 
Table 1. 1   
 
Comparator:  
Blood culture contamination rates 
(BCCR) for the corresponding MAU 
during same period in 2006 (525 BCs) 
and 3 months immediately preceding 
1st intervention period (563 BCs).  
 
 
Biases: None noted 
intervention period, but only 
on MAU1 during 2nd period. 
Duration: Aug-Oct 2007; Dec 
2007- Feb 2008 
- Training: Kit manufacturer 
provided training to DSWs, 
house staff, and nursing 
staff. Infection control staff 
provided training on BC site 
preparation and 
consequences of BC 
contamination.  
- Staff: No changes in 
staffing required to 
implement practice. Units 
staffed by 10 Jr doctors, one 
DSW per day shift and a 
single DSW to cover both 
wards during the night.  
- Cost: Unit cost for prep kit: 
£0.50; unit cost for 70% 
isopropyl alcohol wipes: 
£0.02. 
solid agar; isolates were 
identified by ―multipoint 
methods‖ and bench-level 
diagnostics. The same 
routine methods were in 
use during comparator 
periods. 
 
contamination rate = 8.5% (28/330).  
Not significantly different from either 
1st intervention period (Aug-Oct 
2007) or pre-implementation period 
(May-Jul 2007); (P=0.37 and P=1.0, 
respectively). 
(4) BCRR on MAU2 Dec 2007 – Feb 
2008: 6.4% (18/22), non-significant 
reduction (P = 0.41) compared with 
intervention period, despite the 
absence of prep kit. 
Effect size3:  OR  95% ci  
MAU1 1.16 ..72-1.87 
MAU2 0.89 0..51 – 1.56 
Overall 1.03 .73 – 1.47 
Stat tests & Power: X2 
Statistical power is not discussed 
Results/Conclusion biases:  
Authors present evidence of 
confounding by a time-related factor. 
Drop in contamination rate between 
2006 and 2007 appears unrelated to 
use of prep kits. 
Total Rating(10 pts 
maximum): 8 Good 
Effect Size Rating:  Minimal 
( Relevance: Direct) 
Study: (3 pt maximum): 2 
- 1Comparator period non-
representative 
Practice: (2 pt maximum): 
2 
Outcome measure( 2pt 
max): 2 
Results/findings(3 pt max): 2  
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APPENDIX F. GUIDE TO RATING STUDY QUALITY 
Individual study quality ratings are based on four dimensions of study quality: 
 Study 
 Practice  
 Outcome Measure(s)  
 Findings/Results  
The principles and guidelines for making judgments along these four dimensions are outlined below.  
The objective for rating individual study quality is to judge whether sufficient evidence is available 
concerning a practice‘s effectiveness to support a recommendation of ―best practice‖ (that is, a practice 
likely to be effective in improving one or more outcomes of interest in comparison to other commonly used 
practices). 
The rating methods are designed to be inclusive, so we can make best use of the limited data available, 
which may commonly be in the context of a quality improvement effort. Our methods for rating study 
quality do not penalize studies for not using a randomized design or for not being published in a peer 
reviewed journal. This approach acknowledges that many practices in laboratory medicine do not lend 
themselves to evaluation by traditional research designs, and much useful evidence may be obtained 
though our network affiliates whose priority on service delivery takes precedence over publishing. 
Evaluating Study Quality 
The four study quality dimensions are rated separately, with a rating score assigned up to the 
maximum for a given dimension. The rating scores for each dimension are added to reach a 
single summary score reflecting overall study quality. A total of 10 points are available for each 
study, with points subtracted from the maximum point total according to the guidance below. 
Anytime points are deducted from a study, a justification for the deduction is recorded and 
included in the evidence summary. In this scheme, a rating of zero in any one of the four 
categories is sufficient to exclude a study from further consideration as evidence for a ―best 
practice‖ recommendation. 
Dimension 1. Study (3 points maximum) 
Assess the likely generalizability of the results by evaluating: 
- Study setting 
- Sample  characteristics (representativeness sufficient for practice)   
- Potential study biases (study design, time period/duration and sample selection 
methods)    
Criteria for point deduction 
Rate Facility Description / Study Setting: From the drop-down list provided, rate the uniqueness of the 
study facility and setting with respect to generalization. Generalizability is a judgment on the likelihood 
that the results obtained would achieved in other facilities or settings.  
1. Deduct 0 points. Results are likely to generalize to other facilities and settings. 
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2. Deduct 1 point if the study location is sufficiently distinctive that the results obtained through      
    that setting may not be generalizable to other settings.  
 
3. Deduct 2 points if the study location is sufficiently distinctive that the results obtained through  
    that setting are unlikely to be generalizable to other settings 
4. Deduct 3 points (Score 0) if it is clear that the setting or situation is unique such that the results 
cannot generalize to other settings. 
Rate Study Design / time period / population: From the drop-down list provided, rate the uniqueness of the 
study design, time period, or sample with respect to representativeness. Representativeness is a judgment on 
whether the results obtained through the study design are likely representative of the results of the practice.  
1. Deduct 0 points. The sample / time period / and population is sufficient to be representative of the 
results of the practice. 
2. Deduct 1 point if the sample (either subjects or tests) may not be representative of the likely results 
of the practice with respect to how the sample was obtained or identified  
3. Deduct 2 points if the sample (either subjects or tests) are probably unrepresentative of the results 
of the practice with respect to how the sample was obtained or identified. 
4. Deduct 3 points if the sample is sufficiently unrepresentative based on how it was 
obtained/identified to clearly nullify the generalizability of the results. 
Rate Potential Study Bias: From the drop-down list provided, rate the extent to which you believe that the study 
design, period of measurement, and/or sample selection introduced bias to the results. Bias is systematic error 
that either reliably enhances or suppresses a finding. It is different from error, which reduces the quality of 
measurement, but not in any systematic fashion (can produce findings that are both larger and smaller than the 
true score).   
1. Deduct 0 points  
2. Deduct 1 point if the study design, time period and sample selection methods may introduce a 
study bias that would substantially affect results (i.e., may produce study results interpreted as 
inconsistent with the true results)   
3. Deduct 2 points if the study design, time period and sample selection methods are likely to 
introduce a study bias that would substantially affect results (i.e., would likely produce study results 
interpreted as inconsistent with the true results)   
4. Deduct 3 points if there is reason to believe that the study characteristics can not produce results 
representative of the practice 
Total Points Deducted – Study: Using the information summarized by the three previous Study Rating Items 
(Items Rate Facility Description / Study Setting; Rate Study Design / time period / population; and Rate Potential 
Study Bias respectively), record in this field the maximum number of points deducted in any of the previous three 
Study rating fields. For example, if rows 13 and 23 are each zero, but row 32 equals 3 points deducted, then the 
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Dimension 2. Practice (2 points maximum) 
Assess the description of the practice and its adequacy.  
Criteria for point deduction 
Rate Practice Description: The practice should be well enough described to meaningfully distinguish it from 
alternative practices and provide a clear understanding of its requirements and characteristics (does not require 
that the description be exhaustive or support exact replication).  
Deduct 0 points: The practice is well described 
Deduct 1 point if the practice and its basic characteristics are not sufficiently identified. 
Deduct 2 points (Score 0) points if the practice and its basic characteristics cannot be clearly 
identified. 
Rate Adequacy of Practice Description: Ideally, seven components of practice description would be addressed: 
a) content, b) implementation, c) population / setting, d) training, e) requirements, f) cost, and g) staff responsible 
and implementing.  However, detailed information on all components is not necessary to evaluate the 
effectiveness and feasibility of implementing a practice, and is typically not provided (e.g., cost and training).   
Deduct 0 points: Based on the practice description, the practice could be adopted in other settings. 
Deduct 1 point if an important aspect/component that is likely to critically affect implementation of the 
practice is not well described. 
Total Points Deducted – Practice: Using the information summarized by the two previous Practice Rating Items 
(Rows 16 and 18; Items Rate Practice Description and Rate Adequacy of Practice Description respectively), 
record in this field the maximum number of points deducted in any of the two previous Practice rating fields. The 
options for this item are: 
0 points deducted 1 point deducted 2 points deducted 
 
Dimension 3. Outcome Measure (2 points maximum) 
Outcome measures capture the result of implementing a practice. Evaluation criteria reflect their 
face validity for capturing the outcome(s) of interest, and whether the methods used to record 
results provide an incomplete or inaccurate record of the impact of a practice. 
  
Most studies use multiple outcome measures. Their evaluation should concentrate on measures 
that most directly address the review question, which relates to health care quality (Institute of 
Medicine domains:  safe, timely, effective, patient-centered, efficient, and equitable), and may 
ignore secondary measures, especially those gauging implementation feasibility. 
Criteria for point deduction 
Rate Face Validity of Outcome Measure: Face validity asks if the measure likely captures the construct 
it is intended to measure. Deduct points if the measure as specified/defined and data collected is possibly 
or likely flawed and/or if the measure does not capture the essence of what it was supposed to measure 
(e.g., timeliness). Use the following criteria in making your judgment 
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1. Deduct 0 points/no deduction 
2. Deduct 1 point if:  
 (1) Measure does not capture well the outcome being estimated OR  
 (2) The measure estimates an outcome that is only modestly related to the evidence 
review question (e.g., provider satisfaction, compared with change in a patient 
outcome or an error rate) 
3. Deduct 2 points if the measure is confounded by: 
  (1)The practice itself (that is, the outcome is a direct result of the practice which was not 
available or applicable to both the comparison practice and the tested practice) OR 
 (2) The measure is confounded by the context in which the practice has been 
implemented (that is, the outcome is unlikely to be clearly attributed to the practice).  
Rate Recording Method: The method for recording or documenting practice results should be reliable 
and accurate. As mentioned above, recording methods may be subject to bias or fraud (intentional and 
otherwise). Reliability refers to the ability of a measure to return the same result each time, given the 
same underlying phenomena. Accuracy refers to the precision of the measurement tool. Note that a tool 
can be accurate, but not reliable (e.g., the adage ―measure twice, cut once‖ observes that while the tape 
is accurate, the observation of the result is not reliable). Use the following scale to rate the quality of the 
recording method described. 
1. Deduct 0 points 
2. Deduct 1 point if the recording method is not described OR does not accurately capture all 
instances of the outcome 
3. Deduct 2 points if the method of recording the outcome is unreliable. 
Describe Recording Method Rating: If points were deducted for the recording method of the outcome 
measure, please provide a rationale for the deduction. 
Total Points Deducted – Measurement: Using the information summarized by the two previous 
Measurement Rating Items (Rows 7 and 11; Items Rate Face Validity of Outcome Measure and Rate 
recording method respectively), record in this field the maximum number of points deducted in any of the 
two previous Measures rating fields. The options for this item are: 
2 points deducted 1 point deducted 0 points deducted
Dimension 4. Results/Findings (3 points maximum) 
Results are affected by each of the previous three dimensions of quality. With this dimension, a narrow 
set of criteria specific to the result are evaluated relating to (1) sample sufficiency, (2) appropriateness of 
statistical analysis and, (3) uncontrolled deviations along with results/conclusions bias. 
Criteria for point deduction 
Rate Sample Sufficiency: Many of the outcomes of interest are rare events. If too few observations are obtained 
or if the measurement period is insufficient to capture these events the measure may provide an inaccurate 
representation of the effect of the practice. Even among more common events, there may also be considerable 
variation in the number or rate of events over time. The period of measurement should be sufficiently long to allow 
robust estimates of the impact of the practice. 
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Deduct 0 points 
Deduct 1 point if:  
 (1) Measurement period insufficient to allow robust estimate of practice impact) OR  
 (2) Statistical power not discussed AND the sample may be too small to allow a robust estimate) 
Deduct 2 points if:  
 (1) The number of subjects and/or measurement period not reported)   
 (2) The measurement period is likely insufficient for a robust estimate of practice impact) OR  
 (3) Statistical power is not discussed AND the sample is likely too small to allow a robust 
estimate of the impact of a practice)  
Describe sample sufficiency rating: If points were deducted for the Sample Sufficiency Rating, please provide 
a rationale for the deduction. 
Rate appropriateness of statistical analysis: Determine if the statistical analysis was appropriate for the data. 
Deduct 0 points. 
Deduct 1 point if:  
 (1) Data collected during notably different time periods OR  
 (2) Data do not permit effect size calculation. 
Deduct 2 points if: 
 (1) Results were obtained using different measures or recording practices for two groups 
 (2) Inappropriate statistical analysis AND insufficient data to allow or verify calculation of 
an effect size) 
 
Rate Uncontrolled Deviations and Results/Conclusions biases: Despite the best efforts of 
researchers, studies are sometimes contaminated by unforeseen events or circumstances. Record here 
the extent to which these may apply to the findings being recorded. 
Deduct 0 points 
Deduct 2 points if:  
 (1) Results not due to practice; likely related to different practice(s), OR  
 (2) Unexplained attrition >70% OR  
 (3) Uncontrolled differential attrition OR  
  (4) Results/conclusion not supported by or at odds with the work done/presented 
  
Describe bias rating: If the findings were influenced by Uncontrolled Deviations or Results/Conclusions 
biases, describe the uncontrolled deviations and results/conclusions biases in this field. 
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Total Points Deducted – Findings: Using the information summarized by the three previous Findings 
Rating Items (Rows 15, 17, and 19; Items Rate Sample Sufficiency, Rate appropriateness of statistical 
analysis, and Rate Uncontrolled Deviations and Results/Conclusions biases respectively), record in this 
field the maximum number of points deducted in any of the three previous Findings rating fields. The 










  2 - Study Quality Rating Table 





Rating Criteria Deduct 1 Point if: Deduct 2 Points if: Score Zero if: 
Study 3  
Facility Description 
The study location is sufficiently 
distinctive that the results 
obtained through that setting 
may not be generalizable to 
other settings.  
 
The study location is sufficiently 
distinctive that the results 
obtained through that setting are 
unlikely to be generalizable to 
other settings 
It is clear that the setting or 
situation is unique such that 
the results cannot generalize 
to other settings 
 
Study design/study 




The sample (either subjects or 
tests) may not be representative 
of the results of the practice 
with respect to how the sample 
was obtained or identified AND 
the non-representativeness 
suggests that the results may 
not be generalizable.  
 
The sample (either subjects or 
tests) are unlikely to be 
representative of the results of 
the practice with respect to how 
the sample was obtained or 
identified AND the non-
representativeness suggests that 
the results are unlikely to be 
generalizable.  
 
The sample is sufficiently 
unrepresentative based on 
how it was 
obtained/identified to clearly 






The study design, time period 
and sample selection methods 
may introduce a study bias that 
would substantially affect 
results (i.e., may produce study 
results interpreted as 
inconsistent with the true 
results)   
 
The study design, time period and 
sample selection methods are 
likely to introduce a study bias 
that would substantially affect 
results (i.e., would likely produce 
study results interpreted as 
inconsistent with the true results)   
 
There is reason to believe 
that the study characteristics 
can not produce results 
representative of the practice 
 
Practice 2 Description of 
practice 
 
The practice and its basic 






The practice and its basic 
characteristics can not be 





An important aspect/component 
that is likely to critically affect 
implementation of the practice 







  2 - Study Quality Rating Table 










The ‗best‘ measure from a 
study:  
- Does not capture well the 
outcome being estimated 
OR 
- Estimates an outcome that is 
only modestly related to health 
care quality or patient safety 
(e.g., provider satisfaction, 
compared with change in a 





The ‗best‘ study measure: 
- Is confounded by the 
practice itself (outcome is a 
direct result of the practice; 
not available to the 
comparison) 
OR 
- Is confounded by the 
context in which the practice 
has been implemented 
(outcome is unlikely to be 
clearly attributed to the 
practice). 
OR 
- Does not have the potential 
to contribute to health care 




Method(s) of recording: 
- Not described 
OR 
- Does not accurately capture 




Method of recording the 






The measurement period may 
be insufficient to allow a robust 
estimate of the impact of a 
practice. 
OR 
Statistical power is not 
discussed AND the sample may 
be too small to allow a robust 
estimate of the impact of a 
practice 
Number of subjects not reported 
OR 
Measurement period not reported 
OR 
Measurement period likely 
insufficient for a robust estimate 
of the impact of a practice  
OR 
Statistical power is not discussed 
AND the sample is likely too small 
for a robust estimate of the 
impact of a practice 
 
N/A 
  2 - Study Quality Rating Table 





Compares two practices and 
their estimates are based on 
data collected during notably 
different time periods  
OR 
Does not provide data sufficient 
to allow/verify calculation of an 
effect size  
 
Different measures or different 
recording practices are used 
when comparing the results of 
two practices 
OR 
An inappropriate statistical 
analysis and insufficient data to 
allow/verify calculation of an 













Results/effect size reported not 
clearly attributable to practice 
being evaluated, but instead are 
likely related to significantly 
different practice(s) 
OR 
There is unexplained attrition > 
70% or the study uses a 
randomized design and there is 
differential attrition not controlled 
by analysis 
OR 
Results reported and/or 
conclusions are not 
representative of or supported by 
the work that was done (e.g., 
additional relevant findings are 
mentioned, but not reported 
and/or not incorporated in the 
conclusions; results conflict or are 
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APPENDIX G. EFFECT SIZE RATING GUIDANCE 
Background 
Reports about laboratory medicine practices, whether published or not, are often descriptive and 
opportunistic, taking advantage of data developed for in-house monitoring and practice improvement. 
Less attention is paid to research methods than might be expected. In evaluating reported findings, 
reviewers should pay particular attention to the outcome measures used and methods of measurement. 
Many other issues that are typically evaluated when assessing study quality are either not relevant to 
observational study designs or reported in a way that is evaluable with any degree of sophistication. We 
urge reviewers to give this evidence the benefit of the doubt and as such, not hold it to a standard to 
which it does not aspire. 
Effect Size Rating Categories 
Reviewers will rate the reported effect size for a given study in one of three categories: 
 Substantial • None/Minimal 
 Substantial • Adverse  
These ratings are specific to topic areas, requiring each Expert Panel to specify value ranges for each 
category for the relevant outcome measures. Note that studies may provide a range of results on various 
outcome measures. When rating effect sizes in support of best practice recommendations, please choose 
the highest rating supported by study evidence. That is, if a practice has multiple effect sizes some of 
which are ―moderate‖ and some of which are ―substantial,‖ rate the impact of the practice as substantial.  
 To receive a ―Substantial rating‖ the study reports a measure that directly answers the review 
question and has 
o No relevant adverse effects AND 
o At least one good effect large enough to clearly support practice implementation  
 To receive a ―Moderate rating‖ the study reports a measure that directly answers the review question 
and has 
o No relevant adverse effects AND 
o A good effect large enough to favorably support practice implementation   
 To receive a ―None-minimal rating‖ the study reports  
o No relevant adverse effects AND 
o An  effect size that is similar to zero or slightly positive on a measure that directly answers the 
review question asked  
Considerations for Evaluating Effect Size: Magnitude and Relevance 
Evaluating reported effect sizes involves judgments of both the magnitude of the effect observed, and 
how centrally relevant the measure is to answering the review question. These are two separate 
judgments, and each needs to be considered when evaluating evidence for contributing to a best practice 
recommendation. 
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Judging the magnitude of effect. Little if any of the evidence available for this task will be based on 
randomized designs. The typical LMBP study uses a pre-post one-group design. That is, the study 
provides a before-implementation estimate of a previous standard or ―comparison‖ practice on some 
measure and an after-implementation estimate of the new or ―tested‖ practice on the same measure. The 
next most common design is a single (post-test only) after-implementation estimate on some measure of 
interest.  
In contrast with controlled research, the comparison practice against which a new practice is tested will 
likely vary from study to study. This can affect the difference score (the finding) obtained as much as the 
new practice. When interpreting magnitude of effect, consideration should be given to both halves of the 
comparison as the finding represents the difference between the two that may not be the impact of the 
new practice over a common base. 
To aid reviewers in judging the magnitude of effect between a new/tested practice and a comparison 
practice, when possible we calculated two standardized measures as findings for each reported outcome.   
(1) Odds Ratio (OR) 7 compares the chance of an event occurring in one group versus another group 
(e.g., new/post-practice and standard/pre-practice) for dichotomous outcomes (i.e., 2 possible outcomes 
such as yes/no; error/no error) and has the following interpretation: 
 OR > 1:  new practice is more successful than the standard practice; the larger the number, the 
greater the relative success 
 OR = 1:  new practice is equal to the standard practice,  
 OR<1:  new practice is less successful than the standard practice; the smaller the number, the  
worse its relative success 
For example, OR = 1.5 means the tested practice is half again as successful as the old practice, OR = 2.0 
means the tested practice is twice as successful as the standard practice, and OR 0.66 means the tested 
practice is two thirds as successful as the standard practice.    
(2) Cohen‘s d.8 (d-score) compares an effect size to zero, and has the following interpretation: 
 d-score > 0:  new practice is more successful than standard practice 
 d-score = 0:  no differences between new practice and standard practice 
 d-score <0:  new practice is less successful than standard practice 
The further the d-score is from zero the more successful the practice is relative to the comparison practice 
when positive, and the less successful when negative.   
Quality of the Outcome Measure for Contributing to a Recommendation. Since the studies 
considered were not designed to directly address the LMBP review question, not all outcome measures in 
the findings reported have equal relevance to the LMBP review question.9 The highest quality measures 
                                                                
7 See Attachment A for more details on how these standardized metrics are calculated. 
8 See Attachment A for more details on how these standardized metrics are calculated. 
9 The Study Quality Rating Guide has reviewers rate the quality of the measure for meeting the author‘s purpose, is it 
a reliable and valid measure of their outcome of interest. The Effect Size Rating Guide has reviewers rate the quality 
of the measure for answering LMBP‘s review question. A measure can be rated high when estimating study quality, 
but may rate low with respect to relevance to the review.  
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for the purpose of a review are those that are most responsive to the LMBP review question. In the case 
of the patient-specimen identification practices, the review question‘s objective is accurate matching of 
patient and specimen.. In the case of critical values communication practices, the review question‘s 
objective is timely and accurate reporting of laboratory test critical values to licensed/responsible 
caregivers. 
Proximal outcome measures are of greater value than distal measures. ―Relevant to LMBP review 
questions‖ is not identical to ―improving health outcomes.‖ As our Workgroup and Expert Panel members 
have observed, health outcomes usually result from a number of contributing factors, and while effective 
laboratory medicine practices are necessary contributors, they may not be sufficient.  The best estimates 
of the true impact of a practice should be outcomes that are the direct and immediate consequence of the 
practice.  
Without minimizing the importance of assessing patient health and safety outcomes, the practices being 
studied occur in a continuum of care, so isolating the impact of a change in practice on patient health and 
safety may be confounded by health care delivery and other potential moderating factors.  As a purpose 
of LMBP evidence reviews is to document the evidence for best practice recommendations, reviewers 
should give additional weight to outcomes that are a direct result of a practice that directly address the 
review question, and discount findings that are likely affected by additional aspects of health care delivery 
or other identifiable factors. 
 
Outcome measures that more directly address the review question are more relevant to its effect 
size  
Also reported are measures that should not be interpreted as an outcome of direct interest (i.e., does not 
directly address the review question objective), but may contribute to judgments of feasibility as they are 
within the causal field for the practice (e.g., percentage of patients correctly identified using bar-coding 
but no specimens involved, percentage of critical values reported using a call center without information 
related to accuracy or timeliness),. In the language of causal reasoning, they may be necessary, they 
may be important, but they are not sufficient evidence of practice effectiveness for making a ―best 
practice‖ recommendation. 
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Attachment A: Calculating Effect Sizes 
1. When dichotomous or binary outcomes were addressed (e.g., success versus failure) and the 
findings provided rate or percentage information, we calculated an odds-ratio (See Formula 1) that 
contrasts the two groups in terms of the relative odds of a successful outcome (e.g., the patient either 
is or is not correctly matched with their specimen).  
Table 1: Odds Ratios 
 Frequencies Proportions 
 Success Failure Success Failure 
Tested Practice a B pa = a/(a + b) pb = b/(a + b) 





















ES  Formula 1 (Odds Ratio) 
Where Pa = a/(a + b), Pc = c/(c + d) and a, b, c, and d are proportions in a four-square cross-tabulation 
table. 
2. For both dichotomous outcomes and for outcomes based on continuous data, we calculated a 
Cohen‘s d (See Formula 2), which can be interpreted as the difference between the groups on a 
standardized scale with a mean of zero (meaning no effect) and a standard deviation of 1 (i.e., a 
normal distribution). Positive results signify that the finding favors the post-test or ‘new‘ practice) while 




















ES  Formula 2 (Cohen’s d) 
Where 1GX = 1GX = the mean for Group 1, 2GX = 2GX = the mean for Group 2, pS = pS = the pooled 
standard deviation of the two groups, nG1 = number of tests in Group 1, nG2 = number of tests in Group 2 
sG1 = the standard deviation of tests in Group 1, and sG2 = the standard deviation of tests in Group 2. 
Cohen‘s-d can be approximated from many other reported statistics (e.g., t-tests, chi2, one-way ANOVA, 
frequency, and proportion) and can be converted into multiple indices for interpretation (see Table 2). 




U3 (% of T 
above Xc) 
BESD C v. T 
Success 
Rates 
BESD C v. T 
Differential 
0.0 .0 .0 .50 .50 v .50 .0 
0.1 .05 .003 54 .47 v .52 .05 
0.5 .24 .06 .69 .38 v .62 .24 
1.0 .45 .20 84 .27 v .72 .45 
1.5 .60 .36 93 .20 v .80 .60 
2.0 .71 .50 98 .14 v .85 .71 
2.5 .78 .61 99 .11 v .89 .78 
3.0 .83 .69 99 .08 v .91 .83 
Where r = correlation, T = treatment successful, Xc = comparison median, C = comparison successful; 
BESD = Binomial Effect Size Display  
Data Abstraction Tool 
Pilot Phase Final Report 142 
APPENDIX H. DATA ABSTRACTION CODEBOOK 
This coding manual summarizes the rules and guidelines for abstracting evidence for best practices in laboratory medicine. 
it is appropriate to discuss coding issues to try to reach consensus on coding principles. As a convention, please use NA to 
indicate “not applicable” and NR to record “not reported” in fields where data entry is not fixed (i.e., not restricted to drop-
down options). 
If you have questions or desire guidance, do not hesitate to contact Jim Derzon directly (derzonj@Battelle.org; 703-248-
1640). 
Table 1: References 
This table captures all references identified for the study. It provides tracking information for monitoring document status, 
records how and to which study they are relevant, and includes information on document study eligibility. Note: there may 
be multiple references (documents) for a single study-sample.  
Short Name for Study Citation: Use the format “Topic_Practice_First Author_Year” indicating the Topic, practice, last name 
of the first author, and year of publication or receipt of unpublished data.  Use previously identified and standardized topic 
and practice names (i.e., do not use ones that have not been pre-approved as appropriate for a specific evidence review).   
Topic Area – Practice: Write out the full label for the standardized name of the Topic Area and Practice that the document 
addresses. 
Gives Permission to be Identified  (unpublished only):  
For unpublished studies indicate whether the author has given permission to be identified. Select “1. Yes” if the author 
agrees to be identified, “2. No” if they wish to remain anonymous, and “9. Not Applicable” for published studies. 
How was document identified?: Indicate how the document was originally identified for this review. 
1. Bibliographic literature search 
2. Hand search of relevant journals 
3. Snowball sample (identified through review or another study bibliography) 
4. Response to direct solicitation 
5. Identified by key informant 
6. LMBP Network 
Date eligibility review completed (MM/DD/YY) and Eligibility Reviewer (Initials) 
This information provided by review coordinator making assignments. 
Select the type of document: Select the option that reflects best how the document was made available for dissemination. 
Note that technical reports can be either published or not.  
Published documents 
1. Professional Guidelines 
2. Peer-reviewed journal 
3. Book / book chapter 
4. Technical Report 
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5. Conference proceeding  
Unpublished documents 
6. In-house audit or Quality Control Initiative 
7. Technical Report 
8. Manuscript 




Describe other document type: If “10 Other” is selected describe the document type here. 
Complete Citation or Identifying Information for Unpublished Source. Enter the full citation using standard AMA style. 
Guidance can be found at http://www.nlm.nih.gov/bsd/uniform_requirements.html. For unpublished studies please 
identify the source completely as these files are confidential. 
Author Affiliations [1], [2], etc. Record the affiliations of all authors. Use the convention Author 1 (1,2), Author 2 (2), 
Author 3 (1,3). 1 = Institution 1, 2 = institution 2, 3 = Institution 3. If the document has no authors identified, the affiliation 
of the “First Author” should be the facility or healthcare organization and/or system that provide the study. The affiliation 
for the “second author” should be the alternate point of contact for the facility or health system that provides the 
unpublished study. 
Funding Source(s):  Identify (name) the actual source of funding for the research conducted. 
Reviewer (Initials): Select the initials of reviewer responsible for the abstraction. If it is a consensus review, enter the ‘lead’ 
reviewer, the reviewer who would be most qualified / comfortable responding to questions that could arise later in the 
review process. 
Other references: Enter any other references used to code this study, or sources referenced in the study that offer 
significant information related to the study itself, the practice or topic area  for background or other considerations such as 
applicability, feasibility of implementation, costs or other outcomes.  
Table 2: Study  
This section abstracts information on the study and setting characteristics that may be important for contextualizing the 
results and also abstracts information on the sources of evidence included in the study. This table leans towards describing 
observational studies and contains items that are likely to be valuable in describing findings constraints (e.g., “good 
evidence for this approach, but only for some populations and types of facilities”).  
Short Name for Study Citation: Topic_Practice_Author_Year: Copy and paste using data recorded in the Biblio field of the 
same name. 
Study reviewer: Copy and paste using data recorded in the Biblio field of the same name. 
Name of the facility(ies) or organization(s) where study performed: Enter the name of the facility or group (e.g., Hospital 
A, College of American Pathologists) that is the source of the data. 
Facility/Organization Type: Select from the pull down list the type of facility in which the study was conducted.  
Options include: 
1. Academic Medical Center 
2. Teaching hospital 
3. Non-teaching hospital 
4. VA/Military/Federal Government Hospital 
5. Outpatient Laboratory  
6. Physician Office Laboratory 
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7. Public Health Laboratory 
8. Independent / Commercial Laboratory 
9. Blood Bank 
10. Other (please specify) 
 
Facility/Organization Type - "Other" please specify: If the facility in which the study was conducted is not one of the first 
five options above, use this text field to describe the facility or facilities in which the study was conducted. 
Facility Size: Select from the pull down list the option that best describes the size of the facility in which the study was 
conducted. Options (for hospitals) include:  
1. <100 beds,  2. 100-300 beds  3. >300 beds  4. Not applicable 
 
Total Annual Test Volume: Please enter the option that best corresponds to the annual test volume of the facility in which 
the study was conducted. Use the “Other” field to provided additional information, if appropriate.
1. <100.000 
2. 100,001-500,000 
3. 500,001 – 1,000,000 
4. > 1,000,000 
5. Other 
6. Not available 
Total Annual Test Volume – “Other” please specify 
If total annual test volume standard options do not describe available annual test volume information, or to include 
information about annual test volume that is not inclusive of all laboratory testing (e.g., specific test volume, anatomic 
pathology, microbiology, chemistry) use this text field to describe available test volume information. 
Facility location - Published Study or Unpublished Study with permission to identify [City, State, Country]: Record the 
location of the facility in which published study was conducted. Please include the City, State, and Country separated by 
commas. If multiple locations are represented, please separate locations using a semi-colon.  
Facility location - Unpublished Study  - No permission to identify [Region, Country]: For unpublished studies, record the 
region and country of the facility in which the study was conducted. In the United States, states can are defined by their 






























New Hampshire (R1D1) 
New Jersey (R1D2) 
New Mexico (R4D8) 
New York (R1D2) 
North Dakota (R2D4) 





Rhode Island (R1D1) 
South Carolina (R3D5) 
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West Virginia (R3D5) Wisconsin (R2D3) Wyoming (R4D8) 
Setting within facility / organization where practice implemented: Select from the pull down list the option that setting 
within the facility or organization that best describes where the practice – as tested – was implemented. Options include:
1. Hospital inpatient 
2. Hospital outpatient 
3. Emergency Department 
4. ICU 
5. Physician Office 
6. Other - please specify 
 
Setting: If "Other", please specify: If the setting in which the practice – as tested – was implemented is not well described 
by the first five options above, use this field to describe the setting in which the practice – as tested – was implemented. 
Rate Facility Description / Study Setting: From the drop-down list provided, rate the uniqueness of the study facility and 
setting with respect to generalization. Generalizability is a judgment on the likelihood that the results obtained would 
achieved in other facilities or settings.  
1. Deduct 0 points. Results are likely to generalize to other facilities and settings. 
2. Deduct 1 point if the study location is sufficiently distinctive that the results obtained through that setting 
may not be generalizable to other settings.  
3. Deduct 2 points if the study location is sufficiently distinctive that the results obtained through that setting 
are unlikely to be generalizable to other settings 
4. Deduct 3 points (Score 0) if it is clear that the setting or situation is unique such that the results cannot 
generalize to other settings. 
Additional Information about Facility Description Study Setting Rating: If you deducted points in the item above, provide a 
supporting explanation for point deductions.   
Study Population: Description of the population (patients, specimens, and /or tests) total number: Provide a rich 
description of the study population(s) that are included as units of analyses in the report. Be sure to record all described 
characteristics for both the entire study sample(s) and any breakouts tested. Be sure to include the number of patients 
and/or number of tests and/or number of samples in total and in each condition, information about the patient type, and 
any other characteristics of the patient, specimen, and/or tests that are summarized in the study being coded. 
Data Collection Start Date (MM//DD/YYYY): Record the month and year that data were first collected for this study. 
Although the program formats the data as MM/YYYY, data must be entered using the MM/DD/YYYY format. If the day and 
month are not reported, enter your best estimate of the start of data collection. 
Data Collection End Date (MM/DD/YYYY): Record the month and year that data were last collected for this study. Although 
the program formats the data as MM/YYYY, data must be entered using the MM/DD/YYYY format. If the day and month are 
not reported, enter your best estimate of the end of data collection. 
Describe Data Collection: Many data collection designs are not readily captured using standard start and end dates. Use 
this field to describe the data collection protocol. Be sure to record dates for each condition. For example: The study used a 
pre-post design with comparison practice data collected 12/01/1996 to 12/31/1999 and tested practice data collected 
between 12/01/2007 through 12/01/2009. 
Method for selecting tests: From the drop down list provided, select the option that best describes which tests or samples 
were included in the study. 
 1. Study includes a census of tests (e.g., all tests within a given time period), and the time and/or number of 
tests is sufficient to be representative 
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 2. Study includes a randomized or stratified random sample of tests 
 3. Study used a quasi-random procedure to identify the sample of tests (e.g., every third test was included in 
the study) 
 4. Study used a non-random procedure to identify the sample of tests (e.g., a convenience sample) 
 5. Study includes a census of tests (e.g., all tests within a given time period), but the time and/or number of 
tests is insufficient to be representative 
 6. Study selected a unique and non-representative sample of tests 
Method for selecting patients: From the drop down list provided, select the option that best describes which tests or 
samples were included in the study. 
 1. Study includes a census of patients (e.g., all patients within a given time period), and the time and/or 
number of patients is sufficient to be representative. 
 2. Study includes a randomized or stratified random sample of patients 
 3. Study used a quasi-random procedure to identify the sample of patients 
 4. Study used a non-random procedure to identify the sample of patients 
 5. Study includes a census of patients (e.g., all patients within a given time period), but the time and/or 
number of patients is insufficient to be representative 
 6. Study selected a unique and non-representative sample of patients 
Describe non-representativeness: Describe, if necessary, sources of deviation from test or sample representativeness. This 
text field allows the abstractor to record any sample information they feel restricts our confidence that the study results 
generalize to all tests and populations.  
Study Design: Select from the pull-down list the option that best captures the study design on which the findings are based. 
Note that all comparison designs are included in options 1 – 5, while one group designs are captured in options 6 – 11. If the 
design is not contained in this list of design options, select option 12 – Other.  
Two Group Designs 
1.  Randomized Controlled Study (assignment at individual level) 
2. Group-Randomized Controlled Study 
3. Non-randomized comparison study (e.g., Natural Experiments) 
4. Case Control (Groups defined by outcome, AKA Retrospective cohort study) 
5. Cohort Study (Groups defined by predictor, AKA Prospective cohort study) 
One Group Designs 
6. Cross-Sectional (e.g., outcome only) 
7. Time-series (i.e., One-group over time, multiple measures (e.g., monthly)) 
8. Before-after 
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9. Observational study (e.g., Quality Improvement) 
10. Individual case study (the “what went wrong” write-ups) 
11. Descriptive analysis (e.g., implementation study, feasibility study) 
12. Other specify 
Additional Information about Study Design / time period / population rating: If option 12 Other is selected above, please 
include a description of the design this field. If uncertain of the study design, include a description of the design here. 
Rate Study Design / time period / population: From the drop-down list provided, rate the uniqueness of the study design, 
time period, or sample with respect to representativeness. Representativeness is a judgment on whether the results 
obtained through the study design are likely representative of the results of the practice.  
1. Deduct 0 points 
2. Deduct 1 point if the sample (either subjects or tests) may not be representative of the likely results of the 
practice with respect to how the sample was obtained or identified  
3. Deduct 2 points if the sample (either subjects or tests) are probably unrepresentative of the results of the 
practice with respect to how the sample was obtained or identified. 
4. Deduct 3 points if the sample is sufficiently unrepresentative based on how it was obtained/identified to 
clearly nullify the generalizability of the results. 
Additional Information about Study Design / time period / population rating: If points were deducted in the previous 
item, providing a supporting explanation for how the sample is unlikely representative.  
Comparator Practice(s) - please describe: Provide a rich description of each comparison practice (copy or paraphrase if 
necessary). Ideally, each practice could be replicated from description. As such, include in the description any information 
available about practice: 1) Content and organization, 2) Implementation, 3) Setting (where the practice was implemented), 
4) Training, and 5) Required materials and technology. Costs to implement and maintained should be discussed in a later 
field, under the Practices tab.  
Comparator Practice is Ongoing: Please select from the drop-down list of options whether the practice likely continued 
beyond the period of data collection.  (Does not require knowledge of whether it remains in use today.) 
Describe Relationship of Comparison Practice to Data Collection: Ideally, data are collected on well established practices 
and the practice is maintained throughout the entire period of data collection. Please describe the overlap of data 
collection with practice implementation and practice maintenance. For example, likely statements in this text box could be 
(1) Practice was well established and maintained throughout data collection, (2) Practice was implemented at the start of 
data collection and continued throughout the period of data collection, or (3) Practice was discontinued at the end of data 
collection. 
Quality of randomization: The purpose of randomization is to control for artifact due to historical, maturational, selection, 
etc. In an ideal world, all sources of pretest differences are eliminated, or at least relegated to error variance through the 
law of large numbers. If too few units are assigned, or if there are groupwise differences (e.g., assignment at the group 
level) it is likely that not all differences are controlled for and differences documented by a statistical treatment may be due 
to third factors not controlled by randomization. Attrition, assessed later, may also affect the quality of randomization if the 
attrition is differential (varies by some substantive source). Thus, the critical issue surrounding the quality of randomization 
is whether the randomization process effectively controlled for all substantive factors other than the practice that could 
affect the veracity of the finding. 
1. All relevant baseline differences controlled for by randomization 
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2. Most relevant baseline differences controlled for by randomization 
3. Baseline differences not likely controlled for by randomization 
4. Not relevant to design 
Attrition: Severe, unexplained, or differential attrition after assignment / agreement to participate may invalidate 
randomization and may adversely affect generalizability from an original study sample. Attrition may also be considered 
when the expected number of units in an analysis (subjects, samples, or tests) are not included in a study. Select from the 
drop-down list the option that best describes whether all expected units are included in the analysis: 
1. There is minimal attrition represented in this study 
2. There is attrition, but authors attest there are no problems resulting from attrition 
3. There is attrition, and the authors acknowledge it affected the quality of the randomization 
4. There is obvious attrition but it is not discussed or acknowledged by author 
Rate Potential Study Bias: From the drop-down list provided, rate the extent to which you believe that the study design, 
period of measurement, and/or sample selection introduced bias to the results. Bias is systematic error that either reliably 
enhances or supresses a finding. It is different from error, which reduces the quality of measurement, but not in any 
systematic fashion (can produce findings that are both larger and smaller than the true score).   
1. Deduct 0 points  
2. Deduct 1 point if the study design, time period and sample selection methods may introduce a study bias 
that would substantially affect results (i.e., may produce study results interpreted as inconsistent with the true 
results)   
3. Deduct 2 points if the study design, time period and sample selection methods are likely to introduce a 
study bias that would substantially affect results (i.e., would likely produce study results interpreted as 
inconsistent with the true results)   
4. Deduct 3 points if there is reason to believe that the study characteristics can not produce results 
representative of the practice 
Additional information about Potential Study Bias rating: If points were deducted in the previous item, providing a 
supporting explanation for how the finding is likely biased. 
Total Points Deducted – Study: Using the information summarized by the three previous Study Rating Items (Rows 13, 23, 
and 32; Items Rate Facility Description / Study Setting, Rate Study Design / time period / population, and Rate Potential 
Study Bias respectively), record in this field the maximum number of points deducted in any of the previous three Study 
rating fields. For example, if rows 13 and 23 are each zero, but row 32 equals 3 points deducted, then the total points 





1 point deducted 0 points 
deducted 
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Table 3: Practice. 
This table provides information on the practices described in the study. These practices are linked through the study 
identifier to their bibliographic references and via the outcome measures to the results database. Note that a study may 
summarize multiple practices, contrasting them either directly (e.g., RCTs), or indirectly (e.g., error rates associated with 
each practice). In this database, code each practice separately using a new column for each practice tested in the study.  
Short Name for Study Citation: Topic_Practice_Author_Year: Auto-entered using data recorded in the Biblio field of the 
same name. 
Topic Area – Practice: Auto-entered using data recorded in the Biblio field of the same name. 
Practice Name: Assign a short, standardized name for the practice being documented. In the event that a appropriate short 
name has not been pre-determined, reviewers need to assign one.   
Practice - please describe: Provide a rich description of practice (copy or paraphrase if necessary). Ideally, the practice 
could be replicated from description. As such, include in the description any information available about practice: 1) 
Content and organization, 2) Implementation, 3) Setting (where the practice was implemented) and population, 4) Training, 
and 5) Required materials and technology. Costs to implement and maintained and staff responsible and implementing the 
practice should be discussed in later fields in this worksheet. 
Practice Start Date (MM/DD/YYYY): Record the month and year that the comparison practice for this study was 
implemented. Although the program formats the data as MM/YYYY, data must be entered using the MM/DD/YYYY format. 
If the day and month are not reported, enter your best estimate of the start of data collection. 
Practice End Date (MM/DD/YYYY): Record the month and year that the comparison practice for this study ended. Although 
the program formats the data as MM/YYYY, data must be entered using the MM/DD/YYYY format. If the day and month are 
not reported, enter your best estimate of the start of data collection. 
Practice is Ongoing: Please select from the drop-down list of options whether the practice likely continued beyond the 
period of data collection. 
Please describe any relevant training required for implementation, including problems encountered: Please provide a rich 
description of staff training needs associated with implementing this practice. 
Amount of training required: Enter the option that best describes the amount of training necessary to successfully 
implement the practice.  
1. Training is not discussed. 
2. Training needs are modest. 
3. Training needs are moderate. 
4. Successfully implementing practice requires extensive training and ongoing supervision to 
implement successfully. 
Provide available information on Staffing - Number and type of individuals involved in implementing and carrying out the 
practice: In addition to staff routinely carrying out the practice, some practices require additional staff or staff with unique 
abilities (e.g., information technology staff, hardware support, staff with specialized medical training) to develop, plan 
and/or implement a practice. Include here information on the staff necessary to implement and carry out the practice. 
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Supplies, Equipment, Space, and Other Resources: Please list any additional supplies, equipment, space, or other resources 
necessary to implement and maintain the practice. 
Costs: Start-up costs and ongoing costs for sustaining the practice: In this field please record any cost data provided on 
implementing and maintaining the practice.  In particular, note costs associated with information provided in the fields 
above associated with Training, Staffing, and Supplies, Equipment, Space and Other Resources. 
Problems with implementation: Please describe in this field any problems or difficulties noted by the authors in 
implementing the practice. These can include unanticipated or excessive training needs, problems with technology 
(hardware and/or software issues), unanticipated or excessive implementation costs, and/or other issues related to 
institutional support for the practice. 
Problems sustaining the practice: Please describe in this field any problems or difficulties noted by the authors in sustaining 
the practice. These can include unanticipated or excessive staffing needs, problems with technology (hardware and/or 
software issues), unanticipated or excessive maintenance costs, and/or issues related to institutional support for the 
practice. 
Rate Practice Description: The practice should be well enough described to meaningfully distinguish it from alternative 
practices and provide a clear understanding of its requirements and characteristics (does not require that the description 
be exhaustive or support exact replication).  
Deduct 0 points 
Deduct 1 point if the practice and its basic characteristics are not sufficiently identified. 
Deduct 2 points (Score 0) points if the practice and its basic characteristics cannot be clearly identified. 
Additional Information about Practice Description Rating: If points were deducted for the practice description, provide a 
rationale for the deduction. 
Rate Adequacy of Practice Description: Ideally, seven components of practice description would be addressed: a) content, 
b) implementation, c) population / setting, d) training, e) requirements, f) cost, and g) staff responsible and implementing.  
However, detailed information on all components is not necessary to evaluate the effectiveness and feasibility of 
implementing a practice, and is typically not provided (e.g., cost and training).   
Deduct 0 points 
Deduct 1 point if an important aspect/component that is likely to critically affect implementation of the 
practice is not well described. 
Additional Information about Adequacy Rating: If points were deducted on the adequacy of the practice description, 
provide a rationale for the deduction. 
Total Points Deducted – Practice: Using the information summarized by the two previous Practice Rating Items (Rows 16 
and 18; Items Rate Practice Description and Rate Adequacy of Practice Description respectively), record in this field the 
maximum number of points deducted in any of the two previous Practice rating fields. The options for this item are: 
2 points deducted 
1 point deducted 
0 points deducted 
Additional information: Use this field to record source for any additional information used or additional information useful 
for understanding the record being coded. 
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Any problems with record?: Record any additional information on problems/issues/reservations you had with entering 
your responses to these practice-level items. Also enter any critical additional information that might be necessary to 
understanding the practice being documented.  
Table 4: Outcome Measures Assessed.  
Researchers can estimate the result of any given practice in multiple ways. For example, “time to treat” is one way to 
estimate the impact of critical values reporting while “reduction in errors” might be another. For some practices, the range 
of appropriate outcome measures may be quite constrained and consistently reported. For other practices, the range of 
outcome measures may be limited only by the creativity of the researcher. For the same practice, and within the same 
study, researchers often report the impact of an intervention on multiple outcome measures. Therefore, a new record 
column is created for each outcome measure reported by a study.   For multiple outcome measures in a single study, place 
the most important/direct effectiveness measure first (left), and the corresponding study outcome measure ratings in the 
first column only (i.e., although there may be multiple outcome measures, choose the study outcome measure that has the 
highest rating for face validity and recording method). 
These records will be unique for each study. For example, if five studies each report that the measure used to estimate the 
impact of bar coding is the “error rate” for patient-specimen identification, five separate records would be created, each 
uniquely linked to its parent study and practice. 
Short Name for Study Citation: Topic_Practice_Author_Year: Copy from data recorded in the Biblio worksheet field of the 
same name. 
Outcome Measure: Short name/ description: Provide short name/description of the measure being recorded. Be 
sure to note salient characteristics AND notable and important variations/deviations from standardized short 
name outcome definition. 
Outcome Measure: Long Description: Please provide a rich description of the outcome measure. This can copied 
directly from the source material. If in pdf format the material can often be cut and pasted although hard 
paragraphs will have to be removed prior pasting the content in Excel. To do this, past the language first in MS 
Word, search and replace paragraphs “^p” with a space “ “. Then cut and paste the reformatted text into Excel. 
Relevance rating:  Each outcome measure requires a relevancy rating.  Outcome measures that more directly address the 
review question are more relevant to its effect size.  For an outcome measures to be rated “Less Direct,” the reviewer 
should provide a rationale for how it is likely to impact a direct measure addressing the review question, and make a case 
for a strong relationship to a direct measure.  For “Indirect,” the reviewer should provide a rationale for a likely impact on a 
direct measure with a weak relationship and/or a relationship for an impact on a “Less Direct” measure.  
Also reported are measures that should not be interpreted as an outcome of direct interest (i.e., does not directly address 
the review question objective), but may contribute to judgments of cost or feasibility as they are within the causal field for 
the practice. Use the drop-down menu to summarize how directly the outcome measure recorded addresses the review 
question asked. If not-applicable (e.g., a cost or feasibility of implementation item) select “Not Applicable”. 
1. Direct 
2. Less Direct 
3. Indirect 
4. Not Applicable - e.g., non-effectiveness measures like cost, feasibility, patient and provider satisfaction 
Rate Face Validity of Outcome Measure: Face validity asks if the measure likely captures the construct it is intended to 
measure. Deduct points if the measure as specified/defined and data collected is possibly or likely flawed and/or if the 
measure does not capture the essence of what it was supposed to measure (e.g., timeliness). Use the following criteria in 
making your judgment 
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1. Deduct 0 points/no deduction 
2. Deduct 1 point if:  
 (1) Measure does not capture well the outcome being estimated OR  
 (2) The measure estimates an outcome that is only modestly related to the evidence review question 
(e.g., provider satisfaction, compared with change in a patient outcome or an error rate) 
3. Deduct 2 points if the measure is confounded by: 
  (1)The practice itself (that is, the outcome is a direct result of the practice which was not available or 
applicable to both the comparison practice and the tested practice) OR 
 (2) The measure is confounded by the context in which the practice has been implemented (that is, the 
outcome is unlikely to be clearly attributed to the practice).  
Describe Face Validity rating: If points were deducted for the face validity of the outcome measure, please provide a 
rationale for the deduction. 
Recording Methods Used: Researchers can use different methods for recording the results of a test or trial. Some methods 
may be subject to bias or fraud while others can be quite robust. Indicate here the method used to record data for the 
measure being coded. 
1. Occurrence log 
2. Exception reports 
3. Incident reports 
4. External complain forms 
5. Internal quality control instrument 
6. External quality control instrument 
7. Other recording method - please specify 
If "other" recording method, please specify: If “Other recording method” is selected, please supply a description of the 
recording method used for the measure being coded 
Rate Recording Method: The method for recording or documenting practice results should be reliable and accurate. As 
mentioned above recording methods may be subject to bias or fraud (intentional and otherwise). Reliability refers to the 
ability of a measure to return the same result each time, given the same underlying phenomena. Accuracy refers to the 
precision of the measurement tool. Note that a tool can be accurate, but not reliable (e.g., the adage “measure twice, cut 
once” observes that while the tape is accurate, the observation of the result is not reliable). Use the following scale to rate 
the quality of the recording method described. 
1. Deduct 0 points 
2. Deduct 1 point if the recording method is not described OR does not accurately capture all instances of the 
outcome 
3. Deduct 2 points if the method of recording the outcome is unreliable. 
Describe Recording Method Rating: If points were deducted for the recording method of the outcome measure, please 
provide a rationale for the deduction. 
Data Abstraction Tool 
Phase 3 Final Report 153 
Total Points Deducted – Measurement: Using the information summarized by the two previous Measurement Rating Items 
(Rows 7 and 11; Items Rate Face Validity of Outcome Measure and Rate recording method respectively), record in this field 
the maximum number of points deducted in any of the two previous Measures rating fields. The options for this item are: 
2 points deducted 
1 point deducted 
0 points deducted 
Rank order measures: Using the review question and Relevancy rating (Row 7) as guides, rank order the effectiveness 
measures so that the measure that most directly addresses the review question is ranked “1”, the next most direct measure 
is rated “2”, and so forth. This rating does not assess how responsive the measure is to the review question and is separate 
from measure quality – it is a within-study judgment assigning a value to each the measures reported relative to other 
measures reported by the study. For example, if a study reported three “less direct” measures of a review question, the 
most relevant of these indirect measures would still be ranked “1” and the least direct measure would be ranked “3”. The 
Total Points Deducted for the first ranked item (the measure that is most relevant – “1”) will be used to determine the 
points deducted for measurement quality when developing the overall study quality rating. 
Additional information: Use this field to record source for any additional information used or additional information useful 
for understanding the record being coded. 
Any problems with record?: Record any additional information on problems/issues/reservations you had with entering 
your responses to these practice-level items. Also enter any critical additional information that might be necessary to 
understanding the practice being documented.  
Table 5: Results.  
This table provides information about study outcomes of various study arms. The general rule for creating a new record is 
to create a new record anytime the measure, sample, or practice changes or when recording a different result (e.g., Type of 
Effect Size changes effectiveness to “cost” or “feasibility”). To be eligible for coding a study must contain an effectiveness 
finding (basic inclusion criteria). These can be quantitative information (e.g., error rate, time to treat), cost, or qualitative 
information for feasibility. A study can contain an almost unlimited number of effect sizes (I once coded something in the 
neighborhood of 1,400 effect sizes for a single epidemiological study of 411 youth), or may contain only a single finding. In 
any case, a study must have at least one laboratory practice relevant finding to be coded in this review. Therefore, it is 
strongly recommended that at least one codable finding be identified prior to coding a study. 
Each of the columns/records in this section should represent a single practice/outcome measure combination that 
relates to at least one study population sample group (potentially with sub-groups).  The practices, outcome 
measures and study population groups and sub-groups should all link directly to those identified in the previous 
sections. No new study populations, practices and outcome measures can be “created” in this section, only the 
quantitative and feasibility results related to those previously identified and described. 
Short Name for Study Citation: Topic_Practice_Author_Year: Copy and paste using data recorded in the Biblio field of the 
same name. 
Topic Area – Practice: Copy and paste using data recorded in the Practice field Topic Area - Practice. 
Practice Name:  Copy and paste from the Practice section field (Row 5) 
Outcome Measure: Copy and paste from the Measure field “Outcome Measure: Short Description.” 
Sample Breakout: Breakouts are when the author selects a subsample of the data and provides a separate outcome for 
that subset. An example might be when a study that uses inpatient data provides separate estimates for the ICU and for the 
emergency room. Another might be when an inpatient study breaks the data on time of day or shift. Note that this is not a 
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practices comparison, but a comparison of a given practice in different settings, populations, or facilities. To be a coded as a 
breakout, the break variable should result in mutually exclusive groupings (even if data on only one of the groups is 
reported). 
1. Finding is based on the entire sample 
2. Finding is based on a subset of the available data 
3. Other 
Describe breakout: If findings are based on a subset of the available data, provide a rich description of the subset of data 
on which the finding is based. 
Enter finding page number (if available): Enter page number(s) or other information that would facilitate finding the 
evidence being summarized in the original document. 
Type of finding: Select the type of finding being recorded. All one group trials involving a single point estimate should be 
entered as a non-comparative (single point only) effect size. 
Impact findings 
1. Non-comparative Study, Time series (average) 
2. Comparison (RCT, GRCT, NRCT, cross-sectional, Case control, PCS, RCS) 
3. Pretest-Posttest 
4. Descriptive (one group) 
Other findings 
5. Cost of implementation 
6. Feasibility of implementation (“lessons learned”) 
7. Cost savings/Cost effectiveness 
Finding: Because of the diversity of findings and overall training required to accurately code effectiveness estimates, 
findings including effect sizes will be entered in narrative form at this stage of the review. Always include the number of 
subjects and tests/samples on which the effect size is based, the estimate of central tendency (e.g., mean, mode, ratio) and 
any estimate of dispersion provided (e.g., standard deviation, standard error, variance). For all comparison studies. create 
separate records for each arm of the comparison and a third record for the comparison. For example, a study contrasting 
error rates for bar coding with error rates for technician education could have an effect size for the comparison, and 
separate error rates for each of the bar coding and technician education groups. In this example, each of the three 
estimates should be entered in separate records. For comparisons, be sure to indicate clearly which arm supplies each set 
of findings. If a multivariate finding is recorded, include all variables in the model.  
If the ‘effect size’ captures information on the cost or implementation of a practice, enter that information in the Finding 
field. For this information it is worth being efficient. Enter as much feasibility, cost, implementation, or dissemination data 
in the Finding field as applicable (e.g., one record for each type of non-effectiveness data provided for a study and practice.  
Confirm the direction of effect: For all statistical comparisons, confirm the direction of effect. That is, for effectiveness 
findings indicate whether the comparison favors the treatment group (a positive effect) or the comparison group (a 
negative effect). Be aware that direction of effect can be mediated by item wording. In other words, a practice can have a 
positive impact by reducing errors or increasing accuracy. Note that this variable captures the simple direction of effect, not 
whether the effect is statistically significant. Note also that as a standardized convention, positive impacts will be coded 
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positively (i.e., when a practice results in a reduction in errors there is a positive effect from the practice). Following this 
convention, in a pretest-posttest design an increase in error rates over time would be coded as a negative impact of the 
intervention. Select only one: 
1. Not applicable  
2. Positive impact from the practice 
3. No difference 
4. Negative impact from the practice (i.e., comparison group/pretest group returned a more positive result) 
Type of statistical test: Enter the type of statistical test summarized in Finding. Select only one: 
Quantitative effect sizes 
1. N successful 
2. Proportion successful 
3. Multi-category frequency or % 
4. Means and SDs 
5. T-value (independent) 
6. Probability with N/degrees of freedom 
7. Dependent T-test 
8. One-way ANOVA (2 groups, 1 degree of 
freedom) 
9. One-way ANOVA (>2 groups, >1 degree of 
freedom) 
10. Factorial Design (MANOVA) 
11. Covariance Adjusted (ANCOVA) 
12. Chi-square statistic (1 degree of freedom) 
13. Chi-square (> 2x2 table) 
14. Nonparametric 
15. Correlation coefficient (zero-order) 
16. Means and variances 
17. Means and standard errors 
18. Means and t-test (independent) 
19. Multi-factor ANOVA 







Effect size significance: If a statistical test was conducted, is the result of the test significant? Select only one: 
1. Effect size is significant 
2. Effect size is not significant 
3. Significance not reported 
Statistical power test?: Record if a statistical power test was conducted or statistical power was discussed 
1. Power test was conducted and statistical power was 80% or greater 
2. Power test was conducted and statistical power was less than 80% 
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3. Statistical power is mentioned, but results from the power test are not reported 
4. Statistical power is not discussed 
Rate Sample Sufficiency: Many of the outcomes of interest are rare events. If too few observations are obtained or if the 
measurement period is insufficient to capture these events the measure may provide an inaccurate representation of the 
effect of the practice. Even among more common events, there may also be considerable variation in the number or rate of 
events over time. The period of measurement should be sufficiently long to allow robust estimates of the impact of the 
practice. 
Deduct 0 points 
Deduct 1 point if:  
 (1) Measurement period insufficient to allow robust estimate of practice impact) OR  
 (2) Statistical power not discussed AND the sample may be too small to allow a robust estimate) 
Deduct 2 points if:  
 (1) The number of subjects and/or measurement period not reported)   
 (2) The measurement period is likely insufficient for a robust estimate of practice impact) OR  
 (3) Statistical power is not discussed AND the sample is likely too small to allow a robust estimate of the 
impact of a practice)  
Describe sample sufficiency rating: If points were deducted for the Sample Sufficiency Rating, please provide a rationale for 
the deduction. 
Rate appropriateness of statistical analysis: Determine if the statistical analysis was appropriate for the data. 
Deduct 0 points. 
Deduct 1 point if:  
 (1) Data collected during notably different 
time periods OR  
 (2) Data do not permit effect size 
calculation. 
Deduct 2 points if: 
 (1) Results were obtained using different 
measures or recording practices for two 
groups 
 (2) Inappropriate statistical analysis AND 
insufficient data to allow or verify 
calculation of an effect size) 
 
Describe appropriateness rating: If the statistical analysis is rated as inappropriate, describe the rationale for the rating in 
this field. 
Rate Uncontrolled Deviations and Results/Conclusions biases: Despite the best efforts of researchers, studies are 
sometimes contaminated by unforeseen events or circumstances. Record here the extent to which these may apply to the 
findings being recorded. 
Deduct 0 points 
Deduct 2 points if:  
 (1) Results not due to practice; likely related to different practice(s), OR  
 
Phase 3 Final Report 157 
 (2) Unexplained attrition >70% OR  
 (3) Uncontrolled differential attrition OR  
  (4) Results/conclusion not supported by or at odds with the work done/presented 
Describe bias rating: If the findings were influenced by Uncontrolled Deviations or Results/Conclusions biases, describe the 
uncontrolled deviations and results/conclusions biases in this field. 
Total Points Deducted – Findings: Using the information summarized by the three previous Findings Rating Items (Rows 15, 
17, and 19; Items Rate Sample Sufficiency, Rate appropriateness of statistical analysis, and Rate Uncontrolled Deviations 
and Results/Conclusions biases respectively), record in this field the maximum number of points deducted in any of the 
three previous Findings rating fields. The options for this item are: 
3 points deducted 
2 points deducted 
1 point deducted 
0 points deducted 
Effect Size Magnitude Rating: From the list of available options rate whether the finding obtained is substantial, moderate 
or minimal to none. In contrast to statistical significance, this is a judgment of the clinical significance of the finding. Does 




Identify Key Effectiveness Finding: Identify the comparison records that are based on the highest ranked effectiveness 
measure from Rank Order – Measures (Row 15 of the Measures worksheet). Of the results based on the number “1” rated 
measure, select the result that provides the most accurate estimate of the impact of the program. All things being equal, 
this will usually be the result based on the largest sample. However, if the largest sample finding is based on disparate 
subjects, samples, or subject to other confounds, a finding based on a subset might be more likely representative of the 
effectiveness of a practice. Use the drop-down list to identify the finding that best represents the effectiveness of the 
practice. 
1. Most representative of effectiveness 
2. Not the most representative effectiveness finding  
3. Not applicable, not a comparison 
4. Not applicable, not an effectiveness finding 
The Total Points Deducted for the identified item (the finding that best represents the effectiveness of the practice) will 
be used to determine the points deducted for findings quality when developing the overall study quality rating. 
Justify Key Effectiveness Rating: Please provide a justification for your selection. 
Additional information: Use this field to record source for any additional information used or additional information useful 
for understanding the record being coded. 
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Any problems with record?: Record any additional information on problems/issues/reservations you had with entering 
your responses to these effect size-level items.  
